date,time,title,abstract
2013-01-11,1:15 PM,Merck withdraws cholesterol drug Tredaptive globally,Jan 11 Merck & Co Inc said it would withdraw its cholesterol drug Tredaptive from markets worldwide after European regulators recommended that marketing of the drug be suspended.
2013-01-11,3:55 PM,RPT-UPDATE 1-Merck steers doctors away from HDL cholesterol drug,"Jan 11 U.S. drugmaker Merck & Co said it is taking steps to suspend availability of its drug Tredaptive after the medicine, used to raise ""good"" HDL cholesterol, failed to prevent heart problems in a large study."
2013-01-11,5:40 PM,UPDATE 2-Merck begins overseas recall of HDL cholesterol drug,"Jan 11 Merck & Co said it is recalling Tredaptive, its medicine to raise ""good"" HDL cholesterol levels, in overseas markets where it is sold, after it failed to prevent heart problems in a large study and raised safety concerns."
2013-01-11,1:53 PM,Merck begins overseas recall of HDL cholesterol drug,"Merck & Co said it is recalling Tredaptive, its medicine to raise ""good"" HDL cholesterol levels, in overseas markets where it is sold, after it failed to prevent heart problems in a large study and raised safety concerns."
2013-01-18,10:39 AM,UPDATE 1-EU agency confirms suspension of Merck cholesterol drug,"LONDON, Jan 18 Europe's drug regulator has confirmed it is suspending marketing authorisations for Merck & Co's cholesterol drug Tredaptive in Europe after its failure in a major study raised safety concerns."
2013-01-18,10:49 AM,EU agency confirms suspension of Merck cholesterol drug,LONDON Europe's drug regulator has confirmed it is suspending marketing authorizations for Merck & Co's cholesterol drug Tredaptive in Europe after its failure in a major study raised safety concerns.
2013-01-24,9:01 AM,Merck CEO says jury out on raising good cholesterol,"DAVOS, Switzerland The jury is still out on the benefits of increasing ""good"" HDL cholesterol, but the strategy remains worth pursuing, despite recent setbacks, the chief executive of said on Thursday."
2013-01-25,4:35 PM,FDA OKs over-the-counter version of Merck overactive bladder drug,"Jan 25 U.S. health regulators approved a nonprescription version of Merck & Co Inc's Oxytrol to treat overactive bladder in women ages 18 and older, the agency said on Friday."
2013-01-25,5:40 PM,UPDATE 1-FDA OKs Merck OTC version of overactive bladder drug,"Jan 25 U.S. health regulators approved Merck & Co's  nonprescription version of Oxytrol to treat overactive bladder in women ages 18 and older, the agency said on Friday."
2013-01-25,4:40 PM,FDA OKs Merck OTC version of overactive bladder drug,"Health regulators approved Merck & Co's nonprescription version of Oxytrol to treat overactive bladder in women ages 18 and older, the agency said on Friday."
2013-02-01,12:10 PM,"Merck beats forecast, but issues cautious 2013 view","Feb 1 Merck & Co's quarterly results beat forecasts, helped by strong sales of its Januvia diabetes drug and Gardasil vaccine against cervical cancer, but the company issued a full-year 2013 profit view at the low end of Wall Street expectations"
2013-02-01,12:55 PM,BRIEF-Merck down in premarket trading after results,"NEW YORK, Feb 1 Merck & Co Inc :  * Shares fall 1.2 percent in premarket trading after results"
2013-02-01,2:05 PM,CORRECTED-BRIEF-Merck says continues to believe in osteoporosis drug,"Feb 1 Feb 1 Merck & Co Inc :  * CEO says continues to believe in potential of osteoporosis drug odanacatib  * Said it made decision to delay seeking U.S. approval of drug on its own, without FDA prodding  * Says it will delay marketing application in order to include additional data from an extension trial       (Reporting By Ransdell Pierson)"
2013-02-01,12:25 PM,UPDATE 4-Merck shares fall on worries about osteoporosis drug,"* Delay in filing for osteoporosis drug worries analysts   (Adds CFO comments, details on osteoporosis drugs, updates shares)"
2013-02-01,12:14 PM,Merck shares fall on worries about osteoporosis drug,"Merck & Co Inc's quarterly results beat estimates, but the drugmaker issued a cautious 2013 profit forecast and said it will delay seeking approval for a high-profile osteoporosis drug, sending its shares down 3 percent."
2013-02-04,12:05 AM,Vaccine group funds cervical cancer immunisations for poor,* Over 85 pct of cervical cancer deaths are in poor nations
2013-02-05,7:00 PM,"Merck hit with $285,000 verdict in Fosamax trial","NEW YORK, Feb 5 A federal jury on Tuesday ordered Merck & Co Inc to pay $285,000 in a lawsuit over the risks of its osteoporosis drug Fosamax, only a second loss for the company after several earlier trials."
2013-02-05,8:26 PM,"UPDATE 1-Merck hit with $285,000 verdict in Fosamax trial","NEW YORK, Feb 5 A federal jury on Tuesday ordered Merck & Co Inc to pay $285,000 in a lawsuit over the risks of its osteoporosis drug Fosamax, the second loss for the company after several earlier trials."
2013-02-05,9:00 PM,"Merck hit with $285,000 verdict in Fosamax trial","NEW YORK A federal jury on Tuesday ordered Merck & Co Inc to pay $285,000 in a lawsuit over the risks of its osteoporosis drug Fosamax, the second loss for the company after several earlier trials."
2013-02-07,5:26 PM,Appeals court upholds patent on Merck's Vytorin,"WASHINGTON, Feb 7 A U.S. appeals court on Thursday ruled that the patent on Merck & Co's  cholesterol fighter Zetia and a related drug, Vytorin, was valid."
2013-02-07,6:51 PM,UPDATE 1-Appeals court upholds patent on Merck's Vytorin,* Sales from patent more than $4 billion annually for Merck
2013-02-07,5:31 PM,Appeals court upholds patent on Merck's Vytorin,"WASHINGTON The patent on Merck & Co's cholesterol fighters Zetia and Vytorin, two of the drugmaker's biggest products, is valid, a U.S. appeals court ruled on Thursday."
2013-02-14,1:15 PM,Merck says to pay $688 mln to settle Enhance lawsuits,Feb 14 Merck & Co on Thursday said it has agreed to pay $688 million to settle two U.S. investor lawsuits over its disclosures concerning the Enhance drug study released in early 2008.
2013-02-14,1:55 PM,UPDATE 3-Merck to pay $688 mln to settle Enhance lawsuits,Feb 14 Merck & Co has agreed to pay $688 million to settle two U.S. class-action lawsuits by shareholders who said they lost money because the company concealed the poor results of a clinical trial of the anti-cholesterol drug Vytorin.
2013-02-14,1:18 PM,Merck to pay $688 million to settle Enhance lawsuits,Merck & Co  has agreed to pay $688 million to settle two U.S. class-action lawsuits by shareholders who said they lost money because the company concealed the poor results of a clinical trial of the anti-cholesterol drug Vytorin.
2013-02-14,9:30 PM,TEXT - Fitch says Merck's settlement of Vytorin class actions manageable,"Feb 14 - Merck and Co.'s settlement of two outstanding class action suits today, which could result in $688 million of payments to plaintiffs, is manageable in light of the company's strong liquidity position, according to Fitch Ratings.  The two suits, filed since December 2008, allege that Merck and Schering-Plough  executives delayed the release of unfavorable results from a study that could  have adversely affected sales of the company's Vytorin cholesterol drug. The  suits are pending in th"
2013-02-15,9:05 PM,High-stakes cholesterol study could lift Merck cloud,"NEW YORK Favorable results from a huge heart study could help redeem investors' faith in Merck & Co and its two biggest cholesterol drugs, Vytorin and Zetia, and potentially add billions of dollars in annual revenue."
2013-02-22,12:10 PM,"EU agency recommends Sanofi, Merck paediatric vaccine","LONDON, Feb 22 The European Medicines Agency recommended approval of Hexyon, a new 6-in-1 paediatric vaccine from Sanofi Pasteur MSD, a joint venture between Merck  and Sanofi, the companies said on Friday."
2013-02-22,12:20 PM,"EU agency recommends Sanofi, Merck pediatric vaccine","LONDON The European Medicines Agency recommended approval of Hexyon, a new 6-in-1 pediatric vaccine from Sanofi Pasteur MSD, a joint venture between Merck and Sanofi, the companies said on Friday."
2013-03-07,6:50 PM,"Merck veteran named research chief, after drug setbacks","March 7 Merck & Co will bring back one of its veterans to head research and development, replacing retiring Peter Kim, who leaves behind a mixed record over the past decade at the drugmaker's highly respected laboratories."
2013-03-07,8:45 PM,"UPDATE 1-Merck veteran named R&D chief, after drug setbacks","March 7 Merck & Co will bring back one of its veterans to head research and development, replacing retiring Peter Kim, who leaves behind a mixed record over the past decade at the drugmaker's highly respected laboratories."
2013-03-07,8:05 PM,"Merck veteran named R&D chief, after drug setbacks","Merck & Co will bring back one of its veterans to head research and development, replacing retiring Peter Kim, who leaves behind a mixed record over the past decade at the drugmaker's highly respected laboratories."
2013-03-09,7:45 PM,Serious side effects seen with failed Merck niacin drug -study,"March 9 Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding a final nail to the coffin of niacin therapy for heart patients."
2013-03-09,7:50 PM,Serious side effects seen with failed Merck niacin drug,"SAN FRANCISCO Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding another nail to the coffin of niacin therapy for heart patients."
2013-03-12,12:15 PM,Merck will continue large study of Vytorin after panel review,March 12 Pharmaceutical company Merck & Co Inc  said on Tuesday that an independent monitoring board had allowed it to continue with a huge trial assessing the safety and effectiveness of its blockbuster Vytorin cholesterol treatment.
2013-03-12,12:45 PM,BRIEF-Merck shares up 4.5 percent after says will continue study of vytorin,"NEW YORK, March 12 Merck & Co Inc :  * Shares up 4.5 percent after says will continue study of vytorin"
2013-03-12,12:50 PM,UPDATE 2-Vytorin study to continue after review; Merck shares jump,"March 12 An independent monitoring board said a large trial of Merck & Co's Vytorin cholesterol drug can continue, suggesting no major safety issues have yet been seen with the pill."
2013-03-12,12:25 PM,Vytorin study to continue after review; Merck shares jump,"An independent monitoring board said a large trial of Merck & Co's Vytorin cholesterol drug can continue, suggesting no major safety issues have yet been seen with the pill."
2013-03-14,3:20 PM,FDA studies possible pre-cancerous link with diabetes drugs,"March 14 The U.S. Food and Drug Administration is studying unconfirmed  reports that a widely used class of diabetes drugs, which includes Merck & Co's Januvia, may cause inflammation of the pancreas and pre-cancerous changes to the pancreas.     The agency, in a notice on its website on Thursday, said it is the first time it has communicated potential pre-cancerous links to the medicines, known as incretin mimetics. The oral treatments also include Bristol-Myers Squibb Co's  Onglyza"
2013-03-14,3:40 PM,FDA studies possible pre-cancerous link with diabetes drugs,"The Food and Drug Administration is studying unconfirmed reports that a widely used class of diabetes drugs, which includes Merck & Co's Januvia, may cause inflammation of the pancreas and pre-cancerous changes to the pancreas."
2013-03-15,1:46 PM,BRIEF-Merck says FDA to take extra 3 mos to review sugammadex anesthesia-reversal agent,March 15 Merck & Co Inc :  * Says FDA will take extra 3 months to review sugammadex anesthesia-reversal
2013-03-15,1:55 PM,Merck anesthesia-reversal agent faces new delay,"March 15 The U.S. Food and Drug Administration will not complete its review of Merck & Co's  experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three month delay, the drugmaker said."
2013-03-15,2:35 PM,REFILE-UPDATE 2-Merck anesthesia-reversal agent faces new delay,"March 15 The U.S. Food and Drug Administration will not complete its review of Merck & Co's  experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three-month delay, the drugmaker said."
2013-03-15,2:00 PM,Merck anesthesia-reversal agent faces new delay,"The Food and Drug Administration will not complete its review of Merck & Co's experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three-month delay, the drugmaker said."
2013-04-02,3:11 PM,Merck unit sues India's Glenmark over diabetes drug,"MUMBAI, April 2 A unit of U.S. drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs."
2013-04-02,3:20 PM,Merck unit sues India's Glenmark over diabetes drug,MUMBAI A unit of U.S. drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
2013-04-03,6:51 PM,Experimental sleep drug may cause fewer side effects -Merck study,"CHICAGO, April 3 A study in rats and monkeys suggests an experimental Merck & Co  sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday."
2013-04-24,3:36 PM,Merck melanoma drug wins 'breakthrough' designation,"April 24 U.S. regulators have granted Merck & Co's experimental treatment for advanced melanoma a ""breakthrough therapy"" designation, which could speed development and regulatory review of the product."
2013-04-24,3:41 PM,"Merck melanoma drug wins ""breakthrough"" designation","U.S. regulators have granted Merck & Co's experimental treatment for advanced melanoma a ""breakthrough therapy"" designation, which could speed development and regulatory review of the product."
2013-04-29,12:00 PM,"Merck, Pfizer to jointly develop diabetes drug","April 29 U.S. drugmakers Pfizer Inc and Merck & Co Inc said they would jointly develop Pfizer's experimental type 2 diabetes drug, ertugliflozin, and expect late-stage trials to start later in 2013."
2013-04-29,6:21 PM,"UPDATE 1-Merck, Pfizer to jointly develop diabetes drug","April 29 Pfizer Inc and Merck & Co Inc said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other drugs, including Merck's blockbuster Januvia."
2013-04-29,12:05 PM,"Merck, Pfizer to jointly develop diabetes drug","Pfizer Inc and Merck & Co Inc said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other drugs, including Merck's blockbuster Januvia."
2013-05-01,11:11 AM,Merck first-quarter sales disappoint,"May 1 Merck & Co Inc reported lower than expected first quarter sales, as generic competition hurt demand for its Singulair asthma drug and the stronger dollar hit overseas sales of its medicines."
2013-05-01,11:21 AM,BRIEF-Merck shares down 2.1 pct premarket,"NEW YORK, May 1 Merck & Co Inc :  * Shares down 2.1 percent in premarket trading after results"
2013-05-01,1:16 PM,"US STOCKS-Futures slip ahead of open on Merck, ADP; Fed on tap",* U.S. Fed expected to maintain $85 bln/month in bond buys
2013-05-01,1:36 PM,REFILE-US STOCKS SNAPSHOT - Wall St dips as Merck drags; Fed on tap,"NEW YORK, May 1 Wall Street edged lower at the open on Wednesday, weighed by weak results from Merck as investors waited to hear from the U.S. Federal Reserve on the state of the economy."
2013-05-01,2:31 PM,"US STOCKS-Wall St down on weak data, earnings; Fed on tap","* U.S. companies hire less, manufacturing growth slows in April"
2013-05-01,11:31 AM,"UPDATE 3-Merck's Januvia diabetes drug lags, 2013 forecast cut","May 1 Merck & Co Inc reported a surprising drop in quarterly sales of diabetes medicine Januvia, its biggest product and a frequent driver of quarterly earnings, and the drugmaker cut its full-year profit forecast on Wednesday."
2013-05-01,11:13 AM,"Merck's Januvia diabetes drug lags, 2013 forecast cut","Merck & Co Inc  reported a surprising drop in quarterly sales of diabetes medicine Januvia, its biggest product and a frequent driver of quarterly earnings, and the drugmaker cut its full-year profit forecast on Wednesday."
2013-05-01,11:52 AM,"Wall Street drops on data, earnings; Facebook up late",NEW YORK Stocks fell sharply on Wednesday as the latest economic data continued a trend of indicators pointing to anemic growth while bellwether companies disappointed on revenue. | Video
2013-05-03,2:21 PM,Fitch Affirms Merck & Co.'s IDR at 'A+'; Outlook Negative,"(The following statement was released by the rating agency) CHICAGO, May 03 (Fitch) Fitch Ratings has affirmed Merck & Co.'s (Merck)  ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating Outlook  is revised to Negative from Positive. A full list of ratings affirmed is listed  below.  The ratings apply to approximately $20.5 billion in outstanding debt.  KEY RATING DRIVERS Leveraging Share-Buybacks Pressure Credit Profile On April 1, Merck announced the expansion of its share re"
2013-05-03,7:45 PM,FDA approves Merck combination cholesterol lowering pill,"The U.S. Food and Drug Administration approved a Merck & Co cholesterol lowering pill that combines a generic version of Pfizer Inc's Lipitor with its own Zetia, Merck said on Friday."
2013-05-09,2:30 PM,"Merck sales rep alleges sexual bias, seeks over $100 mln","May 9 A senior sales representative for Merck & Co has sued the drugmaker for more than $100 million, alleging the drugmaker discriminates against female employees in terms of pay and advancement, particularly pregnant employees and female employees with children."
2013-05-09,3:28 PM,"Merck sales representative claims sexual bias, seeks over $100 million","A sales representative for Merck & Co.  filed a more than $100 million sex discrimination lawsuit against the drugmaker on Thursday, claiming that it particularly discriminates against pregnant employees and women with children."
2013-05-22,10:57 PM,"UPDATE 1-FDA panel says Merck's sleep drug safe, effective at lower dose","WASHINGTON, May 22 Merck & Co's  experimental insomnia drug was safe and effective at the lower of two doses studied, a panel of medical experts said on Wednesday, increasing the chance it will be approved by the U.S. Food and Drug Administration."
2013-05-22,9:36 PM,"FDA panel says Merck's sleep drug safe, effective at lower dose","WASHINGTON Merck & Co's experimental insomnia drug was safe and effective at the lower of two doses studied, a panel of medical experts said on Wednesday, increasing the chance it will be approved by the U.S. Food and Drug Administration."
2013-05-23,12:50 AM,UPDATE 2-Merck's insomnia drug moves a step closer to U.S. approval,"* FDA panel says suvorexant safe, effective at lower doses"
2013-05-23,9:37 PM,Merck halts development of experimental Parkinson's drug,"May 23 Merck & Co has ended development of preladenant, an experimental drug for Parkinson's disease, after initial data from three late-stage trials proved disappointing."
2013-06-02,8:16 PM,UPDATE 1-Merck melanoma drug shrinks tumors in 38 percent of patients,"* Among those who got the highest dose, 52 percent responded"
2013-06-03,2:30 PM,"US STOCKS SNAPSHOT - Dow hits session highs, Merck rallies","NEW YORK, June 3 U.S. stocks rose on Monday, with the Dow rising to a session high on strength in blue chip names."
2013-06-03,10:48 AM,"Exclusive: EU to fine Lundbeck, others for blocking generic drugs","BRUSSELS A European regulator will fine Denmark's Lundbeck and eight other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said, its first sanction against ""pay-for-delay"" deals."
2013-06-25,11:26 AM,Merck & Co wins injunction against Indian firm over diabetes drugs,"MUMBAI, June 25 MSD, a unit of U.S. drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India."
2013-06-25,11:31 AM,Merck & Co wins injunction against Indian firm over diabetes drugs,"MUMBAI MSD, a unit of U.S. drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India."
2013-06-27,10:11 AM,BRIEF-South Africa's Aspen in $1 bln deal with Merck,"JOHANNESBURG, June 27 Aspen Pharmacare Holdings Ltd  :  * Signing of an agreement to acquire api manufacturing facilities  * Agreement on an option to acquire a portfolio of products from msd  * Agreement with Merck for the acquisition of an active pharmaceutical"
2013-06-27,10:46 AM,South Africa's Aspen in $1 bln deal with Merck,"JOHANNESBURG, June 27 Aspen Pharmacare  said on Thursday that it would acquire drugs and a plant from U.S. firm Merck in a $1 billion deal that bolsters its presence in Europe, Latin America and Asia."
2013-06-27,10:56 AM,South Africa's Aspen in $1 billion deal with Merck,"JOHANNESBURG Aspen Pharmacare said on Thursday that it would acquire drugs and a plant from U.S. firm Merck in a $1 billion deal that bolsters its presence in Europe, Latin America and Asia."
2013-06-27,3:16 PM,UPDATE 1-Aspen adds $1 bln deal with Merck to drug acquisition drive,"JOHANNESBURG, June 27 South Africa's Aspen Pharmacare said on Thursday it would acquire drugs and a manufacturing business from U.S. drugmaker Merck in a $1 billion deal to bolster its presence in Europe, Latin America and Asia."
2013-07-01,12:25 PM,FDA rejects Merck's insomnia drug,"Merck & Co Inc said the U.S. Food and Drug Administration rejected the company's experimental insomnia drug, citing safety issues."
2013-07-01,2:40 PM,"FDA rejects Merck insomnia drug, seeks lower-dose","U.S. health regulators have rejected Merck & Co's new insomnia drug application but opened the door to approving a lower-dose version of the medication, the company said on Monday."
2013-07-04,11:31 AM,"UPDATE 1-China probes pricing at drugmakers including GSK, Merck","* Top agency to review costs, prices at dozens of drugmakers"
2013-07-04,5:47 AM,"China probes pricing at drugmakers including GSK, Merck","SHANGHAI China's top economic planning agency is investigating costs and prices charged by drugmakers, including units of GlaxoSmithKline and Merck, as foreign firms come under pressure from Beijing over possible price-fixing."
2013-07-16,4:00 PM,U.S. FDA cancels advisory committee on Merck's drug sugammadex,"The U.S. Food and Drug Administration canceled an advisory committee meeting set for Thursday to discuss Merck & Co's sugammadex, a drug designed to reverse the effects of muscle-relaxants used during surgery."
2013-07-16,4:16 PM,Merck says FDA needs more time to complete sugammadex review,"July 16 Merck & Co Inc said on Tuesday that U.S. health regulators need more time to review its application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery."
2013-07-16,4:56 PM,UPDATE 3-Merck drug to reverse anesthesia delayed again at FDA,"WASHINGTON, July 16 U.S. health regulators need more time to review Merck & Co's application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery, the company said on Tuesday."
2013-07-16,6:35 PM,Merck drug to reverse anesthesia delayed again at FDA,"WASHINGTON U.S. health regulators need more time to review Merck & Co's application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery, the company said on Tuesday."
2013-07-24,1:45 PM,FDA accepts review of long-delayed Merck blood clot drug,"July 24 - Merck & Co on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke."
2013-07-24,2:46 PM,UPDATE 1-FDA accepts review of long-delayed Merck blood clot drug,"July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke."
2013-07-24,1:45 PM,FDA accepts review of long-delayed Merck blood clot drug,"July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke."
2013-07-30,11:16 AM,"Merck revenue misses mark as diabetes, arthritis drugs lag","July 30 Merck & Co's quarterly revenue fell short of Wall Street expectations, on lower sales of its consumer health and animal health products and weak growth of its treatments for diabetes and arthritis."
2013-07-30,11:37 AM,"UPDATE 2-Merck revenue hit by weak overseas, consumer sales",July 30 Merck & Co Inc's quarterly revenue fell short of  expectations on disappointing results for the company's consumer and animal health products and weak overseas sales of prescription drugs that were slammed by the stronger dollar.
2013-07-30,11:15 AM,"Merck revenues miss mark as diabetes, arthritis drugs lag","Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia."
2013-07-30,8:08 PM,"WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter",July 30 Big Pharma is still relying on belt-tightening to prop up financial results.
2013-07-30,8:10 PM,"Cost controls help Pfizer, Merck weather weak quarter",Big Pharma is still relying on belt-tightening to prop up financial results.
2013-08-08,12:20 AM,UPDATE 2-Tyson Foods to suspend buying cattle fed Zilmax additive,* Tyson concerned about cases of cattle with difficulty walking
2013-08-12,10:40 PM,UPDATE 1-U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay,"WASHINGTON, Aug 12 The U.S. Food and Drug Administration said on Monday it has approved GlaxoSmithKline Plc's drug Tivicay to treat the most common strain of HIV, the virus that causes AIDS."
2013-08-12,9:45 PM,Avanir Pharma to co-promote Merck's diabetes drugs; shares rise,Avanir Pharmaceuticals Inc said it signed a three-year agreement with Merck & Co Inc to co-promote Merck's multibillion-dollar drugs to treat Type 2 diabetes.
2013-08-13,5:31 PM,Merck to study industry use of cattle drug Zilmax,"CHICAGO, Aug 13 In the wake of mounting questions over its popular growth feed additive for cattle, Merck and Co's animal health unit said it is launching a five-step plan to reach out to cattle packers and suppliers in the next 30 days to address questions concerns over its drug Zilmax."
2013-08-13,10:11 PM,UPDATE 1-Merck rolls out new training program for Zilmax customers,"Aug 13 Pharmaceuticals giant, Merck and Co., facing questions from the cattle industry about the effects of its Zilmax feed additive  on the health of cattle, on Tuesday responded with plans for a new quality control program to ensure the popular weight-adding drug is properly used."
2013-08-13,5:35 PM,Merck rolls out new training program for Zilmax customers,"Pharmaceuticals giant, Merck and Co., facing questions from the cattle industry about the effects of its Zilmax feed additive on the health of cattle, on Tuesday responded with plans for a new quality control program to ensure the popular weight-adding drug is properly used."
2013-08-14,1:20 AM,UPDATE 2-Merck rolls out new training program for Zilmax customers,"Aug 13 As questions about the health effects of Merck and Co's Zilmax feed additive intensified in the beef industry, the pharmaceuticals giant on Tuesday unveiled a program to retrain and certify beef producers in administering the weight-adding drug to cattle."
2013-08-14,12:08 AM,Merck rolls out new training program for Zilmax customers,"As questions about the health effects of Merck and Co's Zilmax feed additive intensified in the beef industry, the pharmaceuticals giant on Tuesday unveiled a program to retrain and certify beef producers in administering the weight-adding drug to cattle."
2013-08-16,2:46 PM,"Merck suspends sales of Zilmax, to study use of cattle product","Aug 16 U.S. drugmaker Merck & Co on Friday said it would temporarily suspend sales of its Zilmax food additive following concerns about use of the product, which is given to cattle to increase their weight before slaughter."
2013-08-16,4:52 PM,"UPDATE 2-Amid cattle health concerns, Merck halts Zilmax sales","CHICAGO, Aug 16 U.S. drugmaker Merck & Co  said on Friday it is suspending sales of its Zilmax animal feed additive in the United States and Canada following concerns about animals showing signs of distress after use of the product, which is given to cattle to increase their weight before slaughter."
2013-08-16,4:53 PM,"Amid cattle health concerns, Merck halts Zilmax sales","CHICAGO U.S. drugmaker Merck & Co said on Friday it is suspending sales of its Zilmax animal feed additive in the United States and Canada following concerns about animals showing signs of distress after use of the product, which is given to cattle to increase their weight before slaughter."
2013-08-23,7:01 AM,"Q&A:-Animal welfare consultant Grandin on Zilmax, beta-agonists","Aug 22 Merck & Co. recruited Temple Grandin, an advocate for the humane treatment of livestock, to be on a board that will consult on the company's Zilmax feed additive, which has been temporarily taken off the U.S. and Canadian markets following animal welfare concerns."
2013-08-23,11:22 PM,Halt in Zilmax sales fuels demand for rival cattle feed product,* Some new Optaflexx feeders put on waiting list-customers
2013-08-23,11:27 PM,Halt in Zilmax sales fuels demand for rival cattle feed product,"CHICAGO Merck & Co's decision to suspend sales of its Zilmax cattle feed additive has caused such a surge in demand for rival Eli Lilly & Co's Optaflexx that Lilly is telling some new customers it cannot immediately supply them, customers told Reuters."
2013-08-26,11:01 AM,RPT-Halt in Zilmax sales fuels demand for rival cattle feed product,* Some new Optaflexx feeders put on waiting list-customers
2013-09-11,10:59 AM,AstraZeneca pays $50 million for rights to Merck cancer drug,Merck & Co Inc has licensed its experimental cancer drug to AstraZeneca Plc for a $50 million upfront fee in a deal that shows Britain's second-biggest drugmaker continuing to rebuild its pipeline.
2013-09-23,3:29 PM,UPDATE 1-Merck says FDA concerned about aspects of drug study,"Sept 23 Merck & Co Inc said on Monday that health regulators are concerned about operational aspects of a hypersensitivity study for sugammadex, an injection designed to reverse the effects of muscle relaxants used by anesthesiologists during surgery."
2013-09-23,3:33 PM,Merck says FDA concerned about aspects of drug study,"Merck & Co Inc said on Monday that health regulators are concerned about operational aspects of a hypersensitivity study for sugammadex, an injection designed to reverse the effects of muscle relaxants used by anesthesiologists during surgery."
2013-10-01,11:44 AM,"Merck plans $2.5 bln annual cost reductions, 8,500 job cuts","Oct 1 U.S. drugmaker Merck & Co, taking a cue from other drugmakers that have slashed research spending to prop up earnings, on Tuesday said it plans to cut annual operating costs by about $2.5 billion by the end of 2015 and eliminate 8,500 jobs."
2013-10-01,4:37 PM,"US STOCKS-Wall St climbs, expecting government shutdown will be brief",* U.S. government shutdown could hurt markets if prolonged
2013-10-01,12:22 PM,"UPDATE 5-Merck to slash annual costs by $2.5 bln, cut 8,500 jobs","Oct 1 Merck & Co, taking a cue from rival drugmakers that have slashed research spending to bolster earnings, said it will cut annual operating costs by $2.5 billion and eliminate 8,500 jobs, or more than 10 percent of its global workforce."
2013-10-01,11:50 AM,"Merck to slash annual costs by $2.5 billion, cut 8,500 jobs","Merck & Co, taking a cue from rival drugmakers that have slashed research spending to bolster earnings, said it will cut annual operating costs by $2.5 billion and eliminate 8,500 jobs, or more than 10 percent of its global workforce."
2013-10-01,9:34 PM,Merck drug triggers response in 24 pct of lung cancer patients,"Oct 1 Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment."
2013-10-01,9:34 PM,Merck drug triggers response in 24 percent of lung cancer patients,"Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment."
2013-10-09,1:10 AM,South Korea suspends some U.S. beef imports over feed additive,"SEOUL/CHICAGO South Korea has suspended some U.S. beef imports after detecting the cattle feed additive zilpaterol in meat supplied by a unit of JBS USA Holdings Inc, raising concerns that the controversial animal growth enhancer may still be in the supply chain weeks after Merck & Co halted sales of Zilmax, the top-selling zilpaterol-based drug."
2013-10-10,9:00 PM,Swift Beef plant in Texas cannot ship meat to South Korea -USDA,"CHICAGO, Oct 10 A Swift Beef Company plant in Cactus, Texas, is not eligible to ship beef to South Korea, the U.S. Department of Agriculture said on Thursday, one day after the country suspended some U.S. beef imports because it detected the cattle-feed-additive zilpaterol in meat supplied by the company."
2013-10-14,7:05 AM,"Roche to spend $880 million on manufacturing, create 500 jobs","ZURICH Swiss drugmaker Roche is to invest 800 million Swiss francs ($880 million) in its global manufacturing facilities over the next five years, creating 500 jobs, as it prepares for growing demand for its biologic medicines."
2013-10-28,11:20 AM,"Merck Q3 profit beats estimate, but Januvia sales slump","Oct 28 Merck & Co Inc reported better-than-expected third-quarter earnings, helped by cost cutting, but sales of its Januvia diabetes treatment fell, raising more concerns about growth prospects for the company's biggest product."
2013-10-28,12:21 PM,"US STOCKS-Futures edge higher, Apple to highlight earnings",* S&P 500 hit record close Friday after three weeks of gains
2013-10-28,1:15 PM,US STOCKS-Futures point to flat open after rally,* S&P 500 hit record close Friday after three weeks of gains
2013-10-28,2:12 PM,"US STOCKS-Wall St flat near record levels, Merck falls","NEW YORK, Oct 28 U.S. stocks were little change on Monday as investors found few reasons to keep pushing shares higher after the S&P 500 climbed to a series of records on expectations for continuing Federal Reserve stimulus."
2013-10-28,4:22 PM,US STOCKS-Wall St little changed at record levels; Merck slips,"* Dow off 0.08 pct, S&P 500 up 0.04 pct, Nasdaq off 0.26 pct"
2013-10-28,11:30 AM,"UPDATE 4-Merck's Januvia, animal health products slump; shares off","Oct 28 Merck & Co Inc reported lower sales of its Januvia diabetes treatment, fresh evidence its biggest product is losing ground to newer drugs, and also spooked investors with falling  quarterly sales of its animal health products."
2013-10-28,11:20 AM,"Merck's Januvia, animal health products slump; shares off","Merck & Co Inc  reported lower sales of its Januvia diabetes treatment, fresh evidence its biggest product is losing ground to newer drugs, and also spooked investors with falling quarterly sales of its animal health products."
2013-10-28,6:52 PM,US STOCKS-Wall St inches higher on Fed expectations; Apple up,"NEW YORK, Oct 28 U.S. stocks edged higher on Monday, pushing the S&P 500 to another intraday high, with expectations high the Federal Reserve will keep its stimulus in place for the time being."
2013-10-28,8:53 PM,"US STOCKS-S&P 500 ends at record on Fed hopes; Dow, Nasdaq flat","* Dow down 0.01 pct, S&P 500 up 0.1 pct, Nasdaq down 0.1 pct"
2013-10-28,10:07 PM,US STOCKS-S&P 500 ends at record high on Fed hopes,"* Dow down 0.01 pct, S&P 500 up 0.1 pct, Nasdaq down 0.1 pct"
2013-10-29,11:13 AM,Taiwan detects more U.S. beef with banned feed additive,"TAIPEI, Oct 29 Taiwan detected cattle feed additive zilpaterol in U.S. beef, the third such incident in less than a month in Asia, heightening concerns across the region over banned animal growth drugs."
2013-10-29,11:21 AM,Taiwan detects more U.S. beef with banned feed additive,"TAIPEI Taiwan detected cattle feed additive zilpaterol in U.S. beef, the third such incident in less than a month in Asia, heightening concerns across the region over banned animal growth drugs."
2013-10-29,10:21 PM,"Exclusive: Merck works toward bringing Zilmax back to the U.S., Canada market","CHICAGO U.S. drugmaker Merck & Co told Reuters on Tuesday that it plans to bring its Zilmax animal feed additive back for sale in the United States and Canada, after it completes an audit of how the muscle-building cattle feed product is used in the agriculture sector."
2013-10-30,2:49 AM,"Exclusive: Merck works toward bringing Zilmax back to U.S., Canada","CHICAGO U.S. drugmaker Merck & Co plans to resume sales of the controversial Zilmax animal feed additive in the United States and Canada after it completes an audit of how the product is used, a spokeswoman said on Tuesday."
2013-10-31,7:09 PM,"Analysis: For Merck, bringing cattle feed Zilmax back won't be easy","U.S. pharmaceutical giant Merck & Co  faces significant challenges bringing its controversial feed additive Zilmax back to market in the United States and Canada, even after a vote of confidence from South Korea on Thursday."
2013-11-02,1:30 PM,High cure rates seen with Merck oral hepatitis drugs -study,"Nov 2 A combination of two oral hepatitis C treatments developed by Merck & Co led to high cure rates in previously untreated patients, indicating the company is a contender in the race to find new treatments for the liver destroying virus."
2013-11-02,1:40 PM,High cure rates seen with Merck oral hepatitis drugs: study,"A combination of two oral hepatitis C treatments developed by Merck & Co led to high cure rates in previously untreated patients, indicating the company is a contender in the race to find new treatments for the liver destroying virus."
2013-11-03,5:25 PM,Merck experimental vaccine shows promise in cancer trial: WSJ,"Merck & Co Inc's experimental cancer vaccine appeared to provide broader protection against a cancer-causing virus than the company's Gardasil shot did in clinical trials, the Wall Street Journal said on Sunday."
2013-11-13,4:31 PM,U.S. heart guidelines may threaten hot new cholesterol drugs,"Nov 13 New U.S. guidelines on heart health that favor potent statins may threaten use or even approval of a hot new class of experimental cholesterol drugs that have been billed as revolutionary new treatments with blockbuster sales potential, analysts said on Wednesday."
2013-11-13,4:35 PM,U.S. heart guidelines threaten hot new cholesterol drugs,"New U.S. guidelines on heart health that favor potent statins may threaten future use, or even approval, of a hot new class of experimental cholesterol drugs called PCSK9 inhibitors that have been billed as potential blockbuster treatments, analysts said on Wednesday."
2013-11-15,9:46 AM,CORRECTED-Merck invests $107 million in China drug plant,"(Corrects company name and RIC to Merck KGaA in para 1, deletes reference to Merck in para 6)"
2013-11-15,10:10 AM,Merck invests $107 million in China drug plant,"SHANGHAI German drugmaker Merck KGaA has invested 80 million euros ($107.67 million) in a manufacturing plant in China, the company said on Friday, underlining the importance of the market for global drug firms."
2013-11-18,5:00 PM,Merck trial shows more melanoma cancer patients respond to drug,"Nov 18 Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, show that about half of advanced melanoma patients treated with the highest dose of the drug experienced tumor shrinkage."
2013-11-18,5:10 PM,Merck trial shows more melanoma cancer patients respond to drug,"Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, show that about half of advanced melanoma patients treated with the highest dose of the drug experienced tumor shrinkage."
2013-11-19,1:30 PM,Merck brings maternity program from poor nations to U.S. as deaths rise,"NEW YORK, Nov 19 Merck & Co on Tuesday said it is expanding its ""Merck for Mothers"" program, which aims to reduce pregnancy-related deaths from impoverished countries such as Senegal and Zambia, to the United States - a stark reminder of how far the country lags other wealthy nations on key measures of health."
2013-11-19,1:55 PM,Merck brings maternity program from poor nations to U.S. as deaths rise,"NEW YORK Merck & Co on Tuesday said it is expanding its ""Merck for Mothers"" program, which aims to reduce pregnancy-related deaths from impoverished countries such as Senegal and Zambia, to the United States - a stark reminder of how far the country lags other wealthy nations on key measures of health."
2013-12-02,3:25 PM,"Forest Labs plans to buy schizophrenia drug, cut costs","Dec 2 Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it planned to buy rights to a new schizophrenia drug from Merck & Co and cut its annual operating costs by $500 million in 2016."
2013-12-02,5:35 PM,"UPDATE 2-Forest Labs to buy schizophrenia drug, cut costs","Dec 2 Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it plans to buy rights to a new schizophrenia treatment from Merck & Co and cut annual operating costs by $500 million in fiscal 2016."
2013-12-02,3:35 PM,"Forest Labs to buy schizophrenia drug, cut costs","Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it plans to buy rights to a new schizophrenia treatment from Merck & Co and cut annual operating costs by $500 million in fiscal 2016."
2013-12-05,7:26 AM,Merck KGaA to buy AZ Electronic Materials for $2.6 billion,"FRANKFURT, Dec 5 Germany's Merck, the world's largest maker of liquid crystals for flat panel displays, said it agreed to buy Britain's AZ Electronic Materials for about 1.6 billion pounds ($2.61 billion) in cash, to diversify its offering of chemicals for the electronics industry."
2013-12-05,8:36 AM,UPDATE 2-Germany's Merck to buy hi-tech materials firm AZ for $2.6 bln,"FRANKFURT/LONDON, Dec 5 Merck, the world's largest maker of liquid crystals used in TVs, tablet and smartphone screens, has agreed to buy Britain's AZ Electronic Materials for $2.6 billion to expand its range of specialist chemicals for hi-tech gadgets."
2013-12-05,11:36 AM,Germany's Merck to buy hi-tech materials firm AZ for $2.6 billion,"FRANKFURT/LONDON Merck , the world's largest maker of liquid crystals used in TVs, tablet and smartphone screens, has agreed to buy Britain's AZ Electronic Materials  for $2.6 billion to expand its range of specialist chemicals for hi-tech gadgets."
2013-12-05,11:36 AM,European shares continue to wobble amid taper worries,"* FTSEurofirst 300 down 0.1 pct, Euro STOXX 50 off 0.1 pct"
2013-12-05,11:30 AM,Germany's Merck to buy hi-tech materials firm AZ for $2.6 billion,"FRANKFURT/LONDON Merck, the world's largest maker of liquid crystals used in TVs, tablet and smartphone screens, has agreed to buy Britain's AZ Electronic Materials for $2.6 billion to expand its range of specialist chemicals for hi-tech gadgets."
2013-12-09,7:50 PM,Merck agrees to settle litigation over Fosamax jaw injuries,"NEW YORK, Dec 9 Merck & Co has agreed to settle hundreds of lawsuits over jaw injuries allegedly caused by the osteoporosis drug Fosamax, lawyers disclosed at a court hearing Monday."
2013-12-09,10:02 PM,UPDATE 1-Merck agrees to proposed $27.7 mln settlement over Fosamax lawsuits,"NEW YORK, Dec 9 Merck & Co Inc said on Monday that it was prepared to pay $27.7 million to settle lawsuits by hundreds of people who sued the company over allegations that its osteoporosis drug Fosamax caused bones in the jaw to deteriorate."
2013-12-09,7:50 PM,Merck agrees to proposed $27.7 million settlement over Fosamax lawsuits,NEW YORK Merck & Co Inc said on Monday that it was prepared to pay $27.7 million to settle lawsuits by hundreds of people who sued the company over allegations that its osteoporosis drug Fosamax caused bones in the jaw to deteriorate.
2013-12-10,1:45 PM,Merck moves Alzheimer's drug into big trial after safety review,"Dec 10 Merck & Co said it will advance its experimental Alzheimer's drug into late-stage trials among patients with mild to moderate disease, after an independent monitoring board reviewed its safety and recommended the trial continue to recruit patients."
2013-12-10,1:50 PM,Merck moves Alzheimer's drug into big trials after safety review,"Merck & Co said it will begin two late-stage trials of its experimental Alzheimer's drug, one of the industry's best hopes for slowing the memory-robbing disease, after an independent monitoring board reviewed its safety and recommended that more patients be recruited for studies."
2013-12-11,9:36 PM,US FDA panel backs allergy drug of France's Stallergenes,Dec 11 An oral immunotherapy drug for treating grass pollen allergies was backed by an independent advisory panel to the U.S. Food and Drug Administration on Wednesday.
2013-12-12,8:10 PM,FDA panel says Merck's allergy drug effective,Dec 12 A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck & Co  was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children.
2013-12-12,8:30 PM,FDA panel says Merck's allergy drug effective,A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck & Co was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children.
2013-12-13,4:05 PM,FDA panel says Merck's allergy drug effective,A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck & Co was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children.
2013-12-19,2:05 PM,"French watchdog fines Merck, Reckitt in Subutex generics dispute","PARIS, Dec 19 The French competition authority said on Thursday it had fined Schering-Plough, now owned by Merck, 15.3 million euros ($21 million) over what it called a smear campaign against generic competition to Subutex, its drug for opioid addiction."
2013-12-19,2:10 PM,"French watchdog fines Merck, Reckitt in Subutex generics dispute","PARIS The French competition authority said on Thursday it had fined Schering-Plough, now owned by Merck, 15.3 million euros ($21 million) over what it called a smear campaign against generic competition to Subutex, its drug for opioid addiction."
2013-12-23,2:56 PM,UPDATE 1-Weak nausea drug data knocks back Tesaro shares,"Dec 23 Tesaro Inc's experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) failed to show enough benefit in trials to give it an edge over competing drugs, sending its shares down as much as 24 percent."
2013-12-24,2:56 PM,"UPDATE 1-FDA rejects Actavis' contraceptive patch, seeks more data",Dec 24 Actavis Plc said U.S. health regulators denied approval to its contraceptive patch for women and asked for more data.
2013-12-30,8:45 PM,"SPECIAL REPORT-Lost hooves, dead cattle before Merck halted Zilmax sales","WALLA WALLA COUNTY, WASHINGTON, Dec 30 The U.S. beef industry's dependence on the muscle-building drug Zilmax began unraveling here, on a sweltering summer day, in the dusty cattle pens outside a Tyson Foods Inc slaughterhouse in southeastern Washington state."
2013-12-30,9:03 PM,"Special Report: Lost hooves, dead cattle before Merck halted Zilmax sales","WALLA WALLA COUNTY, WASHINGTON The U.S. beef industry's dependence on the muscle-building drug Zilmax began unraveling here, on a sweltering summer day, in the dusty cattle pens outside a Tyson Foods Inc slaughterhouse in southeastern Washington state."
2013-12-31,8:19 AM,"Special Report: Lost hooves, dead cattle before Merck halted Zilmax sales","WALLA WALLA COUNTY, WASHINGTON The U.S. beef industry's dependence on the muscle-building drug Zilmax began unraveling here, on a sweltering summer day, in the dusty cattle pens outside a Tyson Foods Inc slaughterhouse in southeastern Washington state."
2014-01-09,2:50 AM,Novartis in talks with Merck to exchange business units- Bloomberg,"Jan 8 Novartis AG is in talks with Merck & Co Inc to exchange its animal-health and human vaccines businesses for the drugmaker's over-the-counter health-products unit, Bloomberg reported, quoting people familiar with the matter."
2014-01-09,2:20 PM,UPDATE 1-Novartis and Merck discuss earnings-boosting asset swap,"* Novartis may swap animal health, vaccines for Merck's OTC"
2014-01-09,2:25 PM,Novartis and Merck discuss earnings-boosting asset swap,LONDON/FRANKFURT Novartis AG  is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc's  over-the-counter products unit in a deal that could boost earnings at both companies.
2014-01-13,1:35 PM,Merck's anti-blood clot drug should be approved -U.S. FDA staff,"Jan 13 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved based on ""robustly positive"" clinical trial results, according to a preliminary review of the data by the U.S. Food and Drug Administration."
2014-01-13,2:01 PM,Merck says consumer or animal health move possible in 2014,Jan 13 Merck & Co said on Monday it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year.
2014-01-13,1:55 PM,UPDATE 2-Merck's anti-blood clot drug should be approved -U.S. FDA review,"Jan 13 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved, based on ""robustly positive"" clinical trial results, according to a preliminary review of the data by the U.S. Food and Drug Administration."
2014-01-13,2:00 PM,Merck's anti-blood clot drug should be approved: FDA review,"Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved, based on ""robustly positive"" clinical trial results, according to a preliminary review of the data by the U.S. Food and Drug Administration."
2014-01-13,3:15 PM,US STOCKS-Wall St flat on earnings caution; Merck climbs,"* Merck climbs after prelim FDA review, strategic options plans"
2014-01-13,4:55 PM,US STOCKS-Wall St down modestly on earnings caution; Merck gains,"* Indexes: Dow down 0.1 pct, S&P down 0.1 pct, Nasdaq flat"
2014-01-13,6:15 PM,US STOCKS-Wall St dips ahead of earnings flurry,"NEW YORK, Jan 13 U.S. stocks fell on Monday as investors awaited an onslaught of corporate results to gauge how companies are faring amid mixed signs on economic growth."
2014-01-13,5:05 PM,UPDATE 2-Merck shares jump on early filing for skin cancer drug,"Jan 13 Shares of Merck & Co Inc rose as much as 6.5 percent Monday after it filed the first part of an application to market its experimental drug, MK-3475, for advanced melanoma, putting the treatment on track to become the first in a new class of promising cancer drugs to reach the market."
2014-01-13,5:06 PM,Merck shares jump on early filing for skin cancer drug,"Shares of Merck & Co Inc  rose as much as 6.5 percent Monday after it filed the first part of an application to market its experimental drug, MK-3475, for advanced melanoma, putting the treatment on track to become the first in a new class of promising cancer drugs to reach the market."
2014-01-14,4:48 PM,"Merck needs a dose of joie de vivre, research chief says","SAN FRANCISCO Merck & Co's  researchers need to regain their confidence after an eight-year drought in developing important new medicines sapped employee morale, the company's recently hired research chief told Reuters."
2014-01-15,9:21 PM,FDA advisory panel backs Merck's blood clot-preventing drug,"Jan 15 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday."
2014-01-15,10:31 PM,UPDATE 1-FDA advisory panel backs Merck's blood clot-preventing drug,"Jan 15 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday."
2014-01-15,9:20 PM,FDA advisory panel backs Merck's blood clot-preventing drug,"Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday."
2014-01-23,7:40 AM,BRIEF-Hi-tech material firm AZ says Merck's offer extended to Feb. 5,"Jan 23 AZ Electronic Materials SA :  * Announcement of level of acceptances, extension of offer from Merck * Source text for Eikon:  * For more news, please click here"
2014-01-24,5:41 PM,No serious side effects with Merck allergy pill -FDA documents,"Jan 24 No serious safety concerns were raised over Merck & Co's experimental pill for ragweed allergies, according to FDA documents Friday, ahead of a meeting next week of outside medical experts who will discuss whether the drug merits approval."
2014-01-24,5:51 PM,No serious side effects with Merck allergy pill: FDA documents,"No serious safety concerns were raised over Merck & Co's experimental pill for ragweed allergies, according to FDA documents Friday, ahead of a meeting next week of outside medical experts who will discuss whether the drug merits approval."
2014-01-28,6:57 PM,"U.S. FDA panel: data support safety, efficacy of Merck allergy drug","Jan 28 Merck & Co's experimental allergy drug, Ragwitek, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday."
2014-01-28,7:12 PM,"UPDATE 1-U.S. FDA panel: data support safety, efficacy of Merck allergy drug","Jan 28 Merck & Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday."
2014-01-28,7:02 PM,"U.S. FDA panel: data support safety, efficacy of Merck allergy drug","Merck & Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday."
2014-01-31,7:00 PM,Merck gets buyout interest for consumer health unit -sources,"NEW YORK, Jan 31 Merck & Co Inc has received approaches from large consumer companies interested in buying its consumer healthcare business, best known for Coppertone sunscreen and Claritin allergy medicine, according to people familiar with the matter."
2014-01-31,7:06 PM,Merck gets buyout interest for consumer health unit: sources,"NEW YORK Merck & Co Inc  has received approaches from large consumer companies interested in buying its consumer healthcare business, best known for Coppertone sunscreen and Claritin allergy medicine, according to people familiar with the matter."
2014-02-03,6:30 AM,"BRIEF-Ablynx, Merck sign cancer immunotherapy collaboration, licensing agreement","BRUSSELS, Feb 3 Ablynx NV :  * Announces worldwide cancer immunotherapy discovery collaboration and licensing agreement with Merck   * Collaboration, licensing agreement is focused on the discovery and development of several predefined nanobody candidates  * Co will receive an upfront payment of 20 mln euros; up to 10.7 mln euros in research funding during the initial three year  * Is eligible to receive development, regulatory and commercial milestone payments on achieved sales thre"
2014-02-03,7:20 AM,Ablynx signs Merck deal worth up to 1.7 bln euros,"BRUSSELS, Feb 3 Belgian biotech company Ablynx  has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.29 billion) to develop potential new treatments for cancer."
2014-02-03,9:41 AM,"FTSE inches lower, pulled down by Lloyds",* Lloyds falls; delays dividend prospect after mis-selling charge
2014-02-03,12:30 PM,UPDATE 1-Ablynx agrees Merck cancer deal worth up to 1.7 bln euros,"* Ablynx initially to get 20 mln euros, plus 10.7 mln for research"
2014-02-03,7:55 AM,Ablynx agrees Merck cancer deal worth up to 1.7 billion euros,BRUSSELS Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.3 billion) to develop ways of triggering the body to fight cancer by itself.
2014-02-05,12:15 PM,Merck 4th-quarter sales just miss Wall St estimate,"Feb 5 Merck & Co Inc reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines."
2014-02-05,12:55 PM,CORRECTED-US STOCKS-Futures dip modestly ahead of private jobs data,(Corrects time of release of ADP data to 8:15 a.m. from 8:30 a.m.)
2014-02-05,1:30 PM,CANADA STOCKS-TSX may open lower despite strong euro data,Feb 5 Canada's main stock index looked set to reverse the previous session's gains on Wednesday even as upbeat euro zone economic data pointed to a gradual recovery in the currency bloc.
2014-02-05,1:50 PM,US STOCKS-Wall Street to fall after jobs data; services eyed,"* ADP report a tick below expectations, Dec. revised lower"
2014-02-05,12:35 PM,"UPDATE 3-Merck results flag, but cancer-drug deals lift shares","Feb 5 Merck & Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but the company announced potentially lucrative new cancer-drug partnerships with rival U.S. drugmakers."
2014-02-05,12:17 PM,"Merck results flag, but cancer-drug deals lift shares","Merck & Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but the company announced potentially lucrative new cancer-drug partnerships with rival U.S. drugmakers."
2014-02-06,6:26 AM,PRESS DIGEST - Wall Street Journal - Feb 6,Feb 6 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
2014-02-06,9:06 AM,Merck extends offer for AZ Electronic takeover to Feb. 18,"FRANKFURT, Feb 6 Germany's Merck on Thursday extended the offer period for its planned $2.6 billion takeover of Britain's AZ Electronic Materials to Feb. 18."
2014-02-06,2:05 PM,AstraZeneca takes on Merck in Alzheimer's drug race,"LONDON, Feb 6 AstraZeneca is moving an experimental Alzheimer's drug into late-stage development, taking on U.S. rival Merck & Co which announced plans to start similar final-stage research in December."
2014-02-06,11:10 PM,Merck to settle NuvaRing lawsuits for $100 mln -media report,"Feb 6 Merck & Co has agreed to pay $100 million to settle hundreds of lawsuits accusing the U.S. drugmaker of downplaying serious health risks associated with its NuvaRing contraceptive device, Bloomberg reported on Thursday, citing people familiar with the deal."
2014-02-07,3:05 PM,Merck to pay $100 mln in NuvaRing contraceptive settlement,Feb 7 Merck & Co said on Friday it has agreed to pay $100 million to resolve all U.S. product liability lawsuits involving its NuvaRing contraceptive product.
2014-02-07,3:46 PM,UPDATE 2-Merck to pay $100 mln in NuvaRing contraceptive settlement,Feb 7 Merck & Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.
2014-02-07,3:20 PM,Merck to pay $100 million in NuvaRing contraceptive settlement,Merck & Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.
2014-02-07,11:05 PM,"Merck, Utrecht University to research pig virus vaccine","CHICAGO, Feb 7 Merck Animal Health, a division of Merck & Co., entered into a 12-month research agreement with Utrecht University to develop a vaccine for Porcine Epidemic Diarrhea virus (PEDv), a deadly pig virus spreading across the U.S. farm belt, the company said."
2014-02-07,11:10 PM,"Merck, Utrecht University to research pig virus vaccine","CHICAGO Merck Animal Health, a division of Merck & Co., entered into a 12-month research agreement with Utrecht University to develop a vaccine for Porcine Epidemic Diarrhea virus (PEDv), a deadly pig virus spreading across the U.S. farm belt, the company said."
2014-02-10,4:42 PM,Merck joins race to copy Sanofi's diabetes drug Lantus,"Feb 10 U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi's  top-selling insulin treatment Lantus, increasing the long-term threat to the French company's $7 billion-a-year product."
2014-02-10,5:20 PM,Merck joins race to copy Sanofi's diabetes drug Lantus,"U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi's top-selling insulin treatment Lantus, increasing the long-term threat to the French company's $7 billion-a-year product."
2014-02-19,9:15 PM,"Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources","NEW YORK/LONDON A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter."
2014-02-20,4:06 AM,Market Chatter- Corporate finance press digest,Feb 20 The following corporate finance-related stories were reported by media:
2014-02-20,6:00 AM,UPDATE 1-Market Chatter-Corporate finance press digest,Feb 20 The following corporate finance-related stories were reported by media:
2014-03-04,10:30 PM,Merck says dust mite allergy drug reduces symptoms in midstage study,"March 4 An immunotherapy pill to treat an allergy to house dust mites being tested by Merck & Co  significantly reduced common nasal symptoms, such as sneezing and stuffy nose, according to data from a midstage clinical trial, the company said on Tuesday."
2014-03-05,10:57 PM,Merck hepatitis C drugs work in HIV co-infected patients -study,"March 5 A combination of oral drugs for hepatitis C developed by Merck & Co appeared to be well tolerated and highly effective in treating the liver disease in patients also infected with HIV, according to data from a midstage clinical trial presented on Wednesday."
2014-03-14,9:15 PM,CORRECTED-Amgen vaccine triggers immune response in advanced melanoma -study,"(In 2nd paragraph adds dropped word ""not"" to show that vaccine also shrank tumors not injected with the drug.)"
2014-03-26,2:45 PM,Merck plans to propose two-for-one share split,"FRANKFURT, March 26 German liquid crystal maker Merck will propose a two-for-one share split in order to attract more private investors, it said on Wednesday."
2014-03-26,10:26 PM,"Merck, Glaxo end co-pay assistance for Obamacare plans",March 26 Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.
2014-03-26,11:20 PM,"Merck, Glaxo end co-pay assistance for Obamacare plans",Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.
2014-03-27,11:55 AM,CORRECTED-Merck appoints Baxter executive as CFO,"(Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)"
2014-03-27,12:04 PM,Merck appoints Baxter executive as CFO,"Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg."
2014-03-27,12:50 PM,UPDATE 2-Merck names Baxter exec as CFO,"March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators."
2014-03-27,5:03 PM,Merck names Baxter exec as CFO,"Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators."
2014-04-01,3:21 AM,S.Korea to allow sales of Merck's Zilmax from June,"SEOUL, April 1 South Korea will allow certain levels of animal feed additive zilpaterol in beef from June, a government official said on Tuesday, opening the door to imports of some meat containing the growth enhancer and its domestic sale."
2014-04-02,8:46 AM,UPDATE 1-Stallergenes wins U.S. go-ahead for Oralair allergy pill,* Merck and partner ALK Abello expected to launch rival drug this year
2014-04-04,5:45 PM,"Exclusive: Merck wants to test Zilmax on 240,000 cattle but beef industry resists","CHICAGO Merck & Co Inc wants to feed its controversial feed additive Zilmax to 240,000 U.S. cattle to prove it is safe. But there is a problem: giant meat processors like Cargill Inc don't want to touch animals fed with the drug."
2014-04-08,11:07 PM,Untaxed U.S. corporate profits held overseas top $2.1 trln -study,* Senate Finance Committee Chairman Wyden calls for reform
2014-04-10,5:00 AM,Merck hepatitis C drugs shine in easier to treat patients -study,"April 10 A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field."
2014-04-10,5:20 AM,Merck hepatitis C drugs shine in easier to treat patients: study,"A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field."
2014-04-14,10:36 PM,Merck's grass pollen allergy vaccine wins U.S. approval,"April 14 Merck & Co Inc said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy vaccine, Grastek, for patients aged 5 to 65."
2014-04-14,11:58 PM,UPDATE 1-Merck's grass pollen allergy drug wins U.S. approval,"April 14 Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks."
2014-04-14,10:41 PM,Merck's grass pollen allergy drug wins U.S. approval,"Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks."
2014-04-17,7:00 PM,CORRECTED-Merck's ragweed pollen allergy drug gets U.S. approval,"(Corrects fourth paragraph to say Grastek, not Ragwitek, will compete with Stallergenes' drug)"
2014-04-17,7:05 PM,Merck's ragweed pollen allergy drug gets U.S. approval,The U.S. Food and Drug Administration has approved Merck & Co's pollen allergy drug Ragwitek.
2014-04-24,6:12 PM,Fitch Affirms Merck & Co.'s Long-term IDR at 'A+'; Outlook Remains Negative,"(The following statement was released by the rating agency) CHICAGO, April 24 (Fitch) Fitch Ratings has affirmed Merck & Co.'s (Merck)  long-term ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating  Outlook remains Negative. In addition, Fitch has affirmed the company's  short-term ratings at 'F1'. A full list of rating actions follows at the end of  this release.  The ratings apply to approximately $24.6 billion in outstanding debt.  KEY RATING DRIVERS The Negative Outlook ma"
2014-04-26,5:27 PM,Exclusive: Merck in final talks to sell consumer unit for near $14 billion - sources,"LONDON/NEW YORK Merck & Co Inc is in the final stages of selling its consumer healthcare unit for close to $14 billion, with Bayer AG and Reckitt Benckiser Group Plc among final contenders to clinch a deal as soon as next week, people familiar with the matter said."
2014-04-28,4:20 PM,Reckitt Benckiser confirms talks to buy Merck unit,"LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals."
2014-04-28,4:46 PM,RPT-Reckitt Benckiser confirms talks to buy Merck unit,"LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals."
2014-04-28,5:45 PM,UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unit,"LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals."
2014-04-28,4:30 PM,Reckitt Benckiser confirms talks to buy Merck unit,"LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals."
2014-04-28,8:11 PM,Deals of the day- Mergers and acquisitions,"(Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)"
2014-04-29,5:56 PM,"US STOCKS-Wall St gains with upbeat earnings, more deal activity","* Indexes up: Dow 0.6 pct, S&P 0.5 pct, Nasdaq 0.7 pct   (Updates to afternoon, changes byline)"
2014-04-29,11:47 AM,"UPDATE 2-Merck 1st-quarter profit tops estimate, but revenue misses","April 29 Merck & Co Inc reported better-than-expected quarterly earnings, helped by sharply lower research spending and asset sales, but revenue came in slightly below expectations."
2014-04-29,11:24 AM,"Merck first-quarter profit tops estimate, but revenue misses","Merck & Co Inc  reported better-than-expected quarterly earnings, helped by sharply lower research spending and asset sales, but revenue came in slightly below expectations. | Video"
2014-04-29,8:01 PM,"Bayer offers animal health assets, cash for Merck's OTC unit -sources","FRANKFURT/NEW YORK, April 29 Bayer AG  is offering to swap its animal health assets with Merck & Co Inc's consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg up in the $14 billion auction of the Merck business."
2014-04-29,8:35 PM,"US STOCKS-Wall St ends up on earnings, rebound in high-growth shares","* Indexes up: Dow 0.5 pct, S&P 0.5 pct, Nasdaq 0.7 pct   (Updates to close)"
2014-04-29,8:41 PM,"UPDATE 1-Bayer offers animal health assets, cash for Merck's OTC unit -sources","FRANKFURT/NEW YORK, April 29 Bayer AG  is offering to swap its animal health assets for Merck & Co Inc's consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg up in the $14 billion auction of the Merck business."
2014-04-29,8:05 PM,"Bayer offers animal health assets, cash for Merck's OTC unit -sources","FRANKFURT/NEW YORK Bayer AG  is offering to swap its animal health assets for Merck & Co Inc's  consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg up in the $14 billion auction of the Merck business."
2014-04-29,8:55 PM,"US STOCKS-Wall St ends up on earnings, rebound in high-growth shares","* Indexes up: Dow 0.5 pct, S&P 0.5 pct, Nasdaq 0.7 pct   (Updates with eBay down after the bell)"
2014-04-29,11:52 AM,"Wall Street ends up on earnings, rebound in high-growth shares","NEW YORK U.S. stocks rose on Tuesday, boosted by upbeat results from companies including Merck & Co and a rebound in Facebook and other high-growth shares."
2014-04-30,3:02 AM,India Morning Call-Global Markets,"NEW YORK - U.S. stocks rose on Tuesday, boosted by upbeat results from companies including Merck & Co and a rebound in Facebook and other high-growth shares."
2014-04-30,5:11 PM,Reckitt Benckiser says no longer in talks with Merck,"LONDON, April 30 Reckitt Benckiser Group  is no longer in active talks with Merck & Co about buying its consumer health business, the company said on Wednesday."
2014-04-30,5:45 PM,UPDATE 2-Reckitt Benckiser says no longer in talks with Merck,"* No final decision made by Merck   (Adds background, context, byline, bullet points)"
2014-04-30,5:15 PM,Reckitt Benckiser says no longer in talks with Merck,"LONDON Reckitt Benckiser Group  said on Wednesday it was no longer in active talks with Merck & Co  about buying its consumer health business, leaving Germany's Bayer  as a leading contender for the $14 billion business."
2014-04-30,9:56 AM,Deals of the day- Mergers and acquisitions,"(Adds Shell, Vale, Etihad Etisalat, America Movil and others; updates Exelon Corp)"
2014-04-30,8:12 PM,Exclusive: Merck explores $15 billion-plus drug portfolio sale,"NEW YORK/LONDON Merck & Co Inc  is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter, as the U.S. drugmaker continues to streamline businesses to focus on high-growth areas."
2014-05-01,6:06 AM,UK Stocks-Factors to watch on May 1,"LONDON, May 1 Britain's FTSE 100 index is seen opening 5 points higher, or 0.07 percent, according to financial bookmakers."
2014-05-01,6:46 AM,UPDATE 1-UK Stocks-Factors to watch on May 1,"LONDON, May 1 Britain's FTSE 100 index is seen opening 5 points higher, or 0.07 percent, according to financial bookmakers. Futures for the index are up 0.2 percent by 0639 GMT."
2014-05-01,7:26 PM,Bayer nears deal to buy Merck consumer unit: sources,"LONDON/NEW YORK German drugmaker Bayer AG  is nearing an agreement to buy Merck & Co Inc's  consumer healthcare unit, people familiar with the matter said, in a deal that could value the business at around $14 billion."
2014-05-01,7:25 PM,REFILE-Bayer nears deal to buy Merck consumer unit -sources,"LONDON/NEW YORK, May 1 German drugmaker Bayer AG  is nearing an agreement to buy Merck & Co Inc's  consumer healthcare unit, people familiar with the matter said, in a deal that could value the business at around $14 billion."
2014-05-02,12:35 PM,Merck and Endocyte's ovarian cancer drug fails in trial,May 2 Merck & Co Inc and Endocyte Inc  said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.
2014-05-02,12:40 PM,Merck and Endocyte's ovarian cancer drug fails in trial,Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.
2014-05-02,1:35 PM,"UPDATE 2-Endocyte's ovarian cancer drug fails trial, shares sink","* Endocyte shares fall as much as 63 pct   (Adds analyst comments, background; updates stock movement)"
2014-05-02,4:25 PM,"Endocyte's ovarian cancer drug fails trial, shares sink","Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug as it failed to improve survival rates without the cancer worsening, sending Endocyte's shares tumbling as much as 63 percent."
2014-05-04,12:00 PM,DEALTALK-Big Pharma stands to profit by cleaning out its medicine chests,"NEW YORK, May 4 Leading global pharmaceutical companies have started to view their vast portfolios of older, established prescription drugs as vehicles for raising large sums of cash to fuel development of new medicines with far higher profit margins."
2014-05-06,12:32 PM,Bayer says looking for opportunities to grow animal health unit,"FRANKFURT Bayer said it was looking for opportunities to expand its in animal health unit, even after it agreed to buy Merck & Co's non-prescription drugs business for $14.2 billion."
2014-05-06,3:20 PM,"Merck to seek approval of osteoporosis drug, cites safety risks",May 6 Merck & Co said on Tuesday it plans to seek marketing approvals this year for an osteoporosis drug and a product to reverse the effects of anesthesia that have long been delayed by safety concerns.
2014-05-06,3:30 PM,"Merck to seek approval of osteoporosis drug, cites safety risks",Merck & Co said on Tuesday it plans to seek marketing approvals this year for an osteoporosis drug and a product to reverse the effects of anesthesia that have long been delayed by safety concerns.
2014-05-06,4:56 PM,BRIEF-Merck CEO says would be interested in buying animal health brands at right price,May 6 Merck & Co Inc :  * CEO says would be interested in buying animal health brands if they are
2014-05-06,10:40 AM,UPDATE 3-Bayer wins Merck & Co's $14 bln consumer unit auction,* Bayer to become OTC drug market's second biggest operator
2014-05-06,10:14 AM,Bayer wins Merck & Co's $14 billion consumer unit auction,"FRANKFURT Germany's Bayer AG has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare industry."
2014-05-06,11:25 AM,Bayer wins Merck & Co's $14 bln consumer unit auction,"FRANKFURT Germany's Bayer AG has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare industry."
2014-05-06,6:46 PM,Fitch: Merck Consumer Business Sale Improves Its Core Focus,"(The following statement was released by the rating agency) NEW YORK, May 06 (Fitch) The sale of Merck's consumer products business will  increase the company's focus on its core mission of developing and marketing  innovative medicines, according to Fitch Ratings. German-based Bayer AG Tuesday  said it planned to buy Merck's consumer health unit for $14.2 billion. The transaction is consistent with Fitch's expectation that a number of major  pharmaceutical companies will continue to consider di"
2014-05-06,10:00 AM,Deals of the day-Mergers and acquisitions,"(Adds Ardian, Liberty Interactive, Casa Saba, AstraZeneca, Alitalia, B/E Aerospace, Commerzbank, BMW, Wendel, Albania, updates Bayer)"
2014-05-06,9:45 PM,Merck executives say not tempted by merger mania,"Merck & Co  Chief Executive Kenneth Frazier said he does not expect a wave of giant mergers in the drug industry despite a spate of recent activity, adding that Merck will seek out promising medicines rather than lower taxes in any future deals."
2014-05-07,3:55 PM,"In AstraZeneca fight, valuing drugs as much art as science",* $45 bln sales prediction widely seen as over-optimistic
2014-05-08,5:30 AM,"RPT-In AstraZeneca fight, valuing drugs as much art as science",* $45 bln sales prediction widely seen as over-optimistic
2014-05-08,6:16 PM,Merck KGaA to delist AZ Electronic Materials,"FRANKFURT, May 8 German chemicals and pharmaceuticals company Merck on Thursday said it would seek to delist AZ Electronic Materials, after securing control over 97.85 percent of the company."
2014-05-08,10:27 PM,U.S. FDA approves Merck blood clot preventer,May 8 U.S. health regulators on Thursday approved a blood clot preventer developed by Merck & Co  for use by patients who have had a heart attack or who suffer from blockages in the arteries of the legs.
2014-05-08,10:32 PM,U.S. FDA approves Merck blood clot preventer,U.S. health regulators on Thursday approved a blood clot preventer developed by Merck & Co for use by patients who have had a heart attack or who suffer from blockages in the arteries of the legs.
2014-05-14,6:01 AM,Belgium's Ablynx increases cash position after Merck payment,"BRUSSELS, May 14 Belgian biotech group Ablynx  said its cash reserves increased in the first quarter after an upfront payment from Merck & Co as part of a research deal for immune oncology."
2014-05-14,9:01 PM,"Bristol, Merck, Roche immune therapies are cancer meeting darlings","May 14 When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight."
2014-05-14,9:56 PM,"UPDATE 1-Bristol, Merck, Roche immune therapies are cancer meeting focus",(Adds more information on Bristol-Myers Phase III plan in final paragraph)
2014-05-14,9:31 PM,"Bristol, Merck, Roche immune therapies are cancer meeting focus","When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight."
2014-05-15,12:35 PM,UPDATE 1-Boston Scientific buys Bayer's vascular catheter business,* Unit makes catheters to remove clots from arteries and veins
2014-05-28,8:10 PM,"UPDATE 1-Sanofi, Lilly pursue Cialis over-the-counter approval","NEW YORK, May 28 Sanofi and Eli Lilly and Co on Wednesday said they would ask health regulators for permission to sell Cialis, the world's top-selling anti-impotence drug, without a prescription."
2014-06-02,12:20 AM,Novartis appoints Merck executive as oncology chief,"June 2 Swiss drugmaker Novartis AG  said it has appointed Bruno Strigini, one of Merck & Co Inc's  top executives, to head its oncology unit."
2014-06-02,12:25 AM,Novartis appoints Merck executive as oncology chief,"Swiss drugmaker Novartis AG said it has appointed Bruno Strigini, one of Merck & Co Inc's top executives, to head its oncology unit."
2014-06-02,11:31 AM,"Merck immune system-booster effective in skin, lung cancer","June 2 A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck cancer, according to early-stage studies presented on Monday."
2014-06-02,11:36 AM,"Merck immune system-booster effective in skin, lung cancer","A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck cancer, according to early-stage studies presented on Monday."
2014-06-06,4:50 PM,Former Merck dealmaker takes aim at colon germ,"An infectious disease expert and former head dealmaker at Merck & Co is racing against his ex-employer and other drugmakers to develop a treatment for a germ that ravages the colon and kills as many as 14,000 Americans each year."
2014-06-09,11:51 AM,Merck to buy Idenix for about $3.85 billion,June 9 Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.
2014-06-09,12:45 PM,US STOCKS-Futures point to dip at the open despite deals,"* Futures down: Dow 10 pts, S&P 2.4 pts, Nasdaq 4 pts   (Adds Family Dollar news)"
2014-06-09,2:20 PM,"US STOCKS-Wall St edges up, lifted by mergers, acquisitions","* Dow, S&P 500 and Nasdaq all up 0.1 pct   (Updates to open)"
2014-06-09,12:16 PM,UPDATE 3-Merck to buy Idenix to boost hepatitis C drugs portfolio,"(Adds comments from Merck research chief, analysts, details on drugs)"
2014-06-09,11:55 AM,Merck & Co to buy Idenix to boost hepatitis C drugs portfolio,"Merck & Co Inc MRK.N said Monday it would buy Idenix Pharmaceuticals Inc IDIX.O for $3.85 billion and plans to combine the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C."
2014-06-09,6:16 PM,"US STOCKS-Wall St slightly extends gains, lifted by deals","* CBOE Volatility Index up, day after hitting lowest since Feb '07"
2014-06-09,7:01 PM,US STOCKS-Wall St near flat after hitting new highs; VIX gains,"* CBOE Volatility Index up, day after hitting lowest since Feb '07"
2014-06-09,9:01 PM,"US STOCKS-Dow, S&P 500 extend string of record closes; VIX up",* International Game Technology shares fly after Reuters report
2014-06-10,4:40 PM,"CORRECTED-US STOCKS-Wall St edges up, lifted by mergers, acquisitions","(Fixes Rex Macey's job title and firm's name, which both changed recently, to chief allocation officer at Wilmington Trust Investment Advisors from chief investment officer at Wilmington Trust, in this U.S. stock report published June 9)"
2014-06-12,11:10 AM,"Merck, Pfizer, HSBC could be big winners from shareholder case","NEW YORK Within the next two weeks, the U.S. Supreme Court is expected to rule in a major case that could make it much harder for shareholders to band together against public companies in securities fraud class actions."
2014-06-12,3:40 PM,BRIEF-Merck research chief says company aims for big share of hepatitis C market,"June 12 Merck & Co Inc :  * Research chief, speaking at Goldman Sachs healthcare conference, says Merck would be open to big acquisition for biotech"
2014-06-12,7:05 PM,Merck open to more biotech deals: research chief,"Merck & Co Inc's  research chief Roger Perlmutter said the No. 2 U.S. drugmaker would consider big acquisitions of biotech companies for their medicines, rather than to obtain their drug-development technologies."
2014-06-18,10:31 AM,RLPC-Bayer signs $14.2 bln acquisition loan,"LONDON, June 18 Bayer has signed a $14.2 billion acquisition loan backing its purchase of US-based Merck's consumer care business, the lead banks said in a statement on Wednesday."
2014-06-18,10:37 AM,Bayer signs $14.2 billion acquisition loan,"LONDON Bayer  has signed a $14.2 billion acquisition loan backing its purchase of U.S.-based Merck's  consumer care business, the lead banks said in a statement on Wednesday."
2014-06-30,12:25 PM,Merck nausea drug works in children in late-stage trial,"June 30 Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children."
2014-06-30,1:25 PM,UPDATE 1-Merck nausea drug works in children in late-stage trial,"June 30 Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children."
2014-06-30,12:35 PM,Merck nausea drug works in children in late-stage trial,"Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children."
2014-07-01,11:56 AM,CORRECTED-Bayer broadens healthcare line by keeping Merck's consumer brands,"(Corrects fourth paragraph to read ""portfolio acquired from Merck"", not ""portfolio acquired by Merck"")"
2014-07-01,3:30 PM,UPDATE 1-Bayer broadens healthcare line by keeping Merck's consumer brands,"* Coppertone, Dr. Scholl's draw interest after $14 bln deal"
2014-07-11,3:16 PM,UPDATE 1-U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug,"July 11 Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough  treatment for hepatitis C, citing the expense to federal healthcare programs."
2014-07-26,11:36 AM,Merck aims to hike revenues in China to 1 bln eur by 2018,"FRANKFURT, July 26 Merck will start offering non-prescription drugs in China as part of a push to double revenues in the region to 1 billion euros ($1.3 billion) by 2018, Chief Executive Karl-Ludwig Kley told German weekly Wirtschaftswoche."
2014-07-28,5:37 AM,Pfizer's need for deal looms larger with earnings report,"NEW YORK Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline."
2014-07-29,11:11 AM,"Merck beats forecasts, as newer drugs offset generics","July 29 Merck & Co reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition."
2014-07-29,11:51 AM,"US STOCKS-Futures rise on earnings, data on tap","NEW YORK, July 29 U.S. stock index futures edged higher on Tuesday following better-than-expected results from companies such as Pfizer and Merck and ahead of data on home prices and consumer sentiment."
2014-07-29,1:20 PM,"US STOCKS-Wall St to rise on earnings, data weighs","* Futures up: Dow 40 pts, S&P 3 pts, Nasdaq 7 pts   (Updates prices, adds data)"
2014-07-29,11:57 AM,"Wall Street to rise on earnings, data weighs",NEW YORK U.S. stocks were set to rise slightly at the open on Tuesday following better-than-expected results from companies such as Pfizer and Merck and ahead of data on consumer sentiment.
2014-07-29,11:42 AM,UPDATE 3-Merck quarterly profit beats estimates; shares gain,"(Adds comments from CEO, analysts, details on drug pipeline)"
2014-07-29,11:12 AM,Merck quarterly profit beats estimates; shares gain,"Merck & Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading."
2014-07-29,3:10 PM,"CORRECTED-US STOCKS-Wall St gains, telecoms sector lifted by Windstream","(Corrects paragraph 11 to show UPS is on Dow transportation index, not Dow industrials)"
2014-07-29,4:25 PM,US STOCKS-Wall St flat as telecom gains offset by earnings,"* Merck rises as results beat expectations, but Pfizer slips"
2014-07-29,6:50 PM,"US STOCKS-Wall St edges lower on UPS outlook, telecom shares rally","* Merck up as results beat expectations, but Pfizer slips"
2014-07-29,8:30 PM,US STOCKS-Wall Street ends down; Twitter rallies after-hours,"* Merck up as results beat expectations, but Pfizer slips"
2014-08-13,7:46 PM,U.S. FDA approves Merck insomnia drug,"WASHINGTON, Aug 13 The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co.."
2014-08-13,8:41 PM,UPDATE 2-U.S. FDA approves Merck insomnia drug,"WASHINGTON, Aug 13 The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co."
2014-08-13,7:51 PM,U.S. FDA approves Merck insomnia drug,WASHINGTON The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co.
2014-08-25,4:01 AM,"Advaxis, Merck to test immune therapies against prostate cancer",Aug 25 Advaxis Inc on Monday said it will test an experimental immuno-oncology drug in combination with a high-profile immunotherapy from Merck & Co Inc as a treatment for patients with advanced prostate cancer.
2014-08-25,11:01 AM,"RPT-Advaxis, Merck to test immune therapies against prostate cancer",Aug 25 Advaxis Inc on Monday said it will test an experimental immuno-oncology drug in combination with a high-profile immunotherapy from Merck & Co Inc as a treatment for patients with advanced prostate cancer.
2014-08-25,11:06 AM,Exclusive: U.S. approval of Merck cancer immunotherapy expected soon,"LOS ANGELES U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation."
2014-08-26,1:10 PM,Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,"Aug 26 Pfizer Inc on Tuesday said it will test its Xalkori lung cancer drug with Merck & Co's  experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy."
2014-08-26,2:10 PM,UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,"Aug 26 Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's  experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy."
2014-08-26,4:30 PM,RPT-UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,"Aug 26 Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's  experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy."
2014-08-26,1:10 PM,Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,"Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy."
2014-09-02,7:25 AM,UPDATE 1-S.Korea lifts ban on beef with feed additive -food ministry,* Levels scientifically safe - ministry official   (Adds quotes and details)
2014-09-04,6:57 PM,U.S. FDA approves Merck immune-stimulating drug for melanoma,"Sept 4 U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies."
2014-09-04,7:46 PM,UPDATE 2-U.S. approves Merck immune-stimulating drug for melanoma,"Sept 4 U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies."
2014-09-04,7:11 PM,U.S. approves Merck immune-stimulating drug for melanoma,"U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies."
2014-09-06,1:25 AM,Bristol-Myers sues Merck over U.S. immunotherapy patent,Sept 5 Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.
2014-09-06,1:50 AM,Bristol-Myers sues Merck over U.S. immunotherapy patent,Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.
2014-09-09,12:40 PM,BRIEF-Merck CEO says tax inversion deals would not fit its corporate strategy,"Sept 9 Merck & Co Inc :  * Merck CEO, at Morgan Stanley Global Healthcare Conference, says tax inversion deals would not fit its corporate strategy  * CEO says tax inversion benefit would require overly large transaction  * CEO says changes needed to make U.S. tax rate more competitive, but may not"
2014-09-15,5:57 PM,Merck says osteoporosis drug achieves goal in large trial,"Sept 15 Merck & Co on Monday said it expects next year to seek U.S. approval for its experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary effectiveness goals in a late-stage trial."
2014-09-15,6:35 PM,"UPDATE 2-Merck osteoporosis drug passes trial, but side effects hover","(Adds Merck comment, details on side effects, effectiveness)"
2014-09-15,6:05 PM,"Merck osteoporosis drug passes trial, but side effects hover","Merck & Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments."
2014-09-17,2:15 PM,Merck licenses experimental psoriasis drug to India's Sun Pharma,Sept 17 Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.
2014-09-17,2:25 PM,Merck licenses experimental psoriasis drug to India's Sun Pharma,Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.
2014-09-17,10:05 AM,Deals of the day- Mergers and acquisitions,"(Adds Trian Fund Management, Verizon, Endesa, TIM, Allianz, Sulzer, Perutnina Ptuj, Espirito Santo Financial Group, Falabella, UniCredit, Abertis, IAC/Interactive Corp, Hess Corporation, Merck & Co, PZU and Mediobanca)"
2014-09-22,10:16 AM,Germany's Merck to buy Sigma-Aldrich for $17 billion to boost lab supplies operation,"FRANKFURT Drugs and chemicals maker Merck KGaA  agreed on Monday to acquire U.S.-based Sigma-Aldrich Corp  for $17 billion in cash to boost its lab supplies business, the biggest takeover in the German group's history."
2014-09-28,7:16 AM,Merck drug extends immune system fight to stomach cancer,* Merck plans to start Phase II study in first quarter 2015
2014-09-28,7:55 AM,Merck drug extends immune system fight to stomach cancer,"MADRID Merck & Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas  in the United States, also has potential in stomach cancer, new research shows."
2014-09-29,9:00 AM,Merck immunotherapy drug shows promise in bladder cancer,"MADRID, Sept 29 Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year."
2014-09-29,9:20 AM,Merck immunotherapy drug shows promise in bladder cancer,"MADRID Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year."
2014-10-01,3:30 PM,BRIEF-Bayer closes buy of Merck & Co consumer care business,"* Says bayer closes acquisition of consumer care business of merck & co., inc., united states, for usd 14.2 billion"
2014-10-01,3:35 PM,BRIEF-Bayer completes takeover of Merck & Co OTC drug unit,* Completes takeover of merck & co otc drug unit  Further company coverage:
2014-10-01,5:35 PM,Bayer launches US$7bn six-tranche acquisition bond,"NEW YORK, Oct 1 (IFR) - Bayer launched a US$7bn six-tranche acquisition bond financing for Merck's consumer care business Wednesday at levels 10bp-25bp inside of initial price thoughts, leads on the trade said."
2014-10-01,8:05 PM,Esperion drug succeeds in lowering LDL cholesterol -study,"Oct 1 A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc  lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday."
2014-10-01,8:51 PM,UPDATE 1-Esperion drug succeeds in lowering LDL cholesterol -study,"Oct 1 An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's  Zetia in a midstage clinical trial, Esperion said on Wednesday."
2014-10-06,5:37 PM,New Issue- Merck & Co prices multi tranche deal,"Lead Manager(s)         JP Morgan, Deutsche Bank AG, BNP Paribas, BAML, RBS, BBVA,"
2014-10-06,6:11 PM,Fitch Rates Merck's EUR Debt Offering 'A+'; Outlook Negative,"(The following statement was released by the rating agency) CHICAGO, October 06 (Fitch) Fitch Ratings has assigned an 'A+' rating Merck &  Co.'s (Merck) Euro denominated senior unsecured notes offering. Merck intends to  use all or a substantial portion of the net proceeds from the offering to  refinance existing debt. The Rating Outlook is Negative and applies to approximately $23.1 billion in  outstanding debt. A full list of Merck's ratings follows near the end of this  release. KEY RATING DR"
2014-10-14,4:55 PM,Geographic split likely for GSK mature drugs sale -sources,"LONDON, Oct 14 GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process."
2014-10-15,8:05 PM,Merck unit to pay $31 mln to settle fraud claims by U.S. states,"Oct 15, A subsidiary of Merck & Co has agreed to pay U.S. states $31 million to settle claims that it overcharged their Medicaid programs for an antidepressant it had sold at a discount to pharmacy companies, attorney generals from three states said on  Wednesday."
2014-10-15,8:12 PM,Merck unit to pay $31 million to settle fraud claims by U.S. states,"A subsidiary of Merck & Co has agreed to pay U.S. states $31 million to settle claims that it overcharged their Medicaid programs for an antidepressant it had sold at a discount to pharmacy companies, attorney generals from three states said on  Wednesday."
2014-10-17,6:41 AM,"UPDATE 1-Roche, Merck extend immunotherapy fight to breast cancer",(Adds Merck also presenting breast cancer data in December)
2014-10-17,6:50 AM,"Roche, Merck extend immunotherapy fight to breast cancer","LONDON Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumours to another cancer type."
2014-10-17,7:00 AM,"Roche, Merck extend immunotherapy fight to breast cancer","LONDON Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumors to another cancer type."
2014-10-24,5:40 PM,Ex-Bank of New York Mellon trader pleads guilty to insider trading,"NEW YORK, Oct 24 A former Bank of New York Mellon Corp trader on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc  employee about potential pharmaceutical mergers."
2014-10-24,8:45 PM,UPDATE 1-Ex-Bank of New York Mellon employee pleads guilty to insider trading,"NEW YORK, Oct 24 A former Bank of New York Mellon Corp employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc  employee about potential pharmaceutical mergers."
2014-10-24,5:42 PM,Ex-Bank of New York Mellon employee pleads guilty to insider trading,NEW YORK A former Bank of New York Mellon Corp  employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc  employee about potential pharmaceutical mergers.
2014-10-27,11:20 AM,"Merck beats Q3 forecast, cost cuts offset Gardasil decline","Oct 27 Merck & Co reported lower than expected third quarter revenue, hurt by sharply lower sales of its Gardasil vaccine against cervical cancer, but cost cuts enabled the company to beat earnings forecasts."
2014-10-27,11:50 AM,UPDATE 3-Weak Merck sales overshadow Q3 cost cuts,Oct 27 Cost cuts enabled Merck & Co to beat third-quarter earnings forecasts but disappointing sales of its Gardasil cervical cancer vaccine and other big products sent its shares about 2 percent lower.
2014-10-27,11:24 AM,Weak Merck sales overshadow third-quarter cost cuts,Cost cuts enabled Merck & Co to beat third-quarter earnings forecasts but disappointing sales of its Gardasil cervical cancer vaccine and other big products sent its shares about 2 percent lower. | Video
2014-10-27,11:49 AM,Wall St. flat after last week's big gain; energy weighs,"NEW YORK U.S. stocks ended near flat on Monday, pausing after the S&P 500's biggest weekly gain since January 2013, while energy shares fell with another decline in oil prices."
2014-10-30,8:51 AM,UPDATE 1-Bayer Q3 adj profit gains slightly on strong crop chemicals,"* Shares gain 3.5 percent   (Adds details on drug sales, analyst comment, shares)"
2014-11-05,7:06 PM,UPDATE 1-Merck takes steps to return Zilmax to U.S. cattle market,"Nov 5 Merck & Co. is taking steps to resume sales of its controversial cattle feed additive Zilmax by changing the way the drug is administered, hoping to recapture some market share in the beef industry, where the U.S. herd has the fewest animals in more than 60 years."
2014-11-05,3:05 PM,Merck takes steps to return Zilmax to U.S. cattle market,"Merck & Co. is taking steps to resume sales of its controversial cattle feed additive Zilmax by changing the way the drug is administered, hoping to recapture some market share in the beef industry, where the U.S. herd has the fewest animals in more than 60 years."
2014-11-10,12:20 AM,Merck four-week hep C regimen with Gilead's Sovaldi comes up short,"An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study."
2014-11-10,1:25 PM,US STOCKS-Futures inch up after three-week rally; Alibaba active,"* Futures up: Dow 17 pts, S&P 2.5 pts, Nasdaq 10.25 pts   (Adds premarket movers)"
2014-11-10,2:06 PM,US STOCKS-Wall Street set to open flat after three-week run,"* Futures up: Dow 17 pts, S&P 1.75 pts, Nasdaq 9.5 pts   (Adds quote, updates prices)"
2014-11-10,3:00 PM,US STOCKS-Wall Street little changed after three-week rally,"* Dow off 0.05 pct, S&P up 0.01 pct, Nasdaq off 0.08 pct   (Updates to market open)"
2014-11-10,4:10 PM,US STOCKS-Wall Street edges higher after three-week run,* Gilead climbs after Merck's hepatitis C drug trial results
2014-11-10,5:00 PM,US STOCKS-Wall Street climbs modestly after three-week run,* Gilead climbs after Merck's hepatitis C drug trial results
2014-11-10,6:35 PM,US STOCKS-Wall Street climbs to new highs; transports rally,* Gilead climbs after Merck's hepatitis C drug trial results
2014-11-10,8:05 PM,MOVES-Former Bank of America healthcare banker joins Credit Suisse,"Nov 10 A former Bank of America banker who advises clients in the healthcare sector has joined Credit Suisse, according to an internal memo."
2014-11-10,8:35 PM,"Merck expects no writedowns for Zetia, Vytorin cholesterol drugs","Nov 10 Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs."
2014-11-10,8:35 PM,"Merck expects no writedowns for Zetia, Vytorin cholesterol drugs","Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs."
2014-11-12,10:00 PM,Future of Merck cholesterol sales could hang on long-awaited study,"A nine-year, 18,000-patient study of Merck & Co's $4 billion Zetia and Vytorin cholesterol franchise is likely to show some benefit but keep open the question of whether it can significantly reduce heart attacks, strokes and death."
2014-11-12,10:01 PM,U.S. gene study raises hope for Merck cholesterol drug Zetia,"CHICAGO, Nov 12 Rare mutations in a single gene may help lower cholesterol and reduce the risk of a heart attack by half, U.S. researchers said on Wednesday in a study that could have implications for Merck and Co's closely watched heart drug Zetia."
2014-11-12,10:06 PM,U.S. gene study raises hope for Merck cholesterol drug Zetia,"CHICAGO Rare mutations in a single gene may help lower cholesterol and reduce the risk of a heart attack by half, U.S. researchers said on Wednesday in a study that could have implications for Merck and Co's closely watched heart drug Zetia."
2014-11-17,3:15 PM,European shares pare losses after Japan slips into recession,"* Weir hit by renewed slump in crude   (Adds detail, quotes, updates prices)"
2014-11-17,4:40 PM,"Merck's Zetia cuts heart attack, stroke risk in long-awaited study","CHICAGO, Nov 17 After years of uncertainty, a nearly decade-long study showed that Merck & Co's  cholesterol drug Zetia significantly lowered the risk of heart attacks and strokes in high-risk heart patients when used with a highly effective statin."
2014-11-17,4:45 PM,ECB's Draghi helps European shares reverse early losses,"* Weir hit by renewed slump in crude   (Recasts, adds quotes, detail)"
2014-11-17,4:45 PM,Regeneron drug highly effective for those who can't take statins -study,"CHICAGO, Nov 17 Regeneron Corp's  experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their ""bad"" LDL cholesterol down to target levels than Merck & Co's  Zetia, according to data from a clinical trial presented on Monday."
2014-11-17,5:10 PM,Regeneron drug highly effective for those who can't take statins: study,"CHICAGO Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their ""bad"" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday."
2014-11-17,5:25 PM,ECB's Draghi helps European shares reverse early losses,* Weir hit by renewed slump in crude   (Updates with closing prices)
2014-11-17,5:41 PM,"UPDATE 1-Merck's Zetia cuts heart attack, stroke risk in long-awaited study","CHICAGO, Nov 17 After years of uncertainty, a nearly decade-long study showed that Merck & Co's  cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin."
2014-11-17,4:40 PM,"Merck's Zetia cuts heart attack, stroke risk in long-awaited study","CHICAGO After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin."
2014-11-20,12:25 PM,Britain begins review to speed access to new drugs,* Innovative Medicines and MedTech Review to report in 2015
2014-11-24,1:20 PM,Merck buys rights to NewLink's experimental Ebola vaccine,Nov 24 Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's  experimental Ebola vaccine.
2014-11-24,3:40 PM,UPDATE 2-Merck buys rights to NewLink's experimental Ebola vaccine,"(Adds terms of deal, details on WHO-coordinated trials; updates share movement)"
2014-11-24,1:20 PM,Merck buys rights to NewLink's experimental Ebola vaccine,Merck & Co Inc  on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's  experimental vaccine against the Ebola virus.
2014-11-28,2:15 PM,"Germany's Merck aims to grow, not sell $1 bln consumer health arm",* Merck KGaA committed to growing over-the-counter division
2014-12-02,10:05 AM,No serious side effects in Merck/Newlink Ebola vaccine test,"LONDON, Dec 2 The first people vaccinated with an experimental Ebola shot being developed by U.S. drugmaker Merck and Canada's NewLink have had no serious side effects so far but a few experienced mild fever, researchers said on Tuesday."
2014-12-02,11:00 AM,UPDATE 1-No serious side effects in Merck/Newlink Ebola vaccine test,"LONDON, Dec 2 The first people vaccinated with an experimental Ebola shot being developed by Merck and NewLink have had no serious side effects so far, but a few experienced mild fever, Swiss researchers said on Tuesday."
2014-12-02,10:35 AM,No serious side effects in Merck/Newlink Ebola vaccine test,"LONDON The first people vaccinated with an experimental Ebola shot being developed by Merck and NewLink have had no serious side effects so far, but a few experienced mild fever, Swiss researchers said on Tuesday."
2014-12-06,1:26 AM,Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion: NYT,"Merck & Co Inc is in talks to acquire Cubist Pharmaceuticals Inc for more than $7 billion in a deal that could be announced as early as next week, the New York Times reported on Friday, citing people briefed on the matter."
2014-12-06,6:00 PM,Merck immunotherapy drug shows promise against lymphoma -study,"Dec 6 Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting."
2014-12-06,6:10 PM,Merck immunotherapy drug shows promise against lymphoma: study,"Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting."
2014-12-08,1:20 PM,"US STOCKS-Futures lower after China, Japan data disappoints","* Futures down: Dow 56 pts, S&P 6.75 pts, Nasdaq 12.5 pts   (Adds premarket actives data)"
2014-12-08,2:10 PM,"US STOCKS-Wall St to open lower after Japan, China data","* Futures down: Dow 58 pts, S&P 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)"
2014-12-08,2:55 PM,"US STOCKS-Wall St slips after Japan, China data; energy drags","* Indexes down: Dow 0.12 pct, S&P 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)"
2014-12-08,4:15 PM,"US STOCKS-Wall St flat after Japan, China data; biotechs climb","* Indexes: Dow off 0.06 pct, S&P 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)"
2014-12-08,5:50 PM,Cubist options unusually active before Merck deal,"NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium."
2014-12-08,5:55 PM,Cubist options unusually active before Merck deal,NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.
2014-12-08,8:46 PM,Breakingviews: Merck bets $8.4 bln on more profitable antibiotics,"NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable."
2014-12-08,1:00 PM,UPDATE 4-Merck to take on superbugs with Cubist Pharma buy,"* Merck to pay $8.4 bln, plus assumption of $1.1 bln of debt"
2014-12-08,2:51 PM,Merck to take on superbugs with Cubist Pharma buy,"Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs."
2014-12-08,12:20 PM,Merck to take on superbugs with Cubist Pharma buy,"Merck & Co Inc  said it would buy Cubist Pharmaceuticals Inc  for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. | Video"
2014-12-09,6:12 PM,Breakingviews: Merck gives in to M&A frenzy risk assessment,"NEW YORK (Reuters Breakingviews) - The M&A frenzy appears to have influenced Merck's risk assessment. Just hours after unveiling its $8.4 billion acquisition of Cubist Pharmaceuticals on Monday, a judge invalidated patents owned by the antibiotics maker. Potential lost sales are reflected in the billions erased from Merck's market value."
2014-12-09,11:00 AM,Deals of the day- Mergers and acquisitions,"(Adds Merck, AAR Corp, Entergy, Santander, Spirit Aerosystems)"
2014-12-09,2:36 PM,"UPDATE 2-Merck says still plans to buy Cubist, despite patent setback","Dec 9 Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product."
2014-12-09,2:06 PM,"Merck says still plans to buy Cubist, despite patent setback","Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product."
2014-12-09,11:52 PM,Cubist sales force seen as potential boon for Merck intestinal drug,"Dec 9 In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co  will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients."
2014-12-09,11:56 PM,Cubist sales force seen as potential boon for Merck intestinal drug,"In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients."
2014-12-10,1:51 PM,RPT-Cubist sales force seen as potential boon for Merck intestinal drug,"Dec 9 In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co  will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients."
2014-12-11,7:01 AM,One shot or two? Many questions unresolved in Ebola vaccine race,"* Debate over ""prime-boost"" vaccination as epidemic evolves"
2014-12-11,12:02 PM,UPDATE 2-$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag,"* Further funding of up to $90 mln to help vaccine roll-out   (Wraps stories on GAVI funding, NewLink vaccine trial, adds GAVI CEO comment)"
2014-12-11,1:56 PM,UPDATE 2-Ebola vaccine trial halted temporarily after joint pains -Geneva hospital,"* Lausanne says safety data ""satisfactory"" in GSK vaccine trial   (Adds statement on GSK Ebola vaccine, new paras 4-7)"
2014-12-12,8:01 AM,"CORRECTED-India caps prices of 52 more ""essential"" drugs - pricing authority","(Corrects paragraph 4 to say Merck Ltd is a unit of Merck KGaA, not Merck & Co Inc)"
2014-12-15,9:25 PM,TRLPC: Merck looks for $8B bridge for Cubist acquisition,"NEW YORK, Dec 15 Merck & Co Inc is approaching banks about an $8 billion, 364-day bridge loan that will back the drugmaker's plans to acquire Cubist Pharmaceuticals Inc, sources told Thomson Reuters LPC."
2014-12-17,9:21 PM,Tetraphase's antibiotic succeeds in late-stage trial,Dec 17 Tetraphase Pharmaceuticals Inc  said its antibiotic drug to treat complicated intra-abdominal infections was as effective as Merck & co Inc's  ertapenem in a late-stage study.
2014-12-17,9:56 PM,"UPDATE 2-Tetraphase's antibiotic succeeds late-stage trial, shares rise","* Shares rise 17.5 pct in extended trading   (Adds details from conference call, analyst quotes)"
2014-12-17,9:35 PM,"Tetraphase's antibiotic succeeds late-stage trial, shares rise",Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck & Co Inc's ertapenem in a late-stage study.
2014-12-18,4:05 PM,UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data,* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s
2014-12-23,2:15 PM,CORRECTED-Connections between drug makers and educators abound,"(Corrects second paragraph to say ""scholarships funded by Merck, Zoetis, Cargill and others this year."")"
2015-01-05,12:55 PM,Merck-NewLink Ebola vaccine trial resumes at lower dose -Geneva hospital,"GENEVA, Jan 5 The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said."
2015-01-05,3:45 PM,UPDATE 2-Cempra's lead oral antibiotic meets main goal in late-stage trial,"Jan 5 Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial."
2015-01-05,1:00 PM,Merck-NewLink Ebola vaccine trial resumes at lower dose: Geneva hospital,"GENEVA The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said."
2015-01-12,6:50 AM,"Merck speeds up drug-submission plans for Hep C, lung cancer -WSJ","Jan 12 Merck & Co has put on fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in an attempt to close the gap with competitors in two lucrative segments, the Wall Street Journal reported."
2015-01-12,4:00 PM,"UPDATE 1-Merck speeds up drug-submission plans for Hep C, lung cancer",Jan 12 Merck & Co said it would fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval.
2015-01-12,7:00 AM,"Merck speeds up drug-submission plans for Hep C, lung cancer",Merck & Co said it would fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval.
2015-01-12,8:35 PM,"Merck, Bristol heat up immunotherapy race in lung cancer","Jan 12 Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up."
2015-01-12,8:40 PM,"Merck, Bristol heat up immunotherapy race in lung cancer","Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up."
2015-01-13,2:05 PM,"Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",Jan 13 Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.
2015-01-13,2:10 PM,"Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.
2015-01-19,1:05 PM,Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to resume sales,"CHICAGO Merck & Co Inc is funding the testing of lower dosages of its controversial cattle growth drug Zilmax, in a move that livestock experts say is crucial if the company is to resume sales of the product to the U.S. beef industry."
2015-01-20,11:07 PM,Johnson & Johnson's forex warning a sign for rival drugmakers,"Jan 20 Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co."
2015-01-20,11:10 PM,Johnson & Johnson's forex warning a sign for rival drugmakers,"Johnson & Johnson  surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc  and Merck & Co ."
2015-01-23,12:45 PM,Europe recommends seven new medicines for approval,"LONDON, Jan 23 Europe recommended seven new drugs for approval on Friday, including two antibiotics for skin infections and a new treatment option for HIV."
2015-02-02,6:00 AM,"INSIGHT-US companies face billions in Venezuela currency losses, Reuters analysis shows","Feb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows."
2015-02-02,12:01 PM,"RPT-INSIGHT-US companies face billions in Venezuela currency losses, Reuters analysis shows","Feb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows."
2015-02-02,5:56 PM,"RPT-INSIGHT-US companies face billions in Venezuela currency losses, Reuters analysis shows","Feb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows."
2015-02-04,12:30 PM,"Merck issues cautious 2015 forecast, citing dollar","Feb 4 Merck & Co on Wednesday reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts, citing the negative impact of the stronger dollar, as most of its U.S. rivals have done in making their own cautious forecasts."
2015-02-04,2:15 PM,"US STOCKS-Wall St to open lower after 2-day run, ADP data","* Futures off: Dow 18 pts, S&P 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)"
2015-02-04,2:50 PM,US STOCKS-Wall St down after 2-day run after ADP as energy drags,"* Indexes off: Dow 0.2 pct, S&P 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)"
2015-02-04,4:10 PM,US STOCKS-Wall St dips after 2-day run as energy rally stalls,"* Indexes: Dow up 0.16 pct, S&P off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)"
2015-02-04,6:05 PM,"US STOCKS-S&P, Nasdaq down after 2-day run up; biotechs, energy fall","* Indexes: Dow up 0.1 pct, S&P off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)"
2015-02-04,1:25 PM,"UPDATE 3-Merck says hepatitis C treatment to lose ""breakthrough"" status","Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the ""breakthrough therapy"" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months."
2015-02-04,7:35 PM,"US STOCKS-S&P, Nasdaq slip after 2-day run up; energy drops with oil","* Indexes: Dow up 0.1 pct, S&P off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)"
2015-02-04,12:36 PM,"Merck says hepatitis C treatment to lose ""breakthrough"" status","Merck & Co on Wednesday said U.S. regulators intend to rescind the ""breakthrough therapy"" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months."
2015-02-04,10:11 PM,"US STOCKS-Wall St ends lower with oil prices, renewed Greece worries","* Indexes: Dow up 0.04 pct, S&P down 0.4 pct, Nasdaq down 0.2 pct   (Updates to close)"
2015-02-19,9:56 PM,Ex-Merck analyst pleads guilty to U.S. insider trading charges,"NEW YORK, Feb 19 A former Merck & Co Inc  finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp."
2015-02-19,10:02 PM,Ex-Merck analyst pleads guilty to U.S. insider trading charges,NEW YORK A former Merck & Co Inc finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp.
2015-02-25,8:31 AM,Biosimilar copies of blockbuster drug launch in major EU markets,* Biosimilars expected to disrupt market for biotech medicines
2015-02-25,1:50 PM,UPDATE 1-Biosimilar copies of blockbuster drug launch in major EU markets,"* Biosimilars expected to disrupt market for biotech medicines   (Adds detail on price discount, paragraph 7)"
2015-03-05,10:05 AM,Merck-NewLink Ebola vaccine Phase III trial to start March 7,"GENEVA, March 5 Merck & Co and NewLink Genetics Corp's Ebola vaccine will begin a Phase III trial in Guinea on March 7, the final stage of testing, the World Health Organization said on Thursday."
2015-03-05,10:40 AM,UPDATE 2-Guinea to start final trials of Ebola vaccines this week,"* WHO says effective Ebola shot could be a ""game-changer""   (Adds details of ""ring vaccination"" plans, quotes)"
2015-03-05,10:05 AM,Guinea to start final trials of Ebola vaccines this week,"LONDON/GENEVA Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday."
2015-03-11,7:39 AM,Merck cancer drug is first approved under UK early access scheme,"LONDON, March 11 Merck & Co's cancer drug Keytruda, which works by boosting the immune system but has yet to be licensed in Europe, is the first medicine to be made available to patients in Britain under a new early access scheme."
2015-03-11,7:54 AM,Merck cancer drug is first approved under UK early access scheme,"LONDON Merck & Co's cancer drug Keytruda, which works by boosting the immune system but has yet to be licensed in Europe, is the first medicine to be made available to patients in Britain under a new early access scheme."
2015-03-13,8:40 PM,Merck expects to be denied approval for sugammadex injection again,"March 13 Merck & Co Inc said it expected to be denied U.S. approval for its sugammadex injection, after the U.S. Food and Drug Administration said it would conduct additional site inspections related to a study of the drug."
2015-03-13,9:36 PM,UPDATE 1-Merck expects to be denied approval for sugammadex injection again,March 13 Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.
2015-03-13,8:45 PM,Merck expects to be denied approval for sugammadex injection again,Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.
2015-03-20,11:15 AM,Merck KGaA's deputy chief Oschmann set to become CEO - Manager Magazin,"FRANKFURT, March 20 Germany's Merck KGaA  will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources."
2015-04-13,4:21 PM,Fitch Downgrades Merck's L-T IDR to 'A'; Outlook Revised to Stable,"(The following statement was released by the rating agency) CHICAGO, April 13 (Fitch) Fitch Ratings has downgraded Merck & Co.'s (Merck)  long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating  Outlook to Stable from Negative. In addition, the company's short-term IDR has  been affirmed at 'F1'. Merck had $21.7 billion in outstanding debt at Dec. 31, 2014. A full list of  Fitch's ratings actions follows at the end of this release.  KEY RATING DRIVERS --Fitch expects MRK"
2015-04-18,3:20 PM,Merck aims to quickly repay up to $5 bln in loans -CFO in Boersen-Zeitung,"FRANKFURT, April 18 Germany's Merck  aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich, its finance chief told daily Boersen-Zeitung."
2015-04-18,3:30 PM,Merck aims to quickly repay up to $5 billion in loans: CFO in Boersen-Zeitung,"FRANKFURT Germany's Merck  aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich , its finance chief told daily Boersen-Zeitung."
2015-04-19,12:01 PM,Merck files for FDA approval of Keytruda in lung cancer,"April 19 Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease."
2015-04-19,12:05 PM,Merck files for FDA approval of Keytruda in lung cancer,"Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease."
2015-04-19,12:30 PM,"CORRECTED-Merck's Keytruda shrinks lung cancer tumors, FDA approval sought","April 19 Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells."
2015-04-19,12:35 PM,"Merck's Keytruda shrinks lung cancer tumors, FDA approval sought","Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells."
2015-04-24,5:01 AM,Merck oral hepatitis C regimen shows 95 pct cure rate,April 24 Merck and Co Inc presented trial results on Friday showing that a once-daily combination of two experimental pills cured 95 percent of previously untreated hepatitis C patients after 12 weeks.
2015-04-27,9:30 PM,Merck's diabetes drug Januvia succeeds in heart safety trial,"April 27 Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the company on Monday, likely removing a cloud of uncertainty from its biggest product."
2015-04-27,9:35 PM,Merck's diabetes drug Januvia succeeds in heart safety trial,"Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a cloud of uncertainty from its biggest product."
2015-04-27,10:15 PM,UPDATE 2-Merck diabetes drug Januvia meets heart safety target,"April 27 Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a cloud of uncertainty from its biggest product."
2015-04-28,4:26 PM,US STOCKS-Wall St reverses course to trade higher,"* Indexes up: Dow 0.3 pct, S&P 0.2 pct, Nasdaq 0.2 pct   (Adds details, comment, updates prices)"
2015-04-28,11:22 AM,"Merck shares jump on strong earnings, Januvia safety data",Merck & Co's  shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. | Video
2015-04-28,5:40 PM,US STOCKS-Wall St moves higher after erratic early trading,"* Indexes up: Dow 0.4 pct, S&P 0.3 pct, Nasdaq 0.2 pct   (Updates to early afternoon, changes comment)"
2015-04-28,6:40 PM,GLOBAL MARKETS-U.S. shares edge higher; oil pares gains after Iran ship seizure,"NEW YORK, April 28 U.S. shares rebounded in afternoon trading on Tuesday, boosted by strong earnings from Merck and a dividend hike by IBM, while oil prices pared gains on expectations that U.S. crude stockpiles have reached record highs."
2015-04-28,7:05 PM,"US STOCKS-Wall St edges up with Merck, IBM; Nasdaq slips with Apple","* Dow up 0.3 pct, S&P up 0.2 pct, Nasdaq down 0.04 pct   (Updates to late afternoon)"
2015-04-28,8:35 PM,"US STOCKS-Dow, S&P 500 end up with Merck, IBM; Nasdaq slips with Apple","* Dow up 0.4 pct, S&P up 0.28 pct, Nasdaq down 0.1 pct   (Updates to close)"
2015-04-28,11:31 AM,"Dow, S&P 500 end up with Merck, IBM; Nasdaq slips with Apple","The Dow and S&P 500 ended a volatile session higher on Tuesday, helped by strong earnings from Merck and gains in IBM after it boosted its dividend, while the Nasdaq fell with Apple."
2015-04-28,8:40 PM,GLOBAL MARKETS-U.S. shares rebound; oil pares gains after Iran ship seizure,"NEW YORK, April 28 Two of three major U.S. stock indexes rose modestly on Tuesday as Merck posted strong earnings and IBM raised its dividend, while European stocks slid on weak corporate results and oil prices were flat to lower on expectations that U.S. crude stockpiles have reached record highs."
2015-04-28,10:45 PM,Strong Merck cancer drug sales upstage rival Bristol-Myers,Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.
2015-04-28,10:41 PM,Strong Merck cancer drug sales upstage rival Bristol-Myers,April 28 Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.
2015-04-29,11:01 AM,RPT-Strong Merck cancer drug sales upstage rival Bristol-Myers,April 28 Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.
2015-05-14,12:26 AM,Merck loses bid to escape investor lawsuit over Vioxx,"A class action accusing Merck & Co Inc of concealing from investors the risks of its now-withdrawn painkiller Vioxx may go forward, a federal judge has ruled."
2015-05-15,10:51 AM,India's Supreme Court bars Glenmark from selling copies of Merck diabetes drugs-sources,"MUMBAI, May 15 India's Supreme Court has blocked Glenmark Pharmaceuticals Ltd from selling copies of U.S. drugmaker Merck & Co Inc's diabetes drugs Januvia and Janumet, sources with knowledge of the matter said after a court hearing on Friday."
2015-05-15,12:40 PM,UPDATE 1-Indian court bars Glenmark from selling Merck drug copies,"MUMBAI, May 15 India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday."
2015-05-15,3:25 PM,DIARY-U.S. MEETINGS/WEEK AHEAD,"Thomson Reuters May 15, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For"
2015-05-15,3:30 PM,DIARY-U.S. MEETINGS/WEEK AHEAD,"Thomson Reuters May 15, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For"
2015-05-15,10:55 AM,Indian court bars Glenmark from selling Merck drug copies,"MUMBAI India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday."
2015-05-21,2:30 AM,"Brazil's JBS looking for deals in Americas, Australia: CEO","NEW YORK Brazil's JBS SA, the world's largest meatpacker, this year will look at opportunities for acquisitions in North and South America and Australia, Chief Executive Wesley Batista said on Wednesday."
2015-05-22,11:25 AM,Merck follows Bristol with EU green light for immune cancer drug,"May 22 European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo."
2015-05-22,11:30 AM,Merck follows Bristol with EU green light for immune cancer drug,"European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo."
2015-05-26,1:05 PM,DIARY-U.S. MEETINGS/WEEK AHEAD,"Thomson Reuters May 25, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For"
2015-05-27,11:53 AM,Merck offers EU concessions over $17 bln Sigma-Aldrich buy,"BRUSSELS, May 27 German drugmaker Merck  has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp."
2015-05-28,11:21 AM,"New drugs from Bristol, Merck at forefront of cancer meeting",New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body's immune system to fight cancer can be used.
2015-05-29,6:35 PM,UPDATE 1-Merck immunotherapy appears effective in head and neck cancer-study,"May 29 A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday."
2015-05-29,6:10 PM,Merck immunotherapy appears effective in head and neck cancer-study,"A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday."
2015-05-31,1:56 AM,Merck immunotherapy appears effective in head and neck cancer: study,"A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday."
2015-06-04,2:06 PM,Merck accused of stonewalling in mumps vaccine antitrust lawsuit,Two former Merck & Co Inc scientists accusing the drugmaker of falsifying tests of its exclusive mumps vaccine said in a court filing on Monday that Merck is refusing to respond to questions about the efficacy of the vaccine.
2015-06-12,11:05 AM,BRIEF-Rovi signs deal with Merck to market Orvatez in Spain,* Signs an agreement with Merck Sharp & Dohme SA (MSD)  to market Orvatez in Spain
2015-06-15,5:40 PM,European Commission approves Merck's $17 bln Sigma-Aldrich buy,"BRUSSELS, June 15 The European Commission said on Monday it had approved German drugmaker Merck's $17 billion acquisition of Sigma-Aldrich Corp following the U.S. company's pledges to sell assets in Germany."
2015-06-15,5:45 PM,European Commission approves Merck's $17 billion Sigma-Aldrich buy,BRUSSELS The European Commission said on Monday it had approved German drugmaker Merck's $17 billion acquisition of Sigma-Aldrich Corp following the U.S. company's pledges to sell assets in Germany.
2015-06-15,8:00 PM,Deals of the day- Mergers and acquisitions,"June 15 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:"
2015-06-16,9:52 PM,"Merck Manuals health guides go digital, and free, in global push","June 16 Merck Manuals, the widely used health guides provided by drugmaker Merck & Co, are moving to a digital-only format in 10 different languages as part of an effort to educate the global community on medical issues."
2015-06-16,10:00 PM,"Merck Manuals health guides go digital, and free, in global push","Merck Manuals, the widely used health guides provided by drugmaker Merck & Co, are moving to a digital-only format in 10 different languages as part of an effort to educate the global community on medical issues."
2015-06-17,8:30 PM,Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,"NEW YORK, June 17 A unit of Merck & Co Inc  has agreed to pay $5.9 million to resolve claims that it fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday."
2015-06-17,9:40 PM,CORRECTED-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,"NEW YORK, June 17 Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday."
2015-06-17,10:07 PM,UPDATE 1-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,"NEW YORK, June 17 Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday."
2015-06-17,10:11 PM,Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,"NEW YORK Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday."
2015-06-17,10:11 PM,Merck to pay $5.9 million for misleading marketing of pink eye drug: U.S,"NEW YORK Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday."
2015-06-19,9:15 AM,Merck aims to be leader in OLED materials by 2018,"DARMSTADT, Germany, June 19 Germany's Merck  aims to be a leading maker of OLED (organic light-emitting diode) materials by 2018, its head of chemicals said on Friday."
2015-06-19,10:05 AM,UPDATE 1-Merck aims to be leader in OLED materials by 2018,"* Merck is market leader in liquid crystals   (Adds details on competitors, investment)"
2015-07-22,5:20 AM,BRIEF-Ablynx expands its immuno-oncology collaboration with Merck & Co,* Significantly expands its immuno-oncology collaboration with Merck & Co Inc
2015-07-22,5:50 AM,Belgium's Ablynx triples cooperation deal with Merck & Co,"BRUSSELS, July 22 Belgian biotech group Ablynx  on Wednesday said it had tripled its research deal with U.S. drugmaker Merck & Co leading to potential milestone payments of about 4 billion euros ($4.38 billion)."
2015-07-28,11:16 AM,Strong dollar weighs on Merck revenue,July 28 Merck & Co Inc reported a nearly 11 percent drop in quarterly revenue as a strong dollar and the sale of its consumer care business overshadowed strong demand for its diabetes drugs.
2015-07-28,12:00 PM,"UPDATE 1-Merck raises forecast on strong sales of diabetes, cancer drugs",July 28 Merck & Co Inc reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.
2015-07-28,11:25 AM,"Merck raises forecast on strong sales of diabetes, cancer drugs",Merck & Co Inc  reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.
2015-08-24,5:10 AM,German stocks - Factors to watch on August 24,"FRANKFURT/BERLIN, Aug 24 The DAX top-30 index  looked set to open 3.6 percent lower on Monday, according to premarket data from brokerage Lang & Schwarz at 0603 GMT."
2015-08-28,5:40 PM,FDA warns of severe joint pain risk with DPP-4 diabetes drugs,"Aug 28 A class of diabetes drugs that include Merck & Co Inc's Januvia have been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday."
2015-08-28,8:25 PM,UPDATE 1-FDA warns of severe joint pain risk with DPP-4 diabetes drugs,"Aug 28 A class of diabetes drugs that include Merck & Co Inc's Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday."
2015-08-28,5:40 PM,FDA warns of severe joint pain risk with DPP-4 diabetes drugs,"A class of diabetes drugs that include Merck & Co Inc's Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday."
2015-09-07,9:55 AM,UK backs use of Merck cancer immunotherapy after price discount,"LONDON, Sept 7 Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immunotherapy drug Keytruda, after the U.S. drugmaker promised to supply it to the state health service at a discounted price."
2015-09-07,10:00 AM,UK backs use of Merck cancer immunotherapy after price discount,"LONDON Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immunotherapy drug Keytruda, after the U.S. drugmaker promised to supply it to the state health service at a discounted price."
2015-09-08,12:03 PM,Judge nixes Apotex's former expert in new role for Merck,A Delaware federal judge has disqualified an expert retained by New Jersey-based drugmaker Merck & Co in patent litigation against two generic rivals because the expert previously helped defend Apotex Inc against Merck's lawsuit over the same drug.
2015-09-16,2:53 PM,Merck's once-weekly diabetes drug found effective in study,"Merck & Co said its experimental once-weekly diabetes drug was found to be as good as its blockbuster Januvia, which is taken once a day."
2015-09-17,6:15 PM,Advaxis therapy improves survival rates in cervical cancer patients,"Sept 17 Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments."
2015-09-17,6:30 PM,Advaxis therapy improves survival rates in cervical cancer patients,"Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments."
2015-09-17,4:50 PM,UPDATE 3-Lilly diabetes drug slashes deaths in patients with heart risk,"Sept 17 Eli Lilly and Co's new Jardiance pill slashed deaths by 32 percent in patients with type 2 diabetes at risk of heart attack and stroke, a finding that could make it a mainstay diabetes treatment and triple its use, according to researchers and analysts."
2015-09-25,5:35 AM,European Factors to Watch-Shares seen opening higher,"(Adds company news items)     LONDON, Sept 25 European stocks were seen opening higher on Friday, although the region's major indexes could still end the week with a loss following blows dealt to the market this week by an emissions test debacle at Volkswagen and new signs of a slowdown in China.     The prospect of a U.S interest rate rise has also weighed on equity markets, and Federal Reserve head Janet Yellen said late on Thursday that she expects the U.S. central bank to begi"
2015-09-25,5:15 AM,German stocks - Factors to watch on September 25,"FRANKFURT, Sept 25 The DAX top-30 index  looked set to open 1.7 percent higher on Friday, according to premarket data from brokerage Lang & Schwarz at 0605 GMT."
2015-09-25,6:25 AM,European Factors to Watch-Futures rise but markets could still have weekly loss,"(Adds futures prices, company news items)     LONDON, Sept 25 European equity futures rose on Friday, although the region's major indexes could still end the week with a loss following blows dealt to the market this week by an emissions test debacle at Volkswagen and new signs of a slowdown in China.     The prospect of a U.S interest rate rise has also weighed on equities, and Federal Reserve head Janet Yellen said late on Thursday she expects the U.S. central bank to begin raisi"
2015-09-28,6:15 AM,BRIEF-Merck KGaA says closing of Sigma-Aldrich takeover expected soon,* Says is progressing toward completion of Sigma - Aldrich acquisition
2015-09-28,12:20 PM,Merck's once-weekly diabetes drug approved in Japan,"Sept 28 Merck & CO said its Type 2 diabetes drug had been approved in Japan, marking the first approval for the once-weekly drug."
2015-09-28,12:20 PM,Merck's once-weekly diabetes drug approved in Japan,"Merck & CO said its Type 2 diabetes drug had been approved in Japan, marking the first approval for the once-weekly drug."
2015-10-01,1:21 PM,Corrected-Merck KGaA says avelumab alliance with Pfizer on track,"* Says it started investigating a novel, potential first-in- class bi-functional immunotherapy in clinical trials"
2015-10-02,6:01 PM,FDA approves Merck's Keytruda for use in lung cancer,"Oct 2 The U.S. Food and Drug Administration granted accelerated approval for Merck & Co's  immunotherapy, Keytruda, in patients with a form of lung cancer."
2015-10-02,6:45 PM,UPDATE 3-U.S. FDA expands approval of Merck's Keytruda to lung cancer,"Oct 2 The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker."
2015-10-02,6:15 PM,FDA expands approval of Merck's Keytruda to lung cancer,"The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker."
2015-10-08,1:01 AM,"REFILE-BRIEF-Bionomics announces extension of strategic collaboration with Merck & Co., Inc","(Corrects to add RIC in first bullet) Bionomics Ltd :  * Merck investment and pain partnership extended    * Merck &co., inc. to make US$9 million investment in Bionomics  * Says extended its strategic collaboration with Merck & co., inc., Kenilworth NJ  * Says separately, Merck & co., will also purchase 21.7 million ordinary shares at A$0.5938, a 29% premium to bionomics' closing price on 7 October 2015  * Says collaboration the discovery and development of drug candidates for the treatment of"
2015-10-14,12:31 AM,Ex-Merck employees gets 3 years in prison for insider trading,"NEW YORK, Oct 13 A former Merck & Co Inc  employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers."
2015-10-14,12:32 AM,Ex-Merck employees gets three years in prison for insider trading,NEW YORK A former Merck & Co Inc employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers.
2015-10-14,7:15 AM,Germany's Merck KGaA scraps unit brands,"FRANKFURT, Oct 14 Germany's Merck KGaA  said it would scrap its divisional brands Merck Serono and Merck Millipore and do business simply as Merck outside North America."
2015-10-14,8:15 AM,Germany's Merck KGaA scraps unit brands,FRANKFURT Germany's Merck KGaA said it would scrap its divisional brands Merck Serono and Merck Millipore and do business simply as Merck outside North America.
2015-10-14,9:00 PM,India risks missing boat as biosimilars shake up drug industry,"* Only a handful of Indian firms making biosimilars for US, EU"
2015-10-14,9:05 PM,India risks missing boat as biosimilars shake up drug industry,"MUMBAI India, which has dominated the generic drugs industry for decades, is falling behind in the race to make copies of complex biotech drugs, which are expected to generate tens of billions of dollars in sales in the coming years."
2015-10-14,12:37 AM,Ex-Merck employees gets 3 years in prison for insider trading,NEW YORK A former Merck & Co Inc  employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers.
2015-10-15,5:20 AM,BRIEF-Ablynx gets first milestone in immuno-oncology deal with Merck & Co.,"* Achieves first milestone in immuno-oncology collaboration with Merck & Co., Inc."
2015-10-20,10:56 AM,Merck clears major hurdle to Sigma-Aldrich takeover,"FRANKFURT, Oct 20 Merck has cleared a major anti-trust hurdle to its planned $17 billion acquisition of Sigma-Aldrich with the latter's agreed sale of assets to Honeywell, the German drugmaker said on Tuesday."
2015-10-20,11:00 AM,Merck clears major hurdle to Sigma-Aldrich takeover,"FRANKFURT Merck  has cleared a major anti-trust hurdle to its planned $17 billion acquisition of Sigma-Aldrich  with the latter's agreed sale of assets to Honeywell , the German drugmaker said on Tuesday."
2015-10-22,12:36 AM,Specialty pharmacies in spotlight as Valeant ties questioned,"LOS ANGELES, Oct 21 Investor concerns over accounting practices at Valeant Pharmaceuticals International Inc have put a spotlight on the little-known and fast-growing specialty pharmacy industry."
2015-10-26,3:01 PM,Merck's Keytruda extends survival in lung cancer study,Oct 26 Merck & Co's approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.
2015-10-26,3:06 PM,Merck's Keytruda extends survival in lung cancer study,Merck & Co's approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.
2015-10-27,10:57 AM,"Merck revenue down 5 pct, hurt by strong dollar",Oct 27 Drugmaker Merck & Co Inc reported a near 5 percent drop in quarterly revenue as a strong dollar offset strong demand for its diabetes drugs.
2015-10-27,1:31 PM,BRIEF-Merck says expects januvia to retain strong position as add-on diabetes therapy despite favorable data seen with lilly's rival jardiance,* Says januvia sales got a $100 million boost in third quarter from timing of customer buying
2015-10-27,11:40 AM,"UPDATE 3-Merck profit tops estimates on strong diabetes, cancer drug sales",Oct 27 Merck & Co Inc on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.
2015-10-27,10:58 AM,"Merck profit tops estimates on strong diabetes, cancer drug sales",Merck & Co Inc  on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.
2015-10-29,6:55 AM,Bayer adj EBITDA up 28 pct on new drugs,"FRANKFURT, Oct 29 German drugmaker Bayer  saw underlying core earnings gain 28 percent in the third quarter, bolstered by sales of new drugs and the purchase of Merck & Co's consumer health business."
2015-11-06,4:56 PM,Merck & Co under Pennsylvania Attorney's Office probe over pricing,"Nov 6 Merck & Co is being investigated by the U.S. Attorney's Office in Pennsylvania over contracting and pricing of its asthma inhaler product, Dulera, the company said."
2015-11-06,5:20 PM,"UPDATE 1-U.S. federal agencies investigate Merck, Lilly drug pricing","Nov 6 Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices, the companies disclosed."
2015-11-06,5:00 PM,"U.S. federal agencies investigate Merck, Lilly drug pricing","Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices, the companies disclosed."
2015-11-06,8:10 PM,"UPDATE 1-U.S. agencies investigate Merck, Lilly drug pricing","Nov 6 U.S. drugmakers Merck & Co and Eli Lilly & Co are being investigated by federal prosecutors over their drug-pricing practices, the companies disclosed."
2015-11-06,7:35 PM,UPDATE 2-FDA panel backs Merck & Co drug to reverse muscle relaxant effect,"Nov 6 Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval, an independent panel to the U.S. Food and Drug Administration said."
2015-11-06,5:01 PM,"U.S. agencies investigate Merck, Lilly drug pricing","U.S. drugmakers Merck & Co and Eli Lilly & Co are being investigated by federal prosecutors over their drug-pricing practices, the companies disclosed."
2015-11-06,7:40 PM,FDA panel backs Merck & Co drug to reverse muscle relaxant effect,"Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval, an independent panel to the U.S. Food and Drug Administration said."
2015-11-07,1:22 AM,"U.S. federal agencies investigate Merck, Lilly drug pricing","Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices, the companies disclosed."
2015-11-12,10:36 AM,"Germany, U.S. in hot pursuit of ""messenger"" drug molecules","FRANKFURT/LONDON, Nov 12 A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology."
2015-11-12,10:41 AM,"Germany, U.S. in hot pursuit of 'messenger' drug molecules","FRANKFURT/LONDON A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology."
2015-11-12,6:05 PM,U.S. appeals court invalidates four Merck Cubicin patents,"Nov 12 Drugmaker Merck & Co Inc said the U.S. Court of Appeals for the Federal Circuit invalidated four patents related to the antibiotic, Cubicin, that expire in 2019 and 2020."
2015-11-12,6:25 PM,Ex-BNY Mellon employee sentenced to 6 months in U.S. prison,"NEW YORK, Nov 12 A former Bank of New York Mellon Corp employee was sentenced on Thursday to six months in prison after admitting to illegally making $737,000 trading on tips a friend at Merck & Co Inc supplied him about potential pharmaceutical mergers."
2015-11-12,6:17 PM,U.S. appeals court invalidates four Merck Cubicin patents,"Drugmaker Merck & Co Inc said the U.S. Court of Appeals for the Federal Circuit invalidated four patents related to the antibiotic, Cubicin, that expire in 2019 and 2020."
2015-11-13,12:49 AM,Merck to buy Harrisvaccines to boost livestock vaccine portfolio,"CHICAGO, Nov 12 Merck & Co Inc's animal health unit will buy privately held Harrisvaccines Inc to expand its portfolio of animal vaccines as the U.S. livestock industry seeks new defenses against diseases, the companies said on Thursday."
2015-11-13,12:56 AM,Merck to buy Harrisvaccines to boost livestock vaccine portfolio,"CHICAGO Merck & Co Inc's animal health unit will buy privately held Harrisvaccines Inc to expand its portfolio of animal vaccines as the U.S. livestock industry seeks new defenses against diseases, the companies said on Thursday."
2015-11-13,1:13 PM,Panel recommends Merck continue cholesterol drug study,"Nov 13 Merck & Co said an independent data monitoring committee recommended that the company continue a study of its experimental cholesterol drug, anacetrapib."
2015-11-13,1:37 PM,UPDATE 1-Panel recommends Merck & Co continue cholesterol drug study,"Nov 13 Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib."
2015-11-13,1:37 PM,Panel recommends Merck & Co continue cholesterol drug study,"Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib."
2015-11-13,11:26 AM,Deals of the day-Mergers and acquisitions,"Nov 13 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:"
2015-12-14,9:11 AM,"BRIEF-Merck says acquires Ormet Circuits, no purchase price disclosed",* Merck says acquisition to enhance position as semiconductor materials supplier
2015-12-15,9:01 PM,FDA approves Merck drug to reverse effects of muscle relaxants,Dec 15 Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.
2015-12-15,9:05 PM,FDA approves Merck drug to reverse effects of muscle relaxants,Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.
2015-12-16,2:26 AM,FDA approves Merck drug to reverse effects of muscle relaxants,Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.
2016-01-07,7:10 AM,BRIEF-Biocartis Group announces collaboration with Merck,* Biocartis and Merck to collaborate on new liquid biopsy technology for ras biomarker testing  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)
2016-01-12,1:21 PM,"Merck, BioLineRX to study drug combo to fight pancreatic cancer","JERUSALEM, Jan 12 Israeli biopharmaceutical company BioLineRX Ltd said on Tuesday it would collaborate with U.S. industry heavyweight Merck to test a combination of drugs for the treatment of pancreatic cancer."
2016-01-12,1:36 PM,"Merck, BioLineRX to study drug combo to fight pancreatic cancer",JERUSALEM Israeli biopharmaceutical company BioLineRX Ltd said on Tuesday it would collaborate with U.S. industry heavyweight Merck to test a combination of drugs for the treatment of pancreatic cancer.
2016-01-15,2:42 PM,Merck agrees to pay $830 mln to settle Vioxx securities lawsuit,Jan 15 U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.
2016-01-15,2:42 PM,Merck agrees to pay $830 million to settle Vioxx securities lawsuit,U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.
2016-01-15,3:08 PM,Merck agrees to pay $830 mln to settle Vioxx securities lawsuit,U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.
2016-01-15,5:16 PM,Fight over Merck name sees German firm win in British court,"FRANKFURT, Jan 15 Germany's Merck KGaA  said it won a British court's backing in its quest to keep U.S. namesake drugmaker Merck & Co Inc from doing business under the Merck name outside North America, part of an increasingly bitter legal feud."
2016-01-15,5:16 PM,Fight over Merck name sees German firm win in British court,"FRANKFURT Germany's Merck KGaA said it won a British court's backing in its quest to keep U.S. namesake drugmaker Merck & Co Inc from doing business under the Merck name outside North America, part of an increasingly bitter legal feud."
2016-01-20,8:35 AM,Vaccines alliance signs $5 mln advance deal for Merck's Ebola shot,"DAVOS/LONDON, Jan 20 The Gavi global alliance for vaccines and immunisation group signed a $5 million advance purchase commitment on Wednesday to buy a vaccine being developed by Merck to protect against future outbreaks of the deadly Ebola virus."
2016-01-20,8:35 AM,Vaccines alliance signs $5 million advance deal for Merck's Ebola shot,DAVOS/LONDON The Gavi global alliance for vaccines and immunization group signed a $5 million advance purchase commitment on Wednesday to buy a vaccine being developed by Merck to protect against future outbreaks of the deadly Ebola virus.
2016-01-22,4:15 PM,Merck sees deal opportunities as biotech funding gets tighter,"DAVOS, Switzerland U.S. drugmaker Merck & Co is eager to do deals to bring in promising experimental medicines and believes a recent correction in biotechnology stocks should throw up new opportunities."
2016-01-28,9:48 PM,"Bristol-Myers set to lead earnings parade in 2016, beyond","Bristol-Myers Squibb Co  on Thursday positioned itself as a potential earnings pacesetter in 2016, with a forecast of up to 19 percent growth that eclipses profit gains expected by most other large drugmakers."
2016-01-28,11:13 PM,U.S. FDA approves Merck's new hepatitis C pill,Jan 28 U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc.
2016-01-29,11:18 PM,UPDATE 1-U.S. FDA approves Merck's new hepatitis C pill,"Jan 28 U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors."
2016-01-29,11:18 PM,FDA approves Merck's new hepatitis C pill,"U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors."
2016-01-29,6:40 PM,Payers see price leverage with entry of Merck hepatitis C drug,Jan 29 U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.
2016-02-03,12:00 PM,Merck revenue falls as dollar strengthens,"Feb 3 Merck & Co Inc reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment."
2016-02-03,2:15 PM,"BRIEF-Merck sees accelerating declines for Remicade, due to biosimilars","* Says it expects global Januvia/Janumet sales to rise in 2016, when excluding negative impact of strong dollar"
2016-02-03,11:59 AM,UPDATE 3-Merck gives cautious 2016 outlook as sales of top medicines lag,"Feb 3 Merck & Co Inc on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug, sending its shares down nearly 3 percent."
2016-02-03,11:59 AM,Merck gives cautious 2016 outlook as sales of top medicines lag,"Merck & Co Inc  on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug, sending its shares down nearly 3 percent."
2016-02-16,12:55 AM,Merck says U.S. FDA reject its claim that Zetia and Vytorin cut heart risk,Feb 15 Drugmaker Merck & Co Inc said the U.S. Food and Drug Administration declined to approve its claim that cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
2016-02-26,11:22 PM,Judge trims antitrust case against Merck over potassium drug,"A federal judge has narrowed an antitrust class action brought by drug wholesalers alleging that Schering-Plough Corp, now owned by Merck, paid generic rivals to stay out of the market for its potassium supplement K-Dur."
2016-03-07,7:12 AM,BRIEF-Neuron Bio designated as reference laboratory for Merck Millipore,* Has been designated as a reference laboratory for Merck Millipore for marketing of Milliplex technology used for biomarkers determination
2016-03-08,5:56 AM,German stocks - Factors to watch on March 8,"FRANKFURT, March 8 The DAX top-30 index  looked set to open 0.6 percent lower on Tuesday, according to premarket data from brokerage Lang & Schwarz at 0716 GMT."
2016-03-08,1:17 PM,Sanofi Pasteur and Merck end European vaccines venture,"PARIS, March 8 Sanofi said on Tuesday that it was ending its joint vaccines operations in Europe with U.S partner Merck in order to allow both companies to pursue different strategies."
2016-03-08,1:17 PM,UPDATE 1-Sanofi and Merck pull the plug on European vaccines venture,"PARIS, March 8 Sanofi SA and Merck & Co Inc said on Tuesday they were ending a 22-year-old joint venture to sell vaccines in Europe, arguing they would do better by managing their product portfolios independently."
2016-03-08,1:17 PM,Sanofi and Merck pull the plug on European vaccines venture,"PARIS Sanofi SA and Merck & Co Inc said on Tuesday they were ending a 22-year-old joint venture to sell vaccines in Europe, arguing they would do better by managing their product portfolios independently."
2016-03-22,9:30 PM,Merck patents on Hepatitis C treatment found valid in dispute with Gilead,"NEW YORK, March 22 A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C."
2016-03-22,9:51 PM,Merck patents on Hepatitis C treatment found valid in Gilead dispute,"SAN JOSE A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C."
2016-03-23,10:55 PM,UPDATE 3-Merck patents on Hepatitis C treatment found valid in Gilead dispute,"SAN JOSE, March 22 Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C."
2016-03-23,10:55 PM,Merck patents on Hepatitis C treatment found valid in Gilead dispute,SAN JOSE Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.
2016-03-24,12:00 AM,Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,"SAN JOSE, Calif., March 24 A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C."
2016-03-25,12:25 AM,UPDATE 3-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,"SAN JOSE, Calif.,/NEW YORK, March 24 A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C."
2016-03-25,12:25 AM,Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute,"SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc  to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C."
2016-03-25,12:36 AM,Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,"SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C."
2016-03-29,11:11 AM,Gilead says Merck 'deceitful' in hepatitis C drug patent fight,"Gilead Sciences Inc on Wednesday will attempt to wipe out $200 million in damages for infringing two Merck & Co patents with its blockbuster hepatitis C treatments by claiming that Merck was dishonest in obtaining the patents, an argument that attorneys say could be difficult to prove."
2016-04-11,10:40 PM,BRIEF-Merck & Co says CEO Kenneth C. Frazier's total compensation for 2015 was $24.2 MLN,* Merck & Co Inc says CEO Kenneth C. Frazier's total compensation for FY 2015 was $24.2 mln vs $25 mln in FY 2014 - SEC Filing
2016-04-14,7:51 AM,BRIEF-Merck launches Merck for Health project in partnership with H-farm,* Says Merck launches Merck for Health project in partnership with H-Farm  Source text for Eikon:
2016-04-18,12:20 PM,BRIEF-Merck receives breakthrough therapy designation from FDA for use of Keytruda in classical hodgkin lymphoma,"April 18 Merck Says  Fourth Designation For Keytruda Follows Breakthrough Status In Advanced Melanoma, Non"
2016-04-19,9:20 PM,BRIEF-Merck Animal Health to buy worldwide rights to Whisper Veterinary Stethoscope System,* Merck Animal Health to acquire worldwide rights to Whisper Veterinary Stethoscope System
2016-04-25,6:15 AM,BRIEF-Merck KGaA publishes Chinese Phase III study for Erbitux,* Says phase III tailor landmark study  demonstrates  significant  benefits of erbitux in combination  with  folfox over folfox alone
2016-04-27,10:05 PM,Merck sex discrimination case could be collective action -judge,April 27 A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.
2016-04-27,10:11 PM,Merck sex discrimination case could be collective action -judge,A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.
2016-04-27,10:10 PM,UPDATE 1-Merck sex discrimination case could be collective action -judge,April 27 A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.
2016-04-28,10:10 PM,Merck sex discrimination case could be collective action: judge,A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.
2016-05-05,11:00 AM,BRIEF-Merck Q1 earnings per share $0.40,* Q1 earnings per share view $0.85 -- Thomson Reuters I/B/E/S
2016-05-05,11:02 AM,"Merck sales disappoint as Januvia, Remicade fall short","Merck & Co Inc  on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug."
2016-05-05,12:55 PM,"RPT-UPDATE 2-Merck sales disappoint as Januvia, Remicade fall short","May 5 Merck & Co Inc on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug."
2016-05-05,1:10 PM,BRIEF-Merck says EU manufacturer of Zepatier cited for recordkeeping lapses,* Says on conference call that third party manufacturer of its new Zepatier hepatitis C drug cited by EU regulators for inadquate record keeping
2016-05-05,1:45 PM,BRIEF-Merck says EU Zepatier launch may be delayed,* Says European launch of its new Zepatier hepatitis C drug may may be delayed until late 2016 or 2017 after EU regulator cited inadequate record-keeping by a third party manufacturer  Source text for Eikon:  Further company coverage:    (Reporting by Ransdell Pierson)
2016-05-12,12:40 PM,BRIEF-Merck to present Phase 3 data on Ertugliflozin and MK-1293,* Merck to present Phase 3 data on investigational medicines Ertugliflozin and MK-1293 at the 76th scientific sessions of the American Diabetes Association  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)
2016-05-16,11:06 AM,Merck B vitamin formula patent invalid due to on-sale bar - Federal Circuit,"A Merck & Co patent on a crystallized form of a B vitamin is invalid because Merck offered to sell the formula to an American company in 1998, a federal appeals court has ruled, reversing a lower court judge."
2016-05-24,6:40 PM,BRIEF-Merck sets quarterly dividend of 46 cents per share,* Sets quarterly dividend of $0.46 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)
2016-05-27,12:00 PM,BRIEF-Merck receives positive CHMP opinion for Zepatier in the EU,* Merck receives positive CHMP opinion for Zepatier(tm) (Elbasvir and Grazoprevir) in the European Union  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)
2016-05-27,6:05 PM,BRIEF-Merck shareholder proposal for report on disposal of unused or expired drugs defeated,* Shareholder proposal requesting report on disposal of unused or expired drugs was defeated at annual meeting
2016-06-07,12:35 AM,Gileads escapes liability in hepatitis C patent fight with Merck,"NEW YORK, June 6 A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni."
2016-06-07,12:35 AM,UPDATE 2-Gilead escapes liability in hepatitis C patent fight with Merck,"NEW YORK, June 6 A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni."
2016-06-07,12:35 AM,Gilead escapes liability in hepatitis C patent fight with Merck,"NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni."
2016-06-07,1:06 AM,Gilead escapes liability in hepatitis C patent fight with Merck,"NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc  from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni."
2016-06-09,1:20 PM,BRIEF-Agenus announces lead product candidate selection in Merck collaboration,* Agenus announces lead product candidate selection in its collaboration with Merck
2016-06-09,9:35 PM,BRIEF-Merck to acquire Afferent Pharmaceuticals,* Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals
2016-06-09,8:30 PM,U.S. panel backs approval for Merck infectious diarrhea drug,"Merck & Co's experimental drug to treat the most common cause of hospital-associated infectious diarrhea warrants approval, an advisory panel to the U.S. Food and Drug Administration said on Thursday."
2016-06-16,10:50 AM,"BRIEF-Merck's Keytruda shows superior progression-free, overall survival in lung cancer patients",* Merck's keytruda (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer
2016-06-16,1:41 PM,Merck's Keytruda prolongs life in big lung-cancer study,"June 16 Advanced lung cancer patients who took Merck & Co's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday."
2016-06-16,1:41 PM,UPDATE 1-Merck's Keytruda prolongs life in big lung-cancer study,"June 16 Advanced lung cancer patients who took Merck & Co Inc's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday."
2016-06-16,1:41 PM,Merck's Keytruda prolongs life in big lung-cancer study,"Advanced lung cancer patients who took Merck & Co Inc's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday."
2016-06-20,4:51 PM,"BRIEF-Merck announces results of study of Relebactam, in combination with Imipenem/Cilastatin","* Phase 2 study of Relebactam, in combination with Imipenem/Cilastatin for complicated urinary tract infections met primary endpoint"
2016-06-27,10:26 AM,BRIEF-Merck receives CHMP positive opinion for Keytruda in advanced non-small cell lung cancer,* Merck receives chmp positive opinion for keytruda (pembrolizumab) for the treatment of advanced non-small cell lung cancer (nsclc)
2016-06-29,11:21 AM,"After hepatitis C patent win over Merck, Gilead faces other foes","Gilead Sciences Inc may have scored a dramatic and unexpected win over Merck & Co earlier this month in a patent dispute over the world's best-selling hepatitis C cure, but the war over this highly lucrative class of treatments has only just begun."
2016-06-29,11:35 AM,BRIEF-Merck and Moderna announce strategic collaboration,* Merck and Moderna announce strategic collaboration to advance novel MRNA-based personalized cancer vaccines with keytruda (pembrolizumab) for the treatment of multiple types of cancer  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)
2016-06-30,11:16 AM,3rd Circuit to weigh Fosamax warning lawsuits against Merck,"Lawyers for longtime users of an osteoporosis drug will ask a federal appeals court on Thursday to revive their claims that Merck & Co., Inc. waited too long to warn of the risk of unusual leg fractures associated with its use."
2016-06-30,1:30 PM,"BRIEF-Merck, Premier Inc collaborate to improve care for osteoporosis patients",* Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients
2016-07-01,5:40 PM,BRIEF-Merck Animal Health to buy controlling interest in Vallée S.A,"* Will acquire approximately 93 pct of shares of Vallée S.A. at closing, in exchange for a payment of $400 mln"
2016-07-07,11:11 AM,Merck appeals order reversing its $200 mln verdict against Gilead,Merck & Co has appealed a California federal judge's order that overturned a $200 million verdict it won in a patent case against Gilead Sciences over Gilead's lucrative hepatitis C drugs on the grounds that Merck engaged in extensive misconduct.
2016-07-07,12:40 PM,REFILE-BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial,* Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer
2016-07-11,11:30 AM,BRIEF- Merck's Healthcare invests majority stake in Staywell,* Merck's Healthcare Services & Solutions invests in majority stake in Staywell
2016-07-14,11:25 PM,UK charity pockets $150 mln from Merck cancer immunotherapy drug,"LONDON, July 15 British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research."
2016-07-14,11:25 PM,UK charity pockets $150 million from Merck cancer immunotherapy drug,"LONDON British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research."
2016-07-21,8:50 PM,BRIEF-Merck provides regulatory update on Biologics application,* Fda has requested submission of new data and analyses from modify I and modify II clinical trials previously submitted
2016-07-21,8:51 PM,Ruling invalidating Merck patent over on-sale bar stayed,U.S. Supreme Court Chief Justice John Roberts issued a stay on Thursday of an appeals court decision that would allow Actavis PLC to launch generic versions of Bayer AG's birth control drugs Safyral and Beyaz in response to an application from Bayer and Merck & Co.
2016-07-22,11:42 AM,BRIEF-Merck says EMA has accepted file for formulation of Isentress for review,* Says European Medicines Agency (EMA) has accepted file for investigational once-daily formulation of isentress for review
2016-07-25,1:20 PM,BRIEF-Merck designated breakthrough therapy by FDA and gets prime status from EMA for ebola vaccine,"* Merck is responsible for research, development, manufacturing, and regulatory efforts in support of v920"
2016-07-25,9:30 PM,BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck,"* Collaboration focused on qualification and validation of Tau imaging agent developed by Merck, MK-6240"
2016-07-26,6:20 PM,BRIEF-Merck sets quarterly dividend of $0.46 per share,* Sets quarterly dividend of $0.46 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)
2016-07-27,5:25 AM,BRIEF-Merck plans to end partnership agreement with Alk Abello,* Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement
2016-07-28,10:52 AM,Merck seeks to curb plaintiff firm's 'misleading' communications,"Merck & Co Inc has asked a New Jersey federal judge to order law firm Sanford Heisler, which is representing plaintiffs in a sex discrimination lawsuit against the company, to stop what it called misleading communications to potential class members."
2016-07-28,6:21 PM,UPDATE 1-U.S. probes contracts between Eli Lilly and PBMs,"July 28 Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs)."
2016-07-28,6:21 PM,U.S. probes contracts between Eli Lilly and PBMs,"Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs)."
2016-07-28,10:57 AM,"Gilead, Merck lock horns on legal fees in hepatitis C patent fight",Gilead Sciences Inc urged a California federal judge on Tuesday to not put off a decision on whether it is owed $15.5 million in legal fees in a patent fight over a lucrative cure for hepatitis C with drugmaker Merck & Co.
2016-07-29,10:50 AM,BRIEF-Merck Q2 adjusted earnings per share $0.93,"* Q2 januvia/janumet sales $ 1,634 million versus $1,412 million in q1"
2016-07-29,10:55 AM,Merck & Co reports 1 pct rise in quarterly revenue,"July 29 Merck & Co Inc reported a 1 percent rise in quarterly revenue, driven by higher sales of its cancer drug, Keytruda."
2016-07-29,11:01 AM,"UPDATE 2-Merck quarterly results beat forecasts, shares rise","July 29 Merck & Co reported better-than-expected quarterly earnings, fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment, sending its shares up 2 percent in premarket trading."
2016-07-29,11:01 AM,"Merck quarterly results beat forecasts, shares rise","Merck & Co  reported better-than-expected quarterly earnings, fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment, sending its shares up 2 percent in premarket trading."
2016-08-01,7:31 AM,Nanoco signs deal with Merck for use of quantum dot technology,"Aug 1 British quantum dots maker Nanoco Group Plc said it had entered into a non-exclusive licence deal with Merck for the German drugmaker to use its technology in digital displays, sending its shares up as much as 10 percent."
2016-08-01,9:46 PM,Merck motion to bar plaintiff firm's communications denied as moot,"A federal judge has declined to bar the plaintiffs' firm Sanford Heisler from soliciting potential collective action members in a sex discrimination lawsuit against Merck & Co Inc after the firm said it is not planning any more communications to solicit members, denying a motion on Friday by the drugmaker as moot."
2016-08-02,6:50 PM,BRIEF-Biogen has drawn takeover interest from drug companies including Merck & Co and Allergan - WSJ,"* Biogen has drawn takeover interest from drug companies including Merck & Co and Allergan Plc- WSJ, citing sources  Source (http://on.wsj.com/2b0s6q9)   (Bengaluru Newsroom: +1-646-223-8780)"
2016-08-02,7:00 PM,"REFILE-Biogen draws takeover interest from Merck, Allergan - WSJ","Aug 2 Biotechnology giant Biogen Inc  has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc, the Wall Street Journal reported, citing people familiar with the matter."
2016-08-02,10:37 AM,Deals of the day- Mergers and acquisitions,"Aug 2 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:"
2016-08-02,11:51 AM,US STOCKS-Wall St falls as weak auto sales spur growth jitters,"* Indexes down: Dow 0.49 pct, S&P 0.64 pct, Nasdaq 0.9 pct   (Updates to market close)"
2016-08-02,11:51 AM,Wall St. falls as weak auto sales spur growth jitters,"NEW YORK Wall Street stocks fell on Tuesday, with each of the major indexes notching their worst day in about a month as economic data and weaker-than-expected auto sales spurred concerns about growth."
2016-08-02,9:55 PM,BRIEF-European Commission approves Merck's anti-PD-1 therapy KEYTRUDA,* Merck's KEYTRUDA (pembrolizumab) approved by the European Commission for patients with advanced non-small cell lung cancer (nsclc) whose tumors express pd-l1  Source text for Eikon:  Further company coverage:
2016-08-03,10:05 AM,Deals of the day-Mergers and acquisitions,"Aug 3 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:"
2016-08-05,12:19 PM,BRIEF-Merck announces U.S. FDA filing acceptance of new drug application (NDA) for mk-1293,Aug 5 Merck Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Mk
2016-08-05,2:43 PM,"AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes","LONDON AstraZeneca  shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker."
2016-08-05,1:34 PM,UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge,"Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's  rival medicine."
2016-08-05,1:34 PM,Bristol-Myers' Opdivo fails lung cancer trial; shares plunge,"Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's rival medicine."
2016-08-08,12:00 AM,CORRECTED-BRIEF-Merck & Co says FDA approves Keytruda for a type of head and neck cancer (Aug 5),"* Based on its mechanism of action, Keytruda can cause fetal harm when administered to a pregnant woman"
2016-08-12,12:45 AM,Gilead to get attorney fees in hepatitis C patent fight with Merck,"Aug 11 Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled."
2016-08-12,12:45 AM,Gilead to get attorney fees in hepatitis C patent fight with Merck,"Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled."
2016-08-12,12:46 AM,Gilead to get attorney fees in hepatitis C patent fight with Merck,"Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled."
2016-08-24,3:30 PM,BRIEF-Biothera Pharmaceuticals expands relationship with Merck,"* Biothera pharmaceuticals expands relationship with Merck, enters collaboration for combination cancer immunotherapy trials in multiple indications  Source text for Eikon:  Further company coverage:"
2016-08-30,12:21 AM,Judge invalidates Merck's NuvaRing patent claims,"A federal judge in Delaware has struck down Merck & Co's patent infringement claims against Actavis' Warner Chilcott unit, which is seeking to sell a generic version of the NuvaRing contraceptive."
2016-09-02,11:16 AM,REFILE-Merck aborts development of osteoporosis drug due to stroke risk,Sept 2 Merck & Co Inc said it would cease the development of its experimental osteoporosis drug after an independent analysis confirmed that the therapy was associated with an increased risk of stroke.
2016-09-02,11:40 AM,BRIEF-Merck provides update on odanacatib development program,* To discontinue development after independent adjudication of major adverse cardiovascular events confirmed an increased risk of stroke
2016-09-02,11:30 AM,UPDATE 1-Merck scraps development of osteoporosis drug due to stroke risk,Sept 2 Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.
2016-09-02,11:30 AM,Merck scraps development of osteoporosis drug due to stroke risk,Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.
2016-09-07,12:55 PM,"BRIEF-Aralez acquires U.S., Canadian rights to Zontivity from Merck",* Aralez acquires united states and canadian rights to Zontivity from Merck
2016-09-15,1:00 PM,"BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint",* Merck and pfizer announce investigational Ertugliflozin met primary endpoint of A1C reduction when added to Sitagliptin and Metformin in people with type 2 diabetes
2016-09-16,10:45 AM,BRIEF-Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis,* Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis
2016-09-19,5:10 AM,BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar,* Files suit in  U.S. To defend paten rights on Lantus and Lantus Solostar
2016-09-20,5:54 AM,UPDATE 1-Bayer raises sales targets for top-selling drugs after Monsanto deal,"* Bayer shares seen 1.5 pct higher   (Adds consumer care unit target, analyst comment, premarket share price)"
2016-09-20,6:05 AM,BRIEF-Bayer says Merck & Co integration disrupts business more than expected,* Bayer says had underestimated risk from emerging markets volatility related to purchase of merck & co consumer care business
2016-09-27,11:45 AM,Bristol-Myers to test Opdivo with Nektar drug for several cancers,Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.
2016-10-07,10:51 AM,Merck asks justices to change how Federal Circuit reviews PTO trials,The U.S. Supreme Court on Friday will consider a bid by drugmaker Merck & Co to change how a federal appeals court reviews decisions on patent validity made by the U.S. Patent and Trademark Office.
2016-10-09,6:15 AM,Merck drug shines in lung cancer and also works with chemo,* Keytruda cuts risk of death 40 pct in big lung cancer study
2016-10-09,6:20 AM,"'New day' in lung cancer as Merck drug shines, works with chemo","COPENHAGEN Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy."
2016-10-10,3:51 PM,UPDATE 1-Bristol lung-cancer setback puts rival Merck drug in driver seat,"Oct 10 New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday."
2016-10-10,10:06 PM,Judge upholds Merck antibiotic patents against Hospira challenge,"A Delaware federal judge has invalidated Merck & Co Inc patent claims on its antibiotic Invanz in a challenge from rival Hospira Inc, which is seeking to sell a generic version of the drug."
2016-10-11,3:51 PM,Bristol lung-cancer setback puts rival Merck drug in driver seat,"New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday.    The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent.    The data, presented at a medical meeting on Sunday, showed that lung cancer patients fared worse on Opdivo than those on chemotherapy. Merck shares rose nearly 2 percent on stron"
2016-10-11,1:50 PM,BRIEF-Aetna and Merck sign a contract for Januvia and Janumet,* Aetna and Merck sign a unique value-based contract for Januvia and Janumet
2016-10-12,5:06 AM,BRIEF-Ablynx extends research collaboration with Merck & Co,* Ablynx announces second extension of its Ion channel research collaboration with Merck & Co
2016-10-19,11:20 AM,BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint,"* Merck announces pivotal phase 3 study of letermovir, an investigational antiviral medicine for prevention of cytomegalovirus (cmv) infection in high-risk bone marrow transplant patients, met primary endpoint"
2016-10-19,11:50 AM,UPDATE 1-Merck's antiviral drug meets main goal in late-stage trial,Oct 19 Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.
2016-10-19,11:50 AM,Merck's antiviral drug meets main goal in late-stage trial,Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.
2016-10-20,5:30 AM,UPDATE 2-Roche bets on new cancer drugs to offset patent expiries,"* Keeps full-year outlook   (Adds CEO, analyst comment, updates shares)"
2016-10-20,1:00 PM,EU mergers and takeovers (Oct 20),"BRUSSELS, Oct 20 The following are mergers under review by the European Commission and a brief guide to the EU merger process:"
2016-10-20,11:50 AM,BRIEF-Advaxis initiates combination portion of phase 1/2 study with Merck,* Advaxis initiates combination portion of phase 1/2 study with Merck
2016-10-21,11:35 AM,BRIEF-Merck's bladder cancer drug meets primary endpoint and stops early,* Merck's keynote-045 studying Keytruda (pembrolizumab) in advanced bladder cancer (urothelial cancer) meets primary endpoint and stops early
2016-10-21,11:10 AM,UPDATE 1-Merck's Keytruda succeeds in key bladder cancer trial,"Oct 21 Merck & Co Inc said its immunotherapy, Keytruda, helped previously treated patients with advanced bladder cancer live longer in a late-stage study, prompting an independent monitoring panel to recommend stopping the trial early."
2016-10-21,11:10 AM,Merck's Keytruda succeeds in key bladder cancer trial,"Merck & Co Inc said its immunotherapy, Keytruda, helped previously treated patients with advanced bladder cancer live longer in a late-stage study, prompting an independent monitoring panel to recommend stopping the trial early."
2016-10-24,6:25 AM,UPDATE 1-GSK files potential $1 bln shingles vaccine for U.S. approval,"* Consensus forecasts point to $1.05 billion sales in 2021   (Adds sales forecast, background on rival vaccines)"
2016-10-24,4:35 PM,EU mergers and takeovers (Oct 24),"BRUSSELS, Oct 24 The following are mergers under review by the European Commission and a brief guide to the EU merger process:"
2016-10-24,10:15 PM,BRIEF-Merck & Co says FDA also approves a labeling update for Keytruda for treatment of patients with metastatic NSCLC,* FDA approves Merck's KEYTRUDA (pembrolizumab) in metastatic NSCLC for first-line treatment of patients whose tumors have high PD-l1 expression (tumor proportion score  of 50 percent or more) with no EGFR or ALK genomic tumor aberrati
2016-10-25,2:21 AM,U.S. FDA approves Merck's lung cancer drug as first-line treatment,"Oct 24 Merck & Co Inc on Monday said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment."
2016-10-25,10:25 AM,EU mergers and takeovers (Oct 25),"BRUSSELS, Oct 25 The following are mergers under review by the European Commission and a brief guide to the EU merger process:"
2016-10-25,10:55 AM,Merck reports 19.6 pct jump in quarterly profit,"Oct 25 - Merck & Co Inc reported a 19.6 percent rise in quarterly net profit, driven primarily by higher demand for its new cancer drug Keytruda."
2016-10-25,11:25 AM,BRIEF-Merck & Co Q3 non-gaap EPS $1.07,Oct 25 Merck & Co Inc :    Q3 non-gaap earnings per share $1.07
2016-10-25,10:56 AM,"Merck quarterly revenue beats, raises full-year forecast","Merck & Co Inc  reported better-than-expected quarterly revenue due to higher sales of its vaccines and cancer drug Keytruda, which won an early U.S. approval on Monday for use in previously untreated lung cancer patients."
2016-10-25,10:56 AM,UPDATE 3-Merck predicts lung cancer dominance for Keytruda immunotherapy,"NEW YORK, Oct 25 - Merck & Co on Tuesday declared its intention to dominate the large and lucrative lung cancer market, bolstered by a significant expansion of approved U.S. uses for its drug that helps the immune system attack tumors."
2016-10-26,5:35 PM,BRIEF-Merck prices EUR 1 bln debt offering,* priced a EUR 1.0 billion public offering of two series of euro-denominated senior unsecured notes
2016-10-27,5:35 PM,Fitch Rates Merck's Euro Notes Offering 'A',"(The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) Fitch Ratings has assigned an 'A' rating to Merck &  Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows  at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies, an advancing pipeline and manageable patent  expiries should support intermediate- to long-term growth.  --Fitch believes that Merck will pursu"
2016-10-27,9:20 PM,Correction: Fitch Rates Merck's Euro Notes Offering 'A',"(The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) (This is a correction of a release issued Oct. 27,  2016. It clarifies that Merck's existing ratings were not affirmed as was stated  in the original release.)  Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro  notes offering. A complete list of ratings follows at the end of this press  release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently intr"
2016-11-04,7:45 PM,UPDATE 5-Drugmakers under fire for possible U.S. price fixing,"Nov 3 Two prominent U.S. lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co, Merck & Co Inc  and Novo Nordisk A/S colluded to set prices for insulin and other diabetes drugs."
2016-11-11,6:25 PM,BRIEF-Biothera Pharma's announces new preclinical data on its immunotherapy drug,"* Biothera Pharmaceuticals' preclinical data further validate mechanism of its Phase 2 cancer immunotherapy, Imprime PGG"
2016-11-14,12:20 PM,BRIEF-OpGen collaborates with Merck to develop rapid diagnostics and informatics tools to help combat antimicrobial resistance,"* OpGen Inc - entered into research collaboration with Merck to develop rapid diagnostics, it products to help combat threat of antimicrobial resistance  Source text for Eikon:  Further company coverage:"
2016-11-15,10:05 AM,BRIEF-Merck sees continued price pressure for Erbitux in the EU,* CEO says price pressure and competition for Erbitux in the EU will continue  Further company coverage:
2016-11-17,10:06 PM,Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial,"Gilead Sciences Inc has lost a bid to invalidate two Merck & Co patents on hepatitis C treatments, which Merck claims are infringed by Gilead's blockbuster Harvoni and Sovaldi."
2016-11-22,6:25 PM,BRIEF-Merck raises quarterly dividend to $0.47/share from $0.46/share,"* Increased quarterly dividend to $0.47 per share, up $0.01 from $0.46 per outstanding share paid last quarter  Source text for Eikon:  Further company coverage:"
2016-11-28,12:21 PM,"Gilead, Merck to face off before jury over hepatitis C drug patents","Early next month, Gilead Sciences Inc will try to convince a federal jury in Delaware that a Merck & Co patent on hepatitis C drugs is invalid."
2016-11-28,12:45 PM,BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda,* FDA grants priority review to Merck's supplemental biologics license application (SBLA) seeking approval for Keytruda(pembrolizumab) for new indication in microsatellite instability-high cancer  Source text for Eikon:  Further company coverage:
2016-12-02,12:15 AM,Merck wins UK okay for Keytruda in lung cancer after price cut,"LONDON Britain's healthcare cost-effectiveness watchdog NICE has recommended use of Merck's immunotherapy drug Keytruda in certain lung cancer patients, after the U.S. drugmaker cut the price further for the state-run health service."
2016-12-15,9:58 PM,Merck wins $2.54 billion in hepatitis C drug trial against Gilead,Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.
2017-01-09,1:26 PM,BRIEF-Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda,* Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda (pembrolizumab)
2017-01-10,9:23 PM,BRIEF-Merck & Co Inc gets FDA acceptance of supplemental biologics license application for Keytruda in combination with chemotherapy,* Merck receives fda acceptance of supplemental biologics license application for keytruda (pembrolizumab) in combination with chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
2017-01-10,11:13 PM,FDA accepts Merck application for lung cancer combo therapy,"Jan 10 Merck & Co on Tuesday said the FDA agreed to a speedy review of its application to combine its immunotherapy drug Keytruda with chemotherapy as an initial treatment for advanced lung cancer, potentially giving it a major leg up in the competition for the largest cancer market."
2017-01-11,11:56 AM,BRIEF-Eli Lilly and Merck expand immuno-oncology collaboration,* Eli Lilly and co - financial details of collaboration were not disclosed.
2017-01-11,11:28 PM,UPDATE 2-Merck leapfrogs rivals in lung cancer drug combination race,"* Move may put Merck ahead of AstraZeneca, Roche and Bristol   (Updates shares)"
2017-01-11,12:27 PM,"US STOCKS-Wall Street ends choppy session higher, health lags on Trump comments",* Trump criticism helps snaps six-day rally for health stocks
2017-01-11,11:28 PM,Merck leapfrogs rivals in lung cancer drug combination race,"Merck & Co has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer, potentially giving it a major lift in the battle for the largest cancer market."
2017-01-19,4:12 PM,Merck CEO sees Keytruda in pole position in cancer race,"DAVOS, Switzerland Merck & Co's Keytruda cancer drug, which last week won a speedy review from U.S. regulators for use with chemotherapy in lung cancer, is in an increasingly strong position in a fiercely competitive market, the company's CEO said on Thursday."
2017-01-20,9:07 PM,BRIEF-Merck announces license agreement resolving Keytruda patent litigation,* Merck announces settlement and license agreement resolving Keytruda (pembrolizumab) patent litigation
2017-01-20,9:25 PM,"Merck, Bristol-Myers agree to settle Keytruda patent suit","Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve a patent litigation related to its cancer drug, Keytruda."
2017-01-20,9:30 PM,US STOCKS-Wall St ends higher as Trump takes office,"NEW YORK, Jan 20 U.S. stocks closed higher on Friday in a modest but broad-based advance as Donald Trump was sworn in as U.S. President, marking the first time in more than 50 years that a new commander-in-chief has been welcomed by a rising equity market on his first day in office."
2017-01-20,5:14 PM,"UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead","New YORK, Jan 20 Bristol-Myers Squibb Co  shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field."
2017-01-20,5:14 PM,"Bristol-Myers lung cancer delay slams shares, keeps Merck in lead","New YORK Bristol-Myers Squibb Co  shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's  leading position in the burgeoning immuno-oncolgy field."
2017-01-20,10:25 PM,"UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit","Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda."
2017-01-20,10:25 PM,"Merck, Bristol-Myers agree to settle Keytruda patent suit","Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda."
2017-01-20,10:31 PM,"Merck, Bristol-Myers agree to settle Keytruda patent suit","Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co  and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda."
2017-01-23,10:41 AM,BRIEF-Ono Pharmaceutical reaches settlement with Merck and signs license agreement,"* Says the co and BMS reached settlement and signed license agreement with Merck for patent infringement lawsuit against Merck, regarding anti-PD-1 antibody"
2017-01-27,11:11 AM,Roche cancer drug taking bite out of Bristol's Opdivo,"ZURICH, Jan 27 Roche's cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co  but the Swiss drugmaker's treatment is making up lost ground."
2017-01-27,11:11 AM,Roche cancer drug taking bite out of Bristol's Opdivo,ZURICH Roche's cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker's treatment is making up lost ground.
2017-01-27,7:09 PM,Merck reveals 7 years of its U.S. drug price increase history,Jan 27 Merck & Co on Friday posted seven years of information showing a high single-digit percentage annual average price hike across its portfolio of medicines in a move that provides new details on its pricing practices for the U.S. market.
2017-01-27,7:09 PM,Merck reveals seven years of its U.S. drug price increase history,Merck & Co  on Friday posted seven years of information showing a high single-digit percentage annual average price hike across its portfolio of medicines in a move that provides new details on its pricing practices for the U.S. market.
2017-01-31,4:37 PM,U.S. securities class actions soar to two-decade high,"Jan 31 U.S. securities class actions have soared to a two-decade high, topping levels during the financial crisis, after a landmark January 2016 ruling meant to deter lawsuits in Delaware that accomplish nothing for shareholders sent many lawyers scurrying instead to federal courts."
2017-01-31,4:38 PM,U.S. securities class actions soar to two-decade high,"U.S. securities class actions have soared to a two-decade high, topping levels during the financial crisis, after a landmark January 2016 ruling meant to deter lawsuits in Delaware that accomplish nothing for shareholders sent many lawyers scurrying instead to federal courts."
2017-01-31,9:27 PM,BRIEF-European Commission approves Keytruda for first-line treatment of patients with metastatic non-small cell lung cancer,* European Commission approves Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-l1 expression with no EGFR or ALK positive tumor mutations
2017-02-02,11:55 AM,BRIEF-Merck Q4 adjusted earnings per share $0.89,* Merck announces fourth-quarter and full-year 2016 financial results
2017-02-02,11:57 AM,Merck's quarterly sales slip 1 pct,"Feb 2 - Merck & Co Inc reported a 1 percent drop in quarterly sales, hurt by a strong dollar and the loss of market exclusivity on certain drugs."
2017-02-02,2:12 PM,BRIEF-Merck CEO says business development a priority,* Merck & Co CEO says business development a priority with focus on augmenting early and mid-stage pipeline
2017-02-02,12:02 PM,UPDATE 3-Merck 2017 forecast reassuring; full-speed ahead with Keytruda,"Feb 2 Merck & Co Inc, faced with patent expirations and increasing development costs for its high-profile Keytruda cancer immunotherapy, reassured investors on Thursday with a 2017 profit forecast roughly in line with Wall Street expectations."
2017-02-02,12:02 PM,Merck 2017 forecast reassuring; full-speed ahead with Keytruda,"Merck & Co Inc , faced with patent expirations and increasing development costs for its high-profile Keytruda cancer immunotherapy, reassured investors on Thursday with a 2017 profit forecast roughly in line with Wall Street expectations. | Video"
2017-02-03,11:50 AM,BRIEF-Merck says FDA accepts two SBLAs for Keytruda,* FDA accepts two SBLAs for Merck's Keytruda (pembrolizumab) for locally advanced or metastatic urothelial cancer in cisplatin-ineligible first-line and second-line post-platinum failure treatment settings
2017-02-06,1:00 PM,"BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies",* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug
2017-02-13,10:17 PM,BRIEF-Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing,"* Capital World Investors reports 5.1 percent passive stake in Merck & Co Inc as on December 30, 2016 - SEC Filing  Source text: [http://bit.ly/2kkIx8A] Further company coverage:"
2017-02-14,9:42 PM,BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial,"* Merck's doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial"
2017-02-14,10:27 PM,BRIEF-Merck announces Epoch study of Verubecestat,* Merck announces epoch study of verubecestat for the treatment of people with mild to moderate alzheimer's disease to stop for lack of efficacy
2017-02-14,11:06 PM,Merck to halt study of mild to moderate Alzheimer's drug,Feb 14 Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.
2017-02-14,11:12 PM,UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails,"Feb 14 Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease."
2017-02-14,11:12 PM,Merck stopping late stage study as another Alzheimer's drug fails,"Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease."
2017-02-23,2:21 PM,"BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda",* Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and mercks keytruda® (pembrolizumab)
2017-02-23,6:55 PM,Merck drug prevents serious infection after marrow transplant: study,"An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with placebo in a late state study, the company said."
2017-02-23,10:56 PM,BRIEF-Merck to record $2.9 bln impairment charge related to uprifosbuvir program - SEC filing,"* On Feb 17, determined that it will record intangible asset impairment charge related to research program for MK-3682, uprifosbuvir - SEC filing"
2017-02-24,9:04 PM,BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases,"* In first phase 3 trial, Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects"
2017-02-28,4:52 PM,UK rejects Merck's Keytruda as initial treatment for lung cancer,"LONDON, Feb 28 Britain's healthcare watchdog NICE, which assesses the cost-effectiveness of medical treatments, has stopped short of recommending the use by the National Health Service (NHS) of Merck & Co Inc's immunotherapy drug Keytruda in newly diagnosed lung cancer patients, after giving the go-ahead in December for patients who had prior treatment."
2017-02-28,4:52 PM,UK rejects Merck's Keytruda as initial treatment for lung cancer,"LONDON Britain's healthcare watchdog NICE, which assesses the cost-effectiveness of medical treatments, has stopped short of recommending the use by the National Health Service (NHS) of Merck & Co Inc's immunotherapy drug Keytruda in newly diagnosed lung cancer patients, after giving the go-ahead in December for patients who had prior treatment."
2017-02-28,6:49 PM,BRIEF-Merck sets quarterly dividend of $0.47/share,* Sets quarterly dividend of $0.47 per share  Source text for Eikon:  Further company coverage:
2017-03-06,1:34 PM,BRIEF-Merck and pfizer announce U.S. Fda and EMA filing acceptances,* Merck and Pfizer announce U.S. Fda and EMA filing acceptances of 3 marketing applications for ertugliflozin-containing medicines for adults with type 2 diabetes
2017-03-14,8:51 PM,BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA® (pembrolizumab),* Merck provides update on supplemental biologics license application (sbla) for keytruda® (pembrolizumab) in previously treated advanced microsatellite instability-high cancer
2017-03-14,9:21 PM,BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma,"* FDA approves Merck's Keytruda® (pembrolizumab) for adult and pediatric patients with classical hodgkin lymphoma (chl) refractory to treatment, or who have relapsed after three or more prior lines of therapy"
2017-03-14,10:31 PM,Merck's Keytruda wins FDA nod for treating blood cancer,March 14 Merck & Co Inc said on Tuesday it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer.
2017-03-14,10:31 PM,Merck's Keytruda wins FDA nod for treating blood cancer,Merck & Co Inc said on Tuesday it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer.
2017-03-22,12:34 PM,BRIEF-U.S. appeals court revives claims against Merck over Fosamax,March 22 U.S. Appeals Court Revives Hundreds Of Claims Alleging Merck & Co
2017-03-22,12:48 PM,U.S. appeals court revives Fosamax warning claims against Merck,March 22 A federal appeals court on Wednesday revived hundreds of claims by plaintiffs who accused Merck & Co  of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.
2017-03-22,12:58 PM,UPDATE 3-Merck must face renewed Fosamax warning claims -U.S. appeals court,March 22 A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.
2017-03-22,12:58 PM,Merck must face renewed Fosamax warning claims: U.S. appeals court,A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.
2017-03-22,8:37 PM,U.S. appeals court revives Fosamax warning claims against Merck,A federal appeals court on Wednesday revived hundreds of claims by plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.
2017-03-23,9:23 PM,Merck employee's relative settles SEC insider trading case,"A Pennsylvania foot doctor has agreed to pay nearly $123,000 to resolve charges he traded on inside information he received from a relative working at Merck & Co Inc about a planned merger, U.S. securities regulators said on Thursday."
2017-03-24,1:14 PM,BRIEF-European Medicines Agency's CHMP recommends approval of Merck's keytruda,* European Medicines Agency's CHMP recommends approval of Merck's keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical hodgkin lymphoma
2017-03-31,11:12 AM,BRIEF-Incyte and Merck provide additional details on previously announced collaboration,* Incyte and Merck provide additional details on previously announced collaboration investigating epacadostat and Keytruda® (pembrolizumab)
2017-04-06,9:20 PM,Merck seeks to reverse ruling reviving Fosamax injury lawsuits,Merck & Co Inc is urging a U.S. appeals court to reconsider a ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.
2017-04-07,11:45 AM,BRIEF-Merck receives complete response letter from the FDA for Tecos study with sitagliptin,* Merck receives complete response letter from the U.S. FDA for Tecos study with Sitagliptin
2017-04-07,11:55 AM,FDA rejects Merck's application to add heart safety data on diabetes drug labels,April 7 Merck & Co said the U.S. Food and Drug Administration declined an application to include information on the labels of its diabetes drugs that the treatments do not raise the risk of major heart problems.
2017-04-07,12:10 PM,FDA rejects Merck's application to add heart data on diabetes drug labels,Merck & Co said the U.S. Food and Drug Administration declined an application to include information on the labels of its diabetes drugs - Januvia and Janumet - that the treatments  do not raise the risk of major heart problems.
2017-04-07,12:10 PM,UPDATE 2-FDA rejects Merck's bid to add heart data on diabetes drug labels,April 7 Merck & Co Inc said the U.S. Food and Drug Administration (FDA) declined an application to include information on the labels of its diabetes drugs - Januvia and Janumet - that the treatments do not raise the risk of major heart problems.
2017-04-10,8:58 PM,BRIEF-Merck says board of directors to have 13 members,* Dr. John H. Noseworthy nominated to stand for election to Merck board of directors
2017-04-10,9:03 PM,BRIEF-Merck & Co Inc's CEO's 2016 total compensation was $21.8 mln,* Merck & Co Inc - CEO Kenneth C. Frazier's 2016 total compensation was $21.8 million versus $24.2 million
2017-04-11,5:55 AM,BRIEF-KYORIN Holdings unit gets license from Merck for drug KRP-114V,"* Says its pharma unit receives license from US firm Merck & Co Inc for drug KRP-114V, a treatment for overactive bladder, owning exclusive rights to develop and commercialize in Asian area"
2017-04-11,11:21 AM,BRIEF-Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study,* Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study evaluating immunovaccine's DPX-survivac with Merck's pembrolizumab
2017-04-17,8:29 PM,BRIEF-Aurinia completes licensing deal with Merck Animal Health,* Aurinia completes licensing deal with Merck Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome
2017-04-21,12:32 PM,BRIEF-Atara bio announces collaboration with Merck,* Atara Bio announces collaboration with Merck to evaluate keytruda (pembrolizumab) in combination with ATA129 in nasopharyngeal carcinoma (NPC)
2017-04-21,2:36 PM,BRIEF-Merck reports results from real-world observational study in U.S. Veterans Affairs System evaluating use of ZEPATIER,* Real-World observational study in the U.S. Veterans Affairs System evaluating use of MerckS ZEPATIER® (Elbasvir and Grazoprevir) shows high sustained virologic response rates in patients with chronic Hepatitis C
2017-04-24,11:16 AM,BRIEF-PDL BioPharma announces settlement of Keytruda lawsuit with Merck,* PDL BioPharma announces settlement of Keytruda patent infringement lawsuit with Merck
2017-04-24,9:38 PM,Merck to pay PDL BioPharma $19.5 million to settle patent lawsuit,Merck & Co Inc has agreed to pay $19.5 million to resolve a lawsuit claiming its cancer immunotherapy drug Keytruda infringed a patent held by PDL BioPharma Inc.
2017-04-26,2:44 PM,"Fitch: Fresenius Deals Offer Growth, Diversification; No Rating Impact","(The following statement was released by the rating agency) LONDON, April 26 (Fitch) Fitch Ratings says transactions by German healthcare group Fresenius SE & Co KGaA (FSE; BBB-/Stable) - including Fresenius Medical Care AG & Co. KGaA (FMC; together, Fresenius) - that enable its diversification into US generics through Akorn and biosimilars through Merck, will enhance its business risk profile. The group is well anchored in investment-grade territory, although the transactions will exhaust any f"
2017-04-26,8:14 PM,FDA approves Impax generic of Merck's cholesterol drug Vytorin,"April 26 The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck & Co's cholesterol-reducing drug Vytorin, the first cheap competitor for a drug that in 2016 generated more than $1 billion in sales."
2017-04-26,8:19 PM,"UPDATE 1-Merck cholesterol drug Vytorin faces competition from Impax, Teva generics",April 26 Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.
2017-04-26,8:19 PM,"Merck cholesterol drug Vytorin faces competition from Impax, Teva generics",Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.
2017-04-27,11:16 AM,BRIEF-Syndax Pharmaceuticals announces expansion ongoing phase 2 collaboration with Merck unit,"* Syndax Pharmaceuticals announces expansion of encore 601/keynote 142, ongoing phase 2 clinical collaboration with a subsidiary of Merck"
2017-05-02,5:12 PM,UPDATE 3-AstraZeneca immunotherapy wins first approval in bladder cancer,"* AstraZeneca sets durvalumab price at $15,000/month (Adds analyst reaction, sales forecast, latest shares)"
2017-05-02,5:12 PM,AstraZeneca immunotherapy wins first approval in bladder cancer,"U.S. regulators have approved AstraZeneca's key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars."
2017-05-02,10:54 AM,Merck's revenue rises 1.3 pct,"May 2 Merck & Co Inc reported a 1.3 percent rise in quarterly revenue, helped by higher demand for its key immuno-oncology drug Keytruda."
2017-05-02,1:04 PM,BRIEF-Merck expecting somewhat slower animal health growth,"* Merck & Co says expects growth in animal health to be ""more measured"" in subsequent quarters Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)"
2017-05-02,11:10 AM,UPDATE 3-Merck eyes key cancer drug growth as others lose patent protection,"May 2 Merck & Co Inc on Tuesday reported better-than-expected profit in the first quarter as surprisingly strong demand for animal health products, vaccines and its hepatitis C treatment offset nearly $700 million in lower sales from drugs that lost patent protection."
2017-05-02,11:10 AM,Merck eyes key cancer drug growth as others lose patent protection,"Merck & Co Inc  on Tuesday reported better-than-expected profit in the first quarter as surprisingly strong demand for animal health products, vaccines and its hepatitis C treatment offset nearly $700 million in lower sales from drugs that lost patent protection."
2017-05-02,8:16 PM,Merck eyes key cancer drug growth as others lose patent protection,"Merck & Co Inc on Tuesday reported better-than-expected profit in the first quarter as surprisingly strong demand for animal health products, vaccines and its hepatitis C treatment offset nearly $700 million in lower sales from drugs that lost patent protection."
2017-05-04,3:42 PM,BRIEF-Cerveau Technologies says finalization of a clinical supply agreement with Merck,* Cerveau Technologies Inc. Signs clinical supply agreement with merck for investigational tau imaging agent
2017-05-10,10:34 AM,BRIEF-Oncosec announces clinical collaboration with Merck,* Oncosec announces clinical collaboration with Merck to evaluate combination of immunopulse IL-12 and keytruda(pembrolizumab) for metastatic melanoma
2017-05-10,3:44 PM,BRIEF-European Commission grants approval for Merck's new Pergoveris Pen for fertility treatment,* European Commission grants approval for Merck's new Pergoveris® Pen for fertility treatment
2017-05-10,9:39 PM,U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer,"May 10 Merck & Co said on Wednesday that U.S. health regulators  approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer, solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer."
2017-05-10,10:08 PM,BRIEF-U.S. FDA approves Merck's Keytruda chemo combo for lung cancer,"* Fda approves Merck's Keytruda® (pembrolizumab) as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-l1 expression"
2017-05-10,9:43 PM,UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer,"May 10 Merck & Co said on Wednesday U.S. health regulators  approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer, solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer."
2017-05-11,9:43 PM,U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer,"Merck & Co  said on Wednesday U.S. health regulators  approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer, solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer."
2017-05-16,10:34 PM,"Merck, Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case",May 16 Merck & Co Inc and Upsher-Smith Laboratories Inc have agreed to pay $60.2 million to resolve a lawsuit that said they  entered into a deal to unlawfully delay the availability of generic versions of potassium supplement K-Dur.
2017-05-16,10:34 PM,"Merck, Upsher-Smith to pay $60 million in 'pay-for-delay' drug case",Merck & Co Inc and Upsher-Smith Laboratories Inc have agreed to pay $60.2 million to resolve a lawsuit that said they  entered into a deal to unlawfully delay the availability of generic versions of potassium supplement K-Dur.
2017-05-17,12:35 AM,"Merck, Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case",Merck & Co Inc and Upsher-Smith Laboratories Inc have agreed to pay $60.2 million to resolve a lawsuit that said they  entered into a deal to unlawfully delay the availability of generic versions of potassium supplement K-Dur.
2017-05-17,1:15 PM,BRIEF-Aduro Biotech announces clinical collaboration with Merck,* Aduro Biotech announces clinical collaboration with Merck to evaluate combination of Aduro's CRS-207 with Merck's Keytruda for treatment of Mesothelioma
2017-05-17,5:05 PM,BRIEF-Merck's Glucophage SR receives label extension for patients at high risk of type 2 diabetes in UK,* Merck's Glucophage SR receives label extension for patients at high risk of type 2 diabetes in the UK Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)
2017-05-17,9:00 PM,"Merck, Incyte immunotherapy combination effective in lung cancer study","May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday."
2017-05-17,9:00 PM,Merck says test shows Keytruda improves survival for bladder cancer patients,"May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy."
2017-05-17,9:10 PM,"UPDATE 1-Merck, Incyte immunotherapy combination effective in lung cancer study","May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday."
2017-05-17,9:10 PM,"Merck, Incyte immunotherapy combination effective in lung cancer study","A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday."
2017-05-17,9:10 PM,UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients,"May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy."
2017-05-17,9:10 PM,Merck says test shows Keytruda improves survival for bladder cancer patients,"Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy."
2017-05-18,8:46 PM,"Merck, Incyte immunotherapy combination effective in lung cancer study","A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday."
2017-05-19,12:04 PM,BRIEF-Merck receives CHMP positive opinion recommending approval of isentress,* Merck receives chmp positive opinion recommending approval of isentress® (raltegravir) 600 mg in the european union
2017-05-22,5:27 AM,BRIEF-Ablynx to receive 15 million euros milestone payment,* NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE 15 MILLION MILESTONE PAYMENT
2017-05-22,3:38 PM,BRIEF-Merck announces presentation of phase 2 results for MK-7264,"* Merck announces presentation of phase 2 results for MK-7264, an investigational, p2x3 receptor antagonist, being evaluated for the treatment of chronic cough"
2017-05-23,9:04 AM,UK competition watchdog accuses Merck of obstructing biosimilars,"LONDON, May 23 Britain's competition watchdog on Tuesday accused Merck & Co of operating an anti-competitive discount scheme for its medicine Remicade, designed to restrict competition from so-called biosimilar copies of the drug."
2017-05-23,11:19 AM,BRIEF-FDA grants priority review to Merck's supplemental marketing application for Keytruda,* FDA grants priority review to MerckS supplemental biologics license application (sbla) for Keytruda® (pembrolizumab) for treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma
2017-05-23,9:09 AM,UPDATE 2-UK competition watchdog accuses Merck of obstructing biosimilars,"* CMA can fine companies up to 10 pct of global turnover (Adds details on past fines, more on biosimilars market)"
2017-05-23,9:09 AM,UK competition watchdog accuses Merck of obstructing biosimilars,LONDON Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.
2017-05-23,5:59 PM,BRIEF-Merck sets quarterly dividend of $0.47 per share,* Sets quarterly dividend of $0.47 per share Source text for Eikon: Further company coverage:
2017-05-23,7:34 PM,FDA clears Merck's Keytruda for cancer patients with certain biomarkers,"May 23 The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature."
2017-05-23,8:46 PM,UK competition watchdog accuses Merck of obstructing biosimilars,LONDON Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.
2017-05-23,9:01 PM,FDA clears Merck's Keytruda for cancer patients with certain biomarkers,"The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature."
2017-05-23,7:39 PM,"UPDATE 2-FDA clears Merck's Keytruda based on cancer genetics, not location","May 23 Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated."
2017-05-23,7:39 PM,"FDA clears Merck's Keytruda based on cancer genetics, not location","Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated."
2017-05-25,12:12 PM,BRIEF-Merck enters exclusive worldwide license agreement with Teijin Pharma,* Merck enters exclusive worldwide license agreement with Teijin Pharma for investigational antibody candidate targeting TAU
2017-05-25,6:09 PM,BRIEF-Optum and Merck collaborate to advance value-based contracting of pharmaceuticals,* Optum and merck collaborate to advance value-based contracting of pharmaceuticals
2017-05-30,11:01 PM,Britain backs first-line use of Merck's Keytruda under cancer fund,"LONDON, May 31 Britain's cost-effectiveness agency NICE has decided that Merck & Co's immunotherapy drug Keytruda can be used in previously untreated lung cancer patients under special funding arrangements."
2017-06-02,11:43 AM,BRIEF-Merck announces updated longer-term overall survival data from evaluating keytruda,"* announced updated longer-term overall survival (OS) data from Keynote-006, phase 3 study evaluating keytruda (pembrolizumab)"
2017-06-05,11:10 AM,BRIEF-Incyte Corp updates on Echo-202 trial of Incytes Epacadostat in combination with Mercks Keytruda,* Updated data from Echo-202 trial of Incytes Epacadostat in combination with Mercks Keytruda® (Pembrolizumab) demonstrate clinical activity across multiple tumor types
2017-06-05,11:33 AM,BRIEF-Merck presents positive mid-stage data from breast cancer combo therapy,* New data from phase 2 i-spy 2 trial shows improved outcomes with combination of MerckS Keytruda® (pembrolizumab) plus standard neoadjuvant therapy in patients with high-risk breast cancer
2017-06-12,8:22 PM,BRIEF-Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies,* Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda® (pembrolizumab) in combination with other therapies
2017-06-12,8:37 PM,CORRECTED-Merck to pause two late-stage studies testing Keytruda in myeloma,"June 12 Merck & Co said on Monday it paused enrolments in two late-stage studies testing its immunotherapy drug Keytruda used in combination with other therapies to treat multiple myeloma, a type of blood cancer."
2017-06-12,8:42 PM,UPDATE 1-Merck to pause two late-stage studies testing Keytruda in myeloma,"June 12 Merck & Co said it paused enrolments in two late-stage studies testing its immunotherapy drug, Keytruda, for multiple myeloma, in combination with other therapies, as the U.S. drugmaker looks to better understand more reports of death in the Keytruda groups."
2017-06-12,8:42 PM,Merck to pause two late-stage studies testing Keytruda in myeloma,"Merck & Co said it paused enrolments in two late-stage studies testing its immunotherapy drug, Keytruda, for multiple myeloma, in combination with other therapies, as the U.S. drugmaker looks to better understand more reports of death in the Keytruda groups."
2017-06-15,6:53 PM,"BRIEF-Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma","* Human longevity - signed agreement with merck kgaa, darmstadt, germany which operates its biopharmaceutical business as emd serono in u.s. And canada"
2017-06-20,5:21 PM,"BRIEF-Serimmune announces research, development collaboration agreement with subsidiary of Merck",* Announced a research and development collaboration agreement with a subsidiary of Merck
2017-06-20,7:46 PM,BRIEF-PV Nano Cell says cooperating with Merck for single-crystalline metal particles technology applications,* Is entering a cooperation with Merck to develop technology applications for single-crystalline metal particles Source text for Eikon: Further company coverage:
2017-06-21,1:18 PM,BRIEF-Leap Therapeutics announces collaboration with Merck,* Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer
2017-06-21,9:43 PM,BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study,"* Leap Therapeutics -  under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg)"
2017-06-21,10:05 PM,Gilead knocks out Merck patent on hepatitis C treatment,An appeals court handed biopharmaceutical company Gilead Sciences Inc a victory on Tuesday in its litigation with Merck & Co Inc over the blockbuster hepatitis C drug Sovaldi.
2017-06-27,5:11 AM,BRIEF-Ablynx achieves second milestone in immuno-oncology collaboration,"* ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO. , INC., KENILWORTH, NEW JERSEY, USA"
2017-06-27,11:26 AM,Merck's cholesterol drug clears main goal in late-stage study,June 27 Merck & Co Inc said on Tuesday its cholesterol drug met its main goal of reducing coronary heart diseases in a late-stage study.
2017-06-27,11:26 AM,BRIEF-Merck provides update on reveal outcomes study of Anacetrapib,* Merck provides update on reveal outcomes study of Anacetrapib
2017-06-27,11:30 AM,UPDATE 2-Merck heart drug surprises with positive result; questions linger,"June 27 Merck & Co said on Tuesday its experimental cholesterol drug from a class with a history of consistent failure lowered deaths and heart attacks in a large trial, but the company has yet to decide whether to seek approval despite the surprise success."
2017-06-27,11:30 AM,Merck heart drug surprises with positive result; questions linger,"Merck & Co said on Tuesday its experimental cholesterol drug from a class with a history of consistent failure lowered deaths and heart attacks in a large trial, but the company has yet to decide whether to seek approval despite the surprise success."
2017-06-29,7:28 AM,"UPDATE 1-Sales hopes for new Novartis, Merck heart drugs under microscope",* But questions over likely scale of clinical benefits (Recasts with sales forecasts and comments from experts)
2017-06-29,7:28 AM,"Sales hopes for new Novartis, Merck heart drugs under microscope","LONDON Novartis and Merck have both surprised experts in the past week by finding new ways to tackle heart disease, although the jury remains out as to whether this scientific success will translate into blockbuster sales."
2017-07-05,8:35 PM,"BRIEF-Merck provides further update on 3 multiple myeloma studies evaluating Keytruda in combination with Pomalidomide, Lenalidomide",* Merck provides further update on three multiple myeloma studies evaluating Keytruda® (pembrolizumab) in combination with pomalidomide or lenalidomide
2017-07-05,8:48 PM,FDA places clinical hold on Merck's combo therapy for multiple myeloma,"July 5 Merck & Co Inc said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its immunotherapy drug, Keytruda, in combination with other therapies."
2017-07-05,8:53 PM,UPDATE 1-FDA puts hold on Merck multiple myeloma trials after deaths,July 5 Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.
2017-07-06,8:53 PM,FDA puts hold on Merck multiple myeloma trials after deaths,Merck & Co  said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.
2017-07-06,11:07 AM,BRIEF-Merck to present new data from clinical trials at IAS 2017,* Merck to present new data from clinical trials evaluating Isentress HD (raltegravir) and investigational HIV therapies Doravirine and MK-8591 at IAS 2017
2017-07-10,11:05 AM,"BRIEF-NetScientific updates on clinical trial collaboration deal between PDS, unit of Merck & Co","* New clinical trial collaboration agreement between its PDS Biotechnology Corporation and a subsidiary of Merck & Co., Inc. Source text for Eikon: Further company coverage:"
2017-07-10,11:29 AM,BRIEF-PDS Biotechnology enters a clinical trial collaboration agreement with a subsidiary of Merck,* PDS Biotechnology says has entered a clinical trial collaboration agreement with a subsidiary of Merck
2017-07-13,12:29 PM,BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck,* Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody
2017-07-17,11:18 AM,BRIEF-Merck announces presentations of clinical and real-world data at the Alzheimers Association International Conference,* Merck announces presentations of clinical and real-world data at the Alzheimers Association International Conference Source text for Eikon: Further company coverage:
2017-07-20,11:50 AM,BRIEF-Merck announces U.S. FDA grants tentative approval for Lusduna Nexvue,"* Merck announces U.S. FDA grants tentative approval for Lusduna Nexvue (insulin glargine injection), a follow-on biologic basal insulin"
2017-07-20,5:19 PM,FDA tentatively approves Merck's copycat of Sanofi's Lantus,"Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus."
2017-07-20,7:20 PM,UPDATE 1-Trump unveils companies' $500 million U.S. drug packaging project,"WASHINGTON, July 20 President Donald Trump on Thursday announced a $500 million investment that Corning Inc is making with pharmaceutical giants Merck and Pfizer to manufacture a new kind of glass for injectable drug vials."
2017-07-21,11:52 AM,BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda,"* European Medicines Agency's CHMP recommends approval for Merck's Keytruda® (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer"
2017-07-21,7:20 PM,Trump unveils companies' $500 million U.S. drug packaging project,WASHINGTON President Donald Trump on Thursday announced a $500 million investment that Corning Inc is making with pharmaceutical giants Merck and Pfizer to manufacture a new kind of glass for injectable drug vials.
2017-07-24,11:13 AM,BRIEF-Merck announces week 96 results from Oncemrk,"* Merck announces week 96 results from Oncemrk, a study evaluating once-daily Isentress HD (raltegravir), in combination with other antiretroviral agents, for the treatment of HIV-1 infection in appropriate patients"
2017-07-24,12:18 PM,BRIEF-Merck announces U.S. launch of Renflexis,"* Merck announces U.S. Launch of Renflexis(infliximab-abda), a biosimilar of remicade, for all eligible indications Source text for Eikon: Further company coverage:"
2017-07-24,12:07 PM,"UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative","NEW YORK/SEOUL, July 24 Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine."
2017-07-24,12:07 PM,"Merck, Samsung Bioepis launch discounted U.S. Remicade alternative","NEW YORK/SEOUL Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine."
2017-07-24,5:25 PM,"Merck, Samsung Bioepis launch discounted U.S. Remicade alternative","NEW YORK/SEOUL Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine."
2017-07-24,5:01 PM,CORRECTED-FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20),"July 20 Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus."
2017-07-24,5:01 PM,FDA tentatively approves Merck's copycat of Sanofi's Lantus," (In this July 20 story, corrects to ""follow-on biologic"" from ""biosimilar"" in paragraphs 1, 6 and 9; removes reference to ""biosimilar"" throughout the story.)"
2017-07-24,9:07 PM,BRIEF-Merck provides update on phase 3 study of keytruda,* Merck provides update on phase 3 study of keytruda® (pembrolizumab) monotherapy in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma (hnscc)
2017-07-24,10:08 PM,Merck immunotherapy fails to improve survival in head and neck cancer,July 24 Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial.
2017-07-24,10:08 PM,Merck immunotherapy fails to improve survival in head and neck cancer,Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial.
2017-07-25,12:41 PM,"BRIEF-Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint","* Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint of non-inferiority to efavirenz, both in combination with other antiretroviral agents, in pivotal phase 3 trial for treatment of hiv-1 infection"
2017-07-25,8:14 PM,BRIEF-Merck sets quarterly dividend of $0.47 per share,* Sets quarterly dividend of $0.47 per share Source text for Eikon: Further company coverage:
2017-07-27,7:27 AM,BRIEF-Astrazeneca says establish strategic oncology collaboration with Merck,* ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION
2017-07-28,10:51 AM,Merck profit soars 61.5 pct as Keytruda sales surge,"July 28 Merck & Co Inc reported a 61.5 percent jump in quarterly profit on Friday as demand jumped for its key immuno-oncology drug, Keytruda."
2017-07-28,11:06 AM,BRIEF-Merck reports Q2 non-GAAP earnings of $1.01/shr,* Q2 earnings per share view $0.87 -- Thomson Reuters I/B/E/S
2017-07-28,10:49 AM,CORRECTED-UPDATE 1-Bayer cuts profit forecast after consumer health headache,"FRANKFURT, July 27 Bayer, which is buying U.S. seeds company Monsanto, cut its forecast for operating profit growth this year to below 10 percent after declines in sales of consumer health products in the United States and crop chemicals in Brazil."
2017-07-28,10:56 AM,"UPDATE 4-Merck says cyber attack halted production, will hurt profits","NEW YORK/LAS VEGAS, July 28 Drug and vaccine maker Merck & Co Inc said it suffered a worldwide disruption of its operations when it was the victim of an international cyber attack in June, halting production of its drugs, which will hurt its profits for the rest of the year."
2017-07-28,11:55 AM,"UPDATE 3-AbbVie to remain cautious on drug pricing, shares fall","* Co reiterates 2017 adjusted profit forecast (Adds conference call details, shares)"
2017-07-28,10:56 AM,"Merck says cyber attack halted production, will hurt profits","NEW YORK/LAS VEGAS Drug and vaccine maker Merck & Co Inc  said it suffered a worldwide disruption of its operations when it was the victim of an international cyber attack in June, halting production of its drugs, which will hurt its profits for the rest of the year."
2017-07-31,1:37 PM,BRIEF-Generex announces collaboration with Merck to evaluate Keytruda in combination with ae37 in patients with triple-negative breast cancer,* Generex announces collaboration with Merck to evaluate keytruda (pembrolizumab) in combination with ae37 in patients with triple-negative breast cancer
2017-08-03,9:18 PM,Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline,"Aug 3 Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda."
2017-08-03,9:18 PM,Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline,"Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda."
2017-08-07,11:18 AM,"BRIEF-MSD Animal Health to purchase manufacturing facility in Krems, Austria","* MSD Animal Health to purchase manufacturing facility in Krems, Austria"
2017-08-08,9:31 PM,BRIEF-Merck & Co says received investigative subpoena from california insurance commissioners fraud liaison bureau - sec filing,* Merck & co says recently received investigative subpoena from california insurance commissioners fraud liaison bureau - sec filing
2017-08-14,12:32 PM,"BRIEF-Merck CEO Frazier says ""I am resigning from the president's American Manufacturing Council"" - tweet","* Merck CEO Kenneth Frazier says ""I am resigning from the president's American Manufacturing Council"" - tweet"
2017-08-14,1:06 PM,REFILE-UPDATE 1-Merck CEO resigns from Trump council after Charlottesville,"Aug 14 Merck & Co Inc Chief Executive Kenneth Frazier resigned from U.S. President Donald Trump's American Manufacturing Council on Monday, saying he was taking a stand against intolerance and extremism."
2017-08-14,1:08 PM,REFILE-Trump chides Merck CEO after resignation from presidential council,"WASHINGTON, Aug 14 U.S. President Donald Trump chided Merck & Co Inc's Kenneth Frazier after the drugmaker's chief executive resigned from a presidential advisory board earlier on Monday and cited a need for U.S. leaders to denounce bigotry following a violent weekend in Charlottesville, Virginia."
2017-08-14,1:10 PM,Trump chides Merck CEO after resignation from presidential council,"WASHINGTON U.S. President Donald Trump chided Merck & Co Inc's Kenneth Frazier after the drugmaker's chief executive resigned from a presidential advisory board earlier on Monday and cited a need for U.S. leaders to denounce bigotry following a violent weekend in Charlottesville, Virginia."
2017-08-14,1:37 PM,UPDATE 8-Merck CEO resigns from Trump council over Charlottesville,"Aug 14 Merck & Co Inc Chief Executive Kenneth Frazier resigned from U.S. President Donald Trump's American Manufacturing Council on Monday, saying he was taking a stand against intolerance and extremism."
2017-08-15,12:54 PM,UPDATE 10-Three CEOs resign from Trump council over Charlottesville,"Aug 14 The chief executives of Intel Corp , Merck & Co Inc and Under Armour Inc resigned from U.S. President Donald Trump's American Manufacturing Council on Monday, following Trump's initially tepid response to weekend violence at a rally of white supremacists in Charlottesville, Virginia."
2017-08-15,12:54 PM,Three CEOs resign from Trump council over Charlottesville,"The chief executives of Intel Corp, Merck & Co Inc and Under Armour Inc resigned from U.S. President Donald Trump's American Manufacturing Council on Monday, following Trump's initially tepid response to weekend violence at a rally of white supremacists in Charlottesville, Virginia. | Video"
2017-08-15,9:11 AM,"Trump yields to pressure, calls neo-Nazis and KKK criminals","CHARLOTTESVILLE, Va./WASHINGTON U.S. President Donald Trump denounced neo-Nazis and the Ku Klux Klan as criminals and thugs on Monday, bowing to mounting political pressure to condemn such groups explicitly after a white-nationalist rally turned deadly in Virginia. | Video"
2017-08-17,1:44 PM,Fitch Affirms Merck at 'A'; Outlook Stable,"(The following statement was released by the rating agency) CHICAGO, August 17 (Fitch) Fitch Ratings has affirmed Merck & Co., Inc.'s Issuer Default Rating (IDR) at 'A' with a Stable Rating Outlook. The ratings apply to roughly $28.4 billion of debt outstanding at June 30, 2017. KEY RATING DRIVERS New Products/Growth Opportunities: Products approved during the last three years should help to drive intermediate- to long-term, top-line growth for Merck. Most importantly, Keytruda (cancer) is gaini"
2017-08-17,8:35 PM,FDA approves expanded use of AstraZeneca ovarian cancer drug,"Aug 17 The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy."
2017-08-17,8:36 PM,UPDATE 1-FDA expands use of AstraZeneca/Merck ovarian cancer drug,"Aug 17 The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy."
2017-08-17,8:36 PM,FDA expands use of AstraZeneca/Merck ovarian cancer drug,"The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy."
2017-08-29,6:31 AM,Merck cholesterol drug cuts heart risk by 9 pct in study,"Aug 29 A large study of Merck & Co Inc's experimental cholesterol drug anacetrapib found that it cut the risk of heart attack and death by a modest 9 percent, which could be due to its affect on bad LDL cholesterol, researchers said on Tuesday."
2017-08-29,6:43 AM,BRIEF-Merck announces results of REVEAL outcomes study of Anacetrapib,"* Merck announces results of REVEAL outcomes study of Anacetrapib, investigational medicine for cardiovascular disease"
2017-09-05,11:04 AM,BRIEF-European Commission approves MerckS KEYTRUDA (pembrolizumab),"* European Commission approves Mercks KEYTRUDA (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer"
2017-09-06,5:02 PM,Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln,"FRANKFURT, Sept 6 U.S. pharma group Merck & Co has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million), adding a new approach to its development of drugs that spur the immune system to attack tumours."
2017-09-06,10:27 PM,Bristol-Myers says FDA places partial hold on Opdivo myeloma trials,"Sept 6 The U.S. Food and Drug Administration has placed a partial hold on three clinical trials testing Bristol-Myers Squibb's immunotherapy Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies involving a rival drug, the company said on Wednesday."
2017-09-06,5:02 PM,Merck & Co snaps up three year-old German biotech firm for up to $550 million,"FRANKFURT U.S. pharma group Merck & Co  has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million), adding a new approach to its development of drugs that spur the immune system to attack tumors."
2017-09-11,1:18 PM,BRIEF-Merck announces findings from phase 3 study of KEYTRUDA,"* Merck announces findings from phase 3 study of KEYTRUDA (pembrolizumab), compared to standard of care, in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma"
2017-09-12,6:31 PM,BRIEF-Merck says Isentress HD now available in Canada,"* Now available in Canada: Isentress HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in appropriate patients"
2017-09-22,7:47 PM,BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients,* Fda approves Mercks keytruda® (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express pd-l1 (cps greater than or equal to 1)
2017-09-29,11:10 AM,BRIEF-Merck discontinues MK-3682B and MK-3682C development programs,* Merck discontinues MK-3682B and MK-3682C development programs
2017-09-29,12:21 PM,Merck to stop development of hepatitis C treatments,"Sept 29 U.S. drugmaker Merck & Co said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition rises and patient population shrinks."
2017-09-29,12:21 PM,Merck to stop development of hepatitis C treatments,"U.S. drugmaker Merck & Co said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition rises and patient population shrinks."
2017-10-02,11:23 PM,Judge upholds patent on Merck's antifungal drug Noxafil,"A U.S. judge on Friday upheld a Merck & Co Inc patent on its antifungal drug Noxafil against a challenge by Teva Pharmaceutical Industries Ltd, which had sought to sell a generic version of the drug."
2017-10-03,1:43 PM,REFILE-Police search Merck KGaA's French plant in thyroid pill inquiry,"LYON, France, Oct 3 French police searched German drugmaker Merck KGaA's plant in Lyon on Tuesday as part of an investigation into complaints by patients about changes to its thyroid drug Levothyrox, a company spokeswoman said."
2017-10-03,1:43 PM,Police search Merck KGaA's French plant in thyroid pill inquiry,"LYON, France French police searched German drugmaker Merck KGaA's plant in Lyon on Tuesday as part of an investigation into complaints by patients about changes to its thyroid drug Levothyrox, a company spokeswoman said."
2017-10-05,1:25 PM,Roche bladder cancer drug struggles as medics focus on survival,"LONDON, Oct 5 Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer."
2017-10-05,1:25 PM,Roche bladder cancer drug struggles as medics focus on survival,LONDON Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer.
2017-10-10,12:26 PM,BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck,* Kalvista Pharmaceuticals announces collaboration with Merck
2017-10-11,9:08 PM,BRIEF-Merck provides update on Anacetrapib development program,"* Merck & Co Inc - Decision follows a thorough review of clinical profile of Anacetrapib, including discussions with external experts"
2017-10-11,9:26 PM,Merck says will not seek approval of cholesterol treatment,"Oct 11 Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings."
2017-10-11,9:26 PM,Merck says will not seek approval of cholesterol treatment,"Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings."
2017-10-16,2:48 PM,BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck,* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of AegleaS AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer
2017-10-18,6:55 AM,Astra and Merck win speedy review for Lynparza in breast cancer,"LONDON, Oct 18 U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018."
2017-10-18,6:55 AM,Astra and Merck win speedy review for Lynparza in breast cancer,"LONDON U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018."
2017-10-18,11:12 AM,BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA,* Mercks KEYTRUDA® (pembrolizumab) more than doubled median overall survival compared to chemotherapy after two years of follow up in first-line treatment of patients with metastatic non-small cell lung cancer with high levels of PD-L1
2017-10-18,1:01 PM,BRIEF-U.S. FDA accepts regulatory submission for lynparza,* U.S. FDA accepts regulatory submission for lynparza® (olaparib) in metastatic breast cancer and grants priority review
2017-10-19,5:37 PM,CORRECTED-Merck cyber attack may cost insurers $275 mln -Verisk's PCS,"NEW YORK, Oct 19 Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit."
2017-10-19,5:37 PM,Merck cyber attack may cost insurers $275 million: Verisk's PCS,"NEW YORK Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit."
2017-10-20,4:10 PM,"Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care","Oct 20 Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday."
2017-10-20,4:16 PM,"UPDATE 1-Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care","Oct 20 Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday."
2017-10-20,4:16 PM,"Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care","Drugmaker Merck & Co Inc , moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday."
2017-10-23,6:29 AM,BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan,* ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN WITH A SECOND REGULATORY SUBMISSION
2017-10-23,11:05 AM,BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission,* AstraZeneca and Merck rapidly advance LYNPARZA (olaparib) in Japan with a second regulatory submission
2017-10-25,3:10 PM,BRIEF-ACIP votes 8-7 to prefer GSK's shingles vaccine Shingrix over Merck's Zostavax,"Oct 25 Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP), responsible for U.S. vaccination schedules:"
2017-10-25,4:03 PM,U.S. committee recommends GSK shingles vaccine over Merck rival,"LONDON, Oct 25 The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax."
2017-10-25,4:08 PM,UPDATE 1-U.S. committee recommends GSK shingles vaccine over Merck rival,"LONDON, Oct 25 The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax."
2017-10-25,4:08 PM,U.S. committee recommends GSK shingles vaccine over Merck rival,LONDON The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax.
2017-10-26,11:41 AM,"UPDATE 1-Bristol-Myers sales in line, but profit margins worsen","Oct 26 Bristol-Myers Squibb Co reported a 7 percent increase in third-quarter revenue as sales of key drugs met Wall Street expectations, but earnings fell short due to higher costs and an inventory write-off, sending shares down 4 percent."
2017-10-27,10:55 AM,Merck posts quarterly loss vs. year-ago profit,"Oct 27 Merck & Co reported a quarterly loss compared with a year-ago profit on Friday, hurt by a charge related to the formation of a collaboration with AstraZeneca Plc ."
2017-10-27,11:08 AM,BRIEF-Merck reports Q3 loss per share of $0.02,* Q3 earnings per share view $1.03 -- Thomson Reuters I/B/E/S
2017-10-27,1:05 PM,BRIEF-Merck says cyber attack to impact fourth quarter results,* Merck & Co CFO says cyber attack will have similar impact on Q4 results as outlined in Q3
2017-10-27,8:33 PM,BRIEF-Merck withdraws European application for Keytruda,* Merck provides update on European application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for first-line treatment of nonsquamous non-small cell lung cancer (NSCLC)
2017-10-27,8:46 PM,Merck withdraws marketing application for Keytruda in Europe,Oct 27 Merck & Co Inc said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer.
2017-10-27,8:46 PM,Merck withdraws marketing application for Keytruda in Europe,Merck & Co Inc said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer.
2017-10-27,11:00 AM,"UPDATE 4-Merck Keytruda sales soar, but European application pulled","Oct 27 Merck & Co on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time, but it withdrew an application for European use of the drug in lung cancer, raising questions about future sales."
2017-10-27,11:00 AM,"Merck Keytruda sales soar, but European application pulled","Merck & Co  on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time, but it withdrew an application for European use of the drug in lung cancer, raising questions about future sales."
2017-10-30,3:12 PM,Cancer-drug setback sends Merck shares down again,"NEW YORK, Oct 30 A setback for Merck & Co's key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years."
2017-10-30,3:12 PM,UPDATE 1-Cancer-drug setback sends Merck shares down again,"NEW YORK, Oct 30 A setback for Merck & Co's key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years."
2017-10-30,3:12 PM,Cancer-drug setback sends Merck shares down again,"NEW YORK A setback for Merck & Co's  key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years."
2017-10-30,11:22 AM,"US STOCKS-Wall St slips as Merck drops, tax talk rattles","* Indexes down: Dow 0.36 pct, S&P 0.32 pct, Nasdaq 0.03 pct (Updates with close of U.S. market)"
2017-10-30,8:08 PM,"US STOCKS SNAPSHOT-Wall St ends lower; Merck, Trump tax talk weigh","Oct 30 U.S. stocks pulled back from record-high territory on Monday, weighed down by a drop in Merck shares, as investors assessed President Donald Trump's plan for corporate tax cuts."
2017-11-06,1:59 PM,BRIEF-Merck announces any and all tender offers,"* Merck & Co Inc - Offers are being made upon, and are subject to, terms and conditions set forth in offer to purchase, dated Nov. 6, 2017"
2017-11-06,11:36 PM,Top Massachusetts court weighs Merck case over generic drug injury,Massachusetts' top court on Monday weighed whether the makers of brand name drugs like Merck & Co Inc can be sued over injuries blamed not on their own products but generic versions of the drugs other companies made.
2017-11-07,10:02 PM,BRIEF-Merck & Co updates on investigation of co's Italian unit,"* Merck & Co Inc says in July 2017, co learned that the prosecution office of Milan, Italy is investigating certain interactions - SEC filing"
2017-11-09,12:04 PM,BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients,* Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients
2017-11-09,12:30 PM,FDA OKs Merck drug to stop infection post-stem cell transplant,"Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday."
2017-11-09,1:19 PM,UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant,"Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday."
2017-11-09,1:19 PM,FDA OKs Merck drug that prevents infection post-stem cell transplant,"Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday."
2017-11-13,7:25 PM,BRIEF-Merck announces pricing of any and all tender offers,"* Says as of date of offers, aggregate outstanding principal amount of notes was about $2.95 billion"
2017-11-14,12:09 PM,BRIEF-Merck reports final results of any and all tender offers,"* Merck & Co Inc - offers expired at 5:00 p.m., New York City time, on Nov. 13, 2017"
2017-11-15,9:53 PM,BRIEF-Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6,* Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing Source text: [http://bit.ly/2z57b4q] Further company coverage:
2017-11-16,1:27 PM,BRIEF-Cue Biopharma announces collaboration with Merck,* Cue Biopharma says a strategic research collaboration and license agreement with Merck
2017-11-27,12:01 AM,"UK launches plan for industry as Brexit looms, wins Merck investment","LONDON, Nov 27 The British government launched a new strategy for industry on Monday, aiming to intervene in key sectors to tackle weak productivity and bolster businesses to counter any new problems caused by Brexit."
2017-11-27,12:16 AM,"UPDATE 2-As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen","* Drug industry remains concerned about Brexit impact (Adds Prime Minister, Business Secretary comments, reaction)"
2017-11-27,12:16 AM,"As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen","LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union."
2017-11-27,12:16 AM,"As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen","LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union."